{ "criteria": [ [ "Purity & identity", 20, "Chromatographic purity with method and molecular identity. A headline percentage alone earns no points." ], [ "Independent laboratory", 20, "A named external laboratory on an accessible report. Vendor-hosted reports are distinguished from laboratory-authenticated reports." ], [ "Contaminant controls", 30, "Six equally weighted checks: endotoxins, bioburden, sterility, residual solvents, elemental impurities, and peptide-related impurity characterization." ], [ "Quantity & traceability", 20, "Quantified content and identifiable, dated sample or batch records." ], [ "Accountability", 10, "Clear operator and research-use context, plus accessible contact or policy information." ] ], "vendors": [ { "slug": "particle-peptides", "name": "Particle Peptides", "url": "https://particlepeptides.com/en/", "kind": "Research retailer", "products": [ "GHRP-2", "Ipamorelin", "GHK-Cu", "KPV", "Semax", "Selank", "AOD-9604", "Epitalon" ], "note": "Particle publishes a searchable batch COA vault. Newer reports materially broaden the evidence beyond the historical GHRP-2 sample.", "evidence": "Sample report inspected", "levels": [ 0.75, 0.5, 0.375, 0.75, 0.5 ], "lab": "Liquilabs (supplier-hosted reports)", "flag": "New reports added; older endotoxin discrepancy retained", "sources": [ [ "GHRP-2 report: batch 2024224, published 21 Nov 2025", "https://particlepeptides.com/img/cms/test-results/GHRP-2-5mg.pdf" ], [ "Public COA vault", "https://particlepeptides.com/en/coa-vault" ], [ "Official catalogue", "https://particlepeptides.com/en/" ], [ "Testing document — coa 20260903 203243 569cbeac.pdf", "https://particlepeptides.com/modules/be_coa/upload/coa_20260903_203243_569cbeac.pdf" ], [ "Testing document — coa 20260713 190431 f8b54882.pdf", "https://particlepeptides.com/modules/be_coa/upload/coa_20260713_190431_f8b54882.pdf" ] ], "checked": "2026-09-10", "measurements": "BPC-157 5 mg, batch 2026346, LYO-0739, published 3 September 2026: 6.38 ±0.03 mg; purity 99.2 ±0.5%; endotoxins 0.486 ±0.01 EU/mg; aerobic and yeast/mould counts 0 CFU/g. Seven reported elements are each <0.001 ppm. KPV 5 mg, batch 2026335, LYO-0310, published 13 July 2026: 4.64 ±0.02 mg; purity 99.2 ±0.5%; endotoxins 0.025 ±0.001 EU/mg; the same microbial and element panels. These are sample results, not guarantees or universal acceptable limits. Bioburden, endotoxin and elemental documentation each earn 3.75/5 across two dated reports; the other three categories earn zero.", "question": "BPC-157 acceptable-range fields are blank. Report dates are publication dates; current delivered-vial matching and independent sample custody remain unverified. Older GHRP-2 endotoxin discrepancies remain unresolved.", "reviewSections": [ [ "Research scope", "Particle publishes a searchable batch COA vault. Newer reports materially broaden the evidence beyond the historical GHRP-2 sample." ], [ "Testing methods and purification", "New Liquilabs reports include chromatographic purity, retention-time and spectral identity, MS, USP <61> microbial counts, USP <85> chromogenic endotoxins and a seven-element screen. Neither report establishes sterility, residual-solvent clearance or complete related-impurity characterization." ], [ "How often is testing performed?", "The vault lists 91 documents, with visible publication groups in June, July and September 2026. We inspected July KPV and September BPC-157 reports in addition to the older GHRP-2 report. This demonstrates repeated publication, not an audited every-lot schedule." ], [ "What remains unverified", "BPC-157 acceptable-range fields are blank. Report dates are publication dates; current delivered-vial matching and independent sample custody remain unverified. Older GHRP-2 endotoxin discrepancies remain unresolved." ] ], "previousScore": 38, "research": { "reviewed": "2026-09-10", "methods": "New Liquilabs reports include chromatographic purity, retention-time and spectral identity, MS, USP <61> microbial counts, USP <85> chromogenic endotoxins and a seven-element screen. Neither report establishes sterility, residual-solvent clearance or complete related-impurity characterization.", "frequency": "The vault lists 91 documents, with visible publication groups in June, July and September 2026. We inspected July KPV and September BPC-157 reports in addition to the older GHRP-2 report. This demonstrates repeated publication, not an audited every-lot schedule.", "scope": "Particle publishes a searchable batch COA vault. Newer reports materially broaden the evidence beyond the historical GHRP-2 sample.", "gaps": "BPC-157 acceptable-range fields are blank. Report dates are publication dates; current delivered-vial matching and independent sample custody remain unverified. Older GHRP-2 endotoxin discrepancies remain unresolved.", "reportReviewed": true, "sources": [ "https://particlepeptides.com/en/coa-vault", "https://particlepeptides.com/modules/be_coa/upload/coa_20260903_203243_569cbeac.pdf", "https://particlepeptides.com/modules/be_coa/upload/coa_20260713_190431_f8b54882.pdf" ] }, "scoreReasons": [ "15/20: purity and identity results across July KPV and September BPC-157 samples; current inventory coverage is not audited.", "Named external lab on an inspected supplier-hosted report; not directly authenticated.", "11.25/30: endotoxins, bioburden and elements each earn 3.75/5 across two dated reports. Sterility, solvents and related-impurity characterization earn zero.", "15/20: measured content across dated samples (7.5) plus multiple identifiable dated lots (7.5). No independent delivered-vial matching.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Particle Peptides review: new Liquilabs batch reports, endotoxin results, microbial counts, metal screens and unresolved limits.", "score": 56 }, { "slug": "peptidology", "name": "Peptidology", "url": "https://peptidology.co/", "kind": "Research retailer", "products": [ "BPC-157" ], "note": "Peptidology provides a historical BPC-157 document bundle with useful assay results, but the separate sample identifiers limit a combined interpretation.", "evidence": "Sample report inspected", "levels": [ 0.5, 0.5, 0.08333333333333333, 0.25, 0.5 ], "lab": "TrustPointe Analytics (report attribution)", "flag": "Historical / login required", "sources": [ [ "BPC-157 report bundle, February 2025", "https://peptidology.co/wp-content/uploads/2025/04/BPC-157-10mg-February-2025-Final.pdf" ], [ "Current storefront", "https://peptidology.co/" ] ], "checked": "2026-09-10", "measurements": "Vendor-hosted TrustPointe report SPL-0359, published 8 February 2025: BPC-157 purity 99.416%, assay 11.23 mg against a 10 mg label; client ID BPC 10mg 120008. A different sample, SPL-0360 / client ID 120009, reports a sterility pass on 21 February 2025. These are separate samples. The bundle does not demonstrate a single sample passing both tests.", "question": "Request matched sample and lot identifiers across purity, quantity, sterility and endotoxin reports. Explanatory claims that purity alone establishes pharmaceutical grade are not accepted.", "reviewSections": [ [ "Research scope", "Peptidology provides a historical BPC-157 document bundle with useful assay results, but the separate sample identifiers limit a combined interpretation." ], [ "Testing methods and purification", "The February 2025 bundle attributes assay, chromatographic purity and identity controls to TrustPointe Analytics (TM-1006), alongside separate microbiological documentation. Distinct sample identifiers cannot be treated as one comprehensive vial test." ], [ "How often is testing performed?", "One historical report bundle was inspected. No complete public sequence of production lots or fixed retesting interval was established." ], [ "What remains unverified", "Request matched sample and lot identifiers across purity, quantity, sterility and endotoxin reports. Explanatory claims that purity alone establishes pharmaceutical grade are not accepted." ] ], "previousScore": 30, "research": { "reviewed": "2026-09-10", "methods": "The February 2025 bundle attributes assay, chromatographic purity and identity controls to TrustPointe Analytics (TM-1006), alongside separate microbiological documentation. Distinct sample identifiers cannot be treated as one comprehensive vial test.", "frequency": "One historical report bundle was inspected. No complete public sequence of production lots or fixed retesting interval was established.", "scope": "Peptidology provides a historical BPC-157 document bundle with useful assay results, but the separate sample identifiers limit a combined interpretation.", "gaps": "Request matched sample and lot identifiers across purity, quantity, sterility and endotoxin reports. Explanatory claims that purity alone establishes pharmaceutical grade are not accepted.", "reportReviewed": true, "sources": [ "https://peptidology.co/wp-content/uploads/2025/04/BPC-157-10mg-February-2025-Final.pdf" ] }, "scoreReasons": [ "A sample result with purity/identity data was inspected.", "Named external lab on an inspected supplier-hosted report; not directly authenticated.", "2.5/30: limited documentary credit for the separate sterility result. It is not combined with the purity sample as a single batch panel.", "5/20: an assay result earns quantity credit; differing sample identifiers prevent a verified common-batch link across the bundle.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Peptidology review: TrustPointe assay results, historical BPC-157 documents and the limits of mismatched sample identifiers.", "score": 33 }, { "slug": "biotech-peptides", "name": "Biotech Peptides", "url": "https://biotechpeptides.com/", "kind": "Research retailer", "products": [ "BPC-157", "TB-500", "PT-141", "Sermorelin", "Tesamorelin", "AOD-9604", "CJC-1295", "Ipamorelin" ], "note": "Biotech now has an inspectable, dated BPC-157 certificate attributed to MZ Biolabs, supporting more documentary credit than the earlier method-only review.", "evidence": "Sample report inspected", "levels": [ 0.5, 0.5, 0, 0.25, 0.5 ], "lab": "MZ Biolabs (supplier-hosted certificate)", "flag": "", "sources": [ [ "Biotech Peptides — official source", "https://biotechpeptides.com/" ], [ "Testing document — bpc 157", "https://biotechpeptides.com/product/bpc-157/" ], [ "Testing document — COA BPC 157 5mg 3140013 20260721 BP page 0001.webp", "https://biotechpeptides.com/wp-content/uploads/2020/03/COA_BPC-157_5mg_3140013_20260721_BP_page-0001.webp" ], [ "Testing document — COA BPC 157 5mg 3140013 20260721 BP page 0002.webp", "https://biotechpeptides.com/wp-content/uploads/2020/03/COA_BPC-157_5mg_3140013_20260721_BP_page-0002.webp" ] ], "checked": "2026-09-10", "question": "No quantified vial content, endotoxin, sterility, solvent or metal results appear in the inspected two-page certificate. The 5 mg label is not an assay result.", "reviewSections": [ [ "Research scope", "Biotech now has an inspectable, dated BPC-157 certificate attributed to MZ Biolabs, supporting more documentary credit than the earlier method-only review." ], [ "Testing methods and purification", "The inspected MZ Biolabs certificate includes an HPLC-UV chromatogram and HPLC-MS identity spectrum. Biotech describes repeated HPLC purification, but purification cost and number of rounds are not final-product contaminant tests." ], [ "How often is testing performed?", "Biotech claims every-batch third-party testing. One July 2026 BPC-157 lot certificate was inspected; catalogue-wide compliance and calendar retesting were not established." ], [ "What remains unverified", "No quantified vial content, endotoxin, sterility, solvent or metal results appear in the inspected two-page certificate. The 5 mg label is not an assay result." ] ], "previousScore": 10, "research": { "reviewed": "2026-09-10", "methods": "The inspected MZ Biolabs certificate includes an HPLC-UV chromatogram and HPLC-MS identity spectrum. Biotech describes repeated HPLC purification, but purification cost and number of rounds are not final-product contaminant tests.", "frequency": "Biotech claims every-batch third-party testing. One July 2026 BPC-157 lot certificate was inspected; catalogue-wide compliance and calendar retesting were not established.", "scope": "Biotech now has an inspectable, dated BPC-157 certificate attributed to MZ Biolabs, supporting more documentary credit than the earlier method-only review.", "gaps": "No quantified vial content, endotoxin, sterility, solvent or metal results appear in the inspected two-page certificate. The 5 mg label is not an assay result.", "reportReviewed": true, "sources": [ "https://biotechpeptides.com/", "https://biotechpeptides.com/product/bpc-157/", "https://biotechpeptides.com/wp-content/uploads/2020/03/COA_BPC-157_5mg_3140013_20260721_BP_page-0001.webp", "https://biotechpeptides.com/wp-content/uploads/2020/03/COA_BPC-157_5mg_3140013_20260721_BP_page-0002.webp" ] }, "scoreReasons": [ "A sample result with purity/identity data was inspected.", "Named external lab on an inspected supplier-hosted report; not directly authenticated.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "5/20: identifiable lot with a dated document (5); no measured peptide-content result earns quantity credit (0). A print or expiry date does not establish analysis timing.", "Public business/contact and product-use context; no independent audit of the operator." ], "measurements": "BPC-157 5 mg, lot 3140013: analysis date 15 July 2026, certificate signed 22 July. HPLC-UV purity 99.94%; expected monoisotopic mass 1418.70 Da, measured 1418.75 Da. The certificate warns that salts and sugars may not be detected by UV. No measured milligrams per vial are reported.", "metaDescription": "Biotech Peptides review: a dated MZ Biolabs BPC-157 certificate, HPLC purity, mass identity and missing contaminant results.", "score": 30 }, { "slug": "core-peptides", "name": "Core Peptides", "url": "https://www.corepeptides.com/", "kind": "Research retailer", "products": [ "BPC-157", "TB-500", "GHK-Cu", "CJC-1295", "Ipamorelin", "KPV", "MOTS-c", "Semax", "Selank" ], "note": "Core has public product and research-use information; its general testing claim could not be connected to an inspectable BPC-157 batch report.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Core Peptides — official source", "https://www.corepeptides.com/" ], [ "Testing document — bpc 157", "https://www.corepeptides.com/peptides/bpc-157/" ] ], "checked": "2026-09-10", "question": "A specification and clinical reference list do not establish product quality. Request a dated laboratory report with batch, methods, quantity and contaminant results.", "reviewSections": [ [ "Research scope", "Core has public product and research-use information; its general testing claim could not be connected to an inspectable BPC-157 batch report." ], [ "Testing methods and purification", "The homepage claims independent US-laboratory testing. The inspected BPC-157 product page gives a >99% specification, but no accessible batch certificate or named analytical method was found there." ], [ "How often is testing performed?", "No documented testing interval or inspectable series of batch reports was established." ], [ "What remains unverified", "A specification and clinical reference list do not establish product quality. Request a dated laboratory report with batch, methods, quantity and contaminant results." ] ], "previousScore": 5, "research": { "reviewed": "2026-09-10", "methods": "The homepage claims independent US-laboratory testing. The inspected BPC-157 product page gives a >99% specification, but no accessible batch certificate or named analytical method was found there.", "frequency": "No documented testing interval or inspectable series of batch reports was established.", "scope": "Core has public product and research-use information; its general testing claim could not be connected to an inspectable BPC-157 batch report.", "gaps": "A specification and clinical reference list do not establish product quality. Request a dated laboratory report with batch, methods, quantity and contaminant results.", "reportReviewed": false, "sources": [ "https://www.corepeptides.com/", "https://www.corepeptides.com/peptides/bpc-157/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Core Peptides review: third-party testing claims, public BPC-157 specifications and the batch documentation still needed.", "score": 5 }, { "slug": "limitless-biotech", "name": "Limitless Biotech", "url": "https://limitlesslifenootropics.com/", "kind": "Research retailer", "products": [ "Research peptides", "Peptide blends" ], "note": "Limitless describes a broader test programme than purity alone, but this review does not treat the claimed panel as verified batch results.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Limitless Biotech — official source", "https://limitlesslifenootropics.com/" ] ], "checked": "2026-09-10", "question": "Obtain the actual lab name, accreditation scope, limits, methods and same-lot reports. An account-gated report promise receives no contaminant result points.", "reviewSections": [ [ "Research scope", "Limitless describes a broader test programme than purity alone, but this review does not treat the claimed panel as verified batch results." ], [ "Testing methods and purification", "The site describes HPLC/LC-MS, sterility, endotoxin and chemical-contaminant testing by third-party laboratories. These are published claims; no complete lot report was inspected." ], [ "How often is testing performed?", "Every-batch testing is claimed. Account/order access and a public audit trail were not established; no independent cadence verification." ], [ "What remains unverified", "Obtain the actual lab name, accreditation scope, limits, methods and same-lot reports. An account-gated report promise receives no contaminant result points." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The site describes HPLC/LC-MS, sterility, endotoxin and chemical-contaminant testing by third-party laboratories. These are published claims; no complete lot report was inspected.", "frequency": "Every-batch testing is claimed. Account/order access and a public audit trail were not established; no independent cadence verification.", "scope": "Limitless describes a broader test programme than purity alone, but this review does not treat the claimed panel as verified batch results.", "gaps": "Obtain the actual lab name, accreditation scope, limits, methods and same-lot reports. An account-gated report promise receives no contaminant result points.", "reportReviewed": false, "sources": [ "https://limitlesslifenootropics.com/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Limitless Biotech review: claimed batch testing, HPLC/LC-MS, microbial panels and the documents needed to verify coverage.", "score": 10 }, { "slug": "us-chem-labs", "name": "US Chem Labs", "url": "https://www.uschemlabs.com/", "kind": "Research retailer", "products": [ "BPC-157", "Epitalon", "GHK-Cu", "MOTS-c" ], "note": "US Chem Labs describes analytical methods, but a representative product-specific report was not inspected.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "FDA letter · 2024", "sources": [ [ "Official catalogue", "https://www.uschemlabs.com/" ], [ "FDA warning letter, 7 Feb 2024", "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-chem-labs-669074-02072024" ], [ "Testing document — testing services", "https://www.uschemlabs.com/testing-services/" ] ], "checked": "2026-09-10", "question": "Request a named lab, dated lot report and exact test coverage. The previously linked FDA warning remains separate from any finding about chemical purity.", "reviewSections": [ [ "Research scope", "US Chem Labs describes analytical methods, but a representative product-specific report was not inspected." ], [ "Testing methods and purification", "Published HPLC/MS and COA claims coexist with analytical services including LC-MS/MS, quantity and stability. Selling testing services does not prove those tests were performed on every listed product." ], [ "How often is testing performed?", "The site says documentation is available where available; small-batch freshness is not a measurable test frequency." ], [ "What remains unverified", "Request a named lab, dated lot report and exact test coverage. The previously linked FDA warning remains separate from any finding about chemical purity." ] ], "previousScore": 10, "research": { "reviewed": "2026-09-10", "methods": "Published HPLC/MS and COA claims coexist with analytical services including LC-MS/MS, quantity and stability. Selling testing services does not prove those tests were performed on every listed product.", "frequency": "The site says documentation is available where available; small-batch freshness is not a measurable test frequency.", "scope": "US Chem Labs describes analytical methods, but a representative product-specific report was not inspected.", "gaps": "Request a named lab, dated lot report and exact test coverage. The previously linked FDA warning remains separate from any finding about chemical purity.", "reportReviewed": false, "sources": [ "https://www.uschemlabs.com/", "https://www.uschemlabs.com/testing-services/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "US Chem Labs review: HPLC/MS claims, testing services and the difference between analytical capability and product results.", "score": 10 }, { "slug": "swiss-chems", "name": "Swiss Chems", "url": "https://swisschems.is/", "kind": "Research retailer", "products": [ "Catalogue not verified" ], "note": "Swiss Chems remains unscored: available access did not support a defensible review of its testing documents.", "evidence": "Testing policy / evidence gaps", "levels": null, "lab": "Not verified", "flag": "Review incomplete", "sources": [ [ "Vendor test-results page (access blocked)", "https://swisschems.is/independent-test-results/" ], [ "Vendor serial verification", "https://verify.swisschems.is/" ] ], "checked": "2026-09-10", "question": "Provide accessible laboratory verification links and batch-matched certificates before comparing numeric scores.", "reviewSections": [ [ "Research scope", "Swiss Chems remains unscored: available access did not support a defensible review of its testing documents." ], [ "Testing methods and purification", "The independent-results page could not be read in this review. No results from similarly named domains were substituted." ], [ "How often is testing performed?", "Not established because the report records were inaccessible." ], [ "What remains unverified", "Provide accessible laboratory verification links and batch-matched certificates before comparing numeric scores." ] ], "previousScore": null, "research": { "reviewed": "2026-09-10", "methods": "The independent-results page could not be read in this review. No results from similarly named domains were substituted.", "frequency": "Not established because the report records were inaccessible.", "scope": "Swiss Chems remains unscored: available access did not support a defensible review of its testing documents.", "gaps": "Provide accessible laboratory verification links and batch-matched certificates before comparing numeric scores.", "reportReviewed": false, "sources": [ "https://swisschems.is/independent-test-results/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Swiss Chems review: testing-document access limits, unverified batch evidence and why a numeric rating is withheld.", "score": null }, { "slug": "peptide-sciences", "name": "Peptide Sciences", "url": "https://www.peptidesciences.com/", "kind": "Archived", "products": [ "Historical catalogue" ], "note": "Peptide Sciences is recorded as closed according to its official notice. It is excluded from active supplier rankings.", "evidence": "Testing policy / evidence gaps", "levels": null, "lab": "Not verified", "flag": "Closed — do not treat as active supplier", "sources": [ [ "Peptide Sciences — official source", "https://www.peptidesciences.com/" ] ], "checked": "2026-09-10", "question": "Do not transfer historical evidence or identity to sites claiming to be successors.", "reviewSections": [ [ "Research scope", "Peptide Sciences is recorded as closed according to its official notice. It is excluded from active supplier rankings." ], [ "Testing methods and purification", "The official domain displays a closure notice; historical claims do not establish a current testing programme." ], [ "How often is testing performed?", "Not applicable to this archived listing." ], [ "What remains unverified", "Do not transfer historical evidence or identity to sites claiming to be successors." ] ], "previousScore": null, "research": { "reviewed": "2026-09-10", "methods": "The official domain displays a closure notice; historical claims do not establish a current testing programme.", "frequency": "Not applicable to this archived listing.", "scope": "Peptide Sciences is recorded as closed according to its official notice. It is excluded from active supplier rankings.", "gaps": "Do not transfer historical evidence or identity to sites claiming to be successors.", "reportReviewed": false, "sources": [ "https://www.peptidesciences.com/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Peptide Sciences review: the official closure notice, archived supplier status and why historical claims do not validate successor sites.", "score": null }, { "slug": "peptidetech", "name": "PeptideTech", "url": "https://peptidetech.co/", "kind": "Research wholesale", "products": [ "Custom synthesis", "Research peptides" ], "note": "PeptideTech describes a wholesale testing programme, with insufficient accessible report evidence to validate the advertised coverage.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official company page", "https://peptidetech.co/about" ], [ "Official catalogue", "https://peptidetech.co/catalog" ], [ "Testing document — verify", "https://peptidetech.co/verify" ] ], "checked": "2026-09-10", "question": "Request the lab identity, certificate scope and actual lot report. ISO 17025 applies to a lab and defined methods, not automatically to all supplier products.", "reviewSections": [ [ "Research scope", "PeptideTech describes a wholesale testing programme, with insufficient accessible report evidence to validate the advertised coverage." ], [ "Testing methods and purification", "The about page claims ISO 17025 third-party testing for each lot and QR/lot verification. A usable lot-specific report and named laboratory were not inspected." ], [ "How often is testing performed?", "Every-lot testing is claimed; the verification form requires a lot identifier. The claimed totals are not an audited testing log." ], [ "What remains unverified", "Request the lab identity, certificate scope and actual lot report. ISO 17025 applies to a lab and defined methods, not automatically to all supplier products." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The about page claims ISO 17025 third-party testing for each lot and QR/lot verification. A usable lot-specific report and named laboratory were not inspected.", "frequency": "Every-lot testing is claimed; the verification form requires a lot identifier. The claimed totals are not an audited testing log.", "scope": "PeptideTech describes a wholesale testing programme, with insufficient accessible report evidence to validate the advertised coverage.", "gaps": "Request the lab identity, certificate scope and actual lot report. ISO 17025 applies to a lab and defined methods, not automatically to all supplier products.", "reportReviewed": false, "sources": [ "https://peptidetech.co/about", "https://peptidetech.co/verify" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "PeptideTech review: wholesale testing claims, lot verification and the evidence needed to assess third-party lab coverage.", "score": 5 }, { "slug": "genscript", "name": "GenScript", "url": "https://www.genscript.com/peptide.html", "kind": "Institutional supplier", "products": [ "Custom peptides", "Cyclic peptides", "Neoantigens", "Peptide libraries", "GLP-1 research" ], "note": "GenScript documents a custom-peptide QC workflow; optional low-endotoxin services must be specified in the order.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "GenScript: peptide quality control", "https://www.genscript.com/peptide_quality.html" ], [ "Peptide synthesis services", "https://www.genscript.com/peptide.html" ], [ "Testing document — accupep quality.html", "https://www.genscript.com/accupep_quality.html" ] ], "checked": "2026-09-10", "question": "No actual batch result or external laboratory report inspected. Request final-product content, residuals and the ordered endotoxin specification.", "reviewSections": [ [ "Research scope", "GenScript documents a custom-peptide QC workflow; optional low-endotoxin services must be specified in the order." ], [ "Testing methods and purification", "Analytical HPLC and MS are described throughout synthesis and purification. TFA exchange and endotoxin control are additional services rather than universal standard tests." ], [ "How often is testing performed?", "The quality policy describes testing all peptides; no sequence of dated customer lot certificates was inspected." ], [ "What remains unverified", "No actual batch result or external laboratory report inspected. Request final-product content, residuals and the ordered endotoxin specification." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Analytical HPLC and MS are described throughout synthesis and purification. TFA exchange and endotoxin control are additional services rather than universal standard tests.", "frequency": "The quality policy describes testing all peptides; no sequence of dated customer lot certificates was inspected.", "scope": "GenScript documents a custom-peptide QC workflow; optional low-endotoxin services must be specified in the order.", "gaps": "No actual batch result or external laboratory report inspected. Request final-product content, residuals and the ordered endotoxin specification.", "reportReviewed": false, "sources": [ "https://www.genscript.com/accupep_quality.html" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "GenScript review: standard HPLC/MS quality control, optional endotoxin services and the limits of published testing policies.", "score": 10 }, { "slug": "bachem", "name": "Bachem", "url": "https://www.bachem.com/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Peptide APIs", "Research peptides" ], "note": "Bachem provides detailed explanations of peptide analysis and grade-specific custom services. GMP capability is not assumed for every research product.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Bachem — official source", "https://www.bachem.com/" ], [ "Testing document — custom peptide synthesis services", "https://www.bachem.com/custom-peptide-synthesis-services/" ], [ "Testing document — quality control of amino acids peptides a guide", "https://www.bachem.com/knowledge-center/quality-control-of-amino-acids-peptides-a-guide/" ], [ "Testing document — faq frequently asked questions", "https://www.bachem.com/knowledge-center/faq-frequently-asked-questions/" ] ], "checked": "2026-09-10", "question": "Obtain the actual batch ADS and agreed specifications. In-house release testing earns no independent-laboratory points.", "reviewSections": [ [ "Research scope", "Bachem provides detailed explanations of peptide analysis and grade-specific custom services. GMP capability is not assumed for every research product." ], [ "Testing methods and purification", "Standard custom release includes HPLC and MALDI-MS with an analytical data sheet. Amino-acid/elemental analysis, water, counterions, sequencing and endotoxins are extended options; scope varies by grade." ], [ "How often is testing performed?", "Bachem describes batch-specific analytical data sheets and release QC. A current customer lot report and repeat-testing interval were not inspected." ], [ "What remains unverified", "Obtain the actual batch ADS and agreed specifications. In-house release testing earns no independent-laboratory points." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Standard custom release includes HPLC and MALDI-MS with an analytical data sheet. Amino-acid/elemental analysis, water, counterions, sequencing and endotoxins are extended options; scope varies by grade.", "frequency": "Bachem describes batch-specific analytical data sheets and release QC. A current customer lot report and repeat-testing interval were not inspected.", "scope": "Bachem provides detailed explanations of peptide analysis and grade-specific custom services. GMP capability is not assumed for every research product.", "gaps": "Obtain the actual batch ADS and agreed specifications. In-house release testing earns no independent-laboratory points.", "reportReviewed": false, "sources": [ "https://www.bachem.com/custom-peptide-synthesis-services/", "https://www.bachem.com/knowledge-center/quality-control-of-amino-acids-peptides-a-guide/", "https://www.bachem.com/knowledge-center/faq-frequently-asked-questions/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Bachem review: custom peptide HPLC/MS documentation, batch data sheets and the distinction between standard and extra tests.", "score": 10 }, { "slug": "polypeptide", "name": "PolyPeptide", "url": "https://www.polypeptide.com/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Peptide APIs" ], "note": "PolyPeptide publishes a substantial GMP QC framework for contract manufacturing, rather than consumer-vial test results.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "PolyPeptide — official source", "https://www.polypeptide.com/" ], [ "Testing document — quality control", "https://www.polypeptide.com/services/quality-control/" ], [ "Testing document — 1401702924538c4a0cb5e0a.pdf", "https://www.polypeptide.com/wp-content/uploads/2019/10/1401702924538c4a0cb5e0a.pdf" ] ], "checked": "2026-09-10", "question": "Confirm product, site, development phase and release specification. Do not apply provisional GMP specifications to all products or infer a passed contaminant panel.", "reviewSections": [ [ "Research scope", "PolyPeptide publishes a substantial GMP QC framework for contract manufacturing, rather than consumer-vial test results." ], [ "Testing methods and purification", "GMP analytical scope covers UHPLC purity/related substances, MS identity, content, counterions, moisture, residual TFA/solvents and microbial/endotoxin specifications. Published limits are specifications, not results." ], [ "How often is testing performed?", "The QC documentation describes release against predetermined specifications for each lot. No current series of lot COAs or calendar retesting schedule was inspected." ], [ "What remains unverified", "Confirm product, site, development phase and release specification. Do not apply provisional GMP specifications to all products or infer a passed contaminant panel." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "GMP analytical scope covers UHPLC purity/related substances, MS identity, content, counterions, moisture, residual TFA/solvents and microbial/endotoxin specifications. Published limits are specifications, not results.", "frequency": "The QC documentation describes release against predetermined specifications for each lot. No current series of lot COAs or calendar retesting schedule was inspected.", "scope": "PolyPeptide publishes a substantial GMP QC framework for contract manufacturing, rather than consumer-vial test results.", "gaps": "Confirm product, site, development phase and release specification. Do not apply provisional GMP specifications to all products or infer a passed contaminant panel.", "reportReviewed": false, "sources": [ "https://www.polypeptide.com/services/quality-control/", "https://www.polypeptide.com/wp-content/uploads/2019/10/1401702924538c4a0cb5e0a.pdf" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "PolyPeptide review: GMP release specifications, impurity controls and why published test limits are not measured batch results.", "score": 10 }, { "slug": "anaspec", "name": "AnaSpec", "url": "https://www.anaspec.com/en/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Assay peptides", "Proteomic reagents" ], "note": "AnaSpec provides an inspectable Biotin-LC-Angiotensin II certificate with content information beyond chromatographic purity.", "evidence": "Sample report inspected", "levels": [ 0.5, 0, 0, 0.25, 0.5 ], "lab": "AnaSpec in-house QC", "flag": "", "sources": [ [ "AnaSpec — official source", "https://www.anaspec.com/en/" ], [ "Testing document — tds en as 60276 5 angiotensin ii biotin lc.pdf", "https://www.anaspec.com/assets/991060de-41c6-4e93-a8d5-727dd5612ed2/tds-en-as-60276-5-angiotensin-ii-biotin-lc.pdf" ] ], "checked": "2026-09-10", "question": "The undated run record cannot establish current stock. No external-lab attribution or contaminant panel appears in this sample.", "reviewSections": [ [ "Research scope", "AnaSpec provides an inspectable Biotin-LC-Angiotensin II certificate with content information beyond chromatographic purity." ], [ "Testing methods and purification", "The inspected in-house certificate reports HPLC purity, molecular mass and amino-acid analysis/net peptide content." ], [ "How often is testing performed?", "One run-specific certificate was inspected. Its date field is blank; a current lot series or retesting interval was not established." ], [ "What remains unverified", "The undated run record cannot establish current stock. No external-lab attribution or contaminant panel appears in this sample." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The inspected in-house certificate reports HPLC purity, molecular mass and amino-acid analysis/net peptide content.", "frequency": "One run-specific certificate was inspected. Its date field is blank; a current lot series or retesting interval was not established.", "scope": "AnaSpec provides an inspectable Biotin-LC-Angiotensin II certificate with content information beyond chromatographic purity.", "gaps": "The undated run record cannot establish current stock. No external-lab attribution or contaminant panel appears in this sample.", "reportReviewed": true, "sources": [ "https://www.anaspec.com/assets/991060de-41c6-4e93-a8d5-727dd5612ed2/tds-en-as-60276-5-angiotensin-ii-biotin-lc.pdf" ] }, "scoreReasons": [ "A sample result with purity/identity data was inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "5/20: measured net peptide content (5); the run-specific certificate has no release date, so traceability receives no points (0).", "Public business/contact and product-use context; no independent audit of the operator." ], "measurements": "AS-60276-5, run 31997: HPLC purity >95%; expected [M+H]+ 1386.7, found 1386.8; peptide content 70.4% by amino-acid analysis; 5 mg net peptide packed. Release date is blank.", "metaDescription": "AnaSpec review: an inspectable peptide COA, mass identity, amino-acid analysis and the difference between purity and content.", "score": 20 }, { "slug": "peptide-protein-research", "name": "Peptide Protein Research", "url": "https://www.peptidesynthetics.co.uk/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Peptide synthesis" ], "note": "Peptide Protein Research documents in-house synthesis and standard LC-MS data supplied with custom orders. Public chromatograms are examples.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Peptide Protein Research — official source", "https://www.peptidesynthetics.co.uk/" ], [ "Testing document — questions", "https://www.peptidesynthetics.co.uk/questions/" ], [ "Testing document — delivery", "https://www.peptidesynthetics.co.uk/delivery/" ] ], "checked": "2026-09-10", "question": "Example data are not a current customer batch. Salt exchange is not proof of residual-solvent removal or sterility.", "reviewSections": [ [ "Research scope", "Peptide Protein Research documents in-house synthesis and standard LC-MS data supplied with custom orders. Public chromatograms are examples." ], [ "Testing methods and purification", "PPR says all peptides are supplied with RP-HPLC and electrospray MS data. CHN, amino-acid analysis and N-terminal sequencing cost extra. Delivery information offers TFA salts, with HCl/acetate by request." ], [ "How often is testing performed?", "Per-order analytical delivery is explicitly described; no dated lot series or routine retest interval was established." ], [ "What remains unverified", "Example data are not a current customer batch. Salt exchange is not proof of residual-solvent removal or sterility." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "PPR says all peptides are supplied with RP-HPLC and electrospray MS data. CHN, amino-acid analysis and N-terminal sequencing cost extra. Delivery information offers TFA salts, with HCl/acetate by request.", "frequency": "Per-order analytical delivery is explicitly described; no dated lot series or routine retest interval was established.", "scope": "Peptide Protein Research documents in-house synthesis and standard LC-MS data supplied with custom orders. Public chromatograms are examples.", "gaps": "Example data are not a current customer batch. Salt exchange is not proof of residual-solvent removal or sterility.", "reportReviewed": false, "sources": [ "https://www.peptidesynthetics.co.uk/questions/", "https://www.peptidesynthetics.co.uk/delivery/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Peptide Protein Research review: in-house synthesis, RP-HPLC and electrospray MS data, optional tests and batch evidence gaps.", "score": 10 }, { "slug": "biosynth", "name": "Biosynth", "url": "https://www.biosynth.com/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Research reagents" ], "note": "Biosynth publishes an identifiable research-peptide COA with an unusually important purity-definition caveat: two chemical forms count together.", "evidence": "Sample report inspected", "levels": [ 0.5, 0, 0, 0.25, 0.5 ], "lab": "Biosynth in-house certificate", "flag": "", "sources": [ [ "Biosynth — official source", "https://www.biosynth.com/" ], [ "Testing document — PP51304 Lot LB22 B1121 20250820.pdf", "https://www.biosynth.com/Files/CoA/PP/51/PP51304_Lot_LB22-B1121_20250820.pdf" ], [ "Testing document — gmp peptides", "https://www.biosynth.com/peptides/gmp-peptides" ] ], "checked": "2026-09-10", "question": "The COA explicitly counts target and pGlu-form peaks toward purity in an unknown ratio. It does not demonstrate 95.8% of a single form or a clean contaminant panel.", "reviewSections": [ [ "Research scope", "Biosynth publishes an identifiable research-peptide COA with an unusually important purity-definition caveat: two chemical forms count together." ], [ "Testing methods and purification", "The inspected research-grade COA uses UPLC at 215 nm and ESI-MS. GMP service pages separately describe content, solvents, counterions, water, endotoxin and microbial testing." ], [ "How often is testing performed?", "A dated lot certificate was inspected. GMP release capabilities do not establish a universal test cadence across research catalogue products." ], [ "What remains unverified", "The COA explicitly counts target and pGlu-form peaks toward purity in an unknown ratio. It does not demonstrate 95.8% of a single form or a clean contaminant panel." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The inspected research-grade COA uses UPLC at 215 nm and ESI-MS. GMP service pages separately describe content, solvents, counterions, water, endotoxin and microbial testing.", "frequency": "A dated lot certificate was inspected. GMP release capabilities do not establish a universal test cadence across research catalogue products.", "scope": "Biosynth publishes an identifiable research-peptide COA with an unusually important purity-definition caveat: two chemical forms count together.", "gaps": "The COA explicitly counts target and pGlu-form peaks toward purity in an unknown ratio. It does not demonstrate 95.8% of a single form or a clean contaminant panel.", "reportReviewed": true, "sources": [ "https://www.biosynth.com/Files/CoA/PP/51/PP51304_Lot_LB22-B1121_20250820.pdf", "https://www.biosynth.com/peptides/gmp-peptides" ] }, "scoreReasons": [ "A sample result with purity/identity data was inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "5/20: identifiable lot with a dated document (5); no measured peptide-content result earns quantity credit (0). A print or expiry date does not establish analysis timing.", "Public business/contact and product-use context; no independent audit of the operator." ], "measurements": "PP51304, H-QPTESIVRF-OH, lot LB22-B1121, issued 20 August 2025: UPLC purity 95.8% (minimum 95%); ESI-MS 1076.6. The TFA-salt certificate states that target peptide and pGlu-form peptide are present in an unknown ratio and both peaks count toward final purity. No measured peptide content is supplied.", "metaDescription": "Biosynth review: a batch COA, UPLC/MS results and a purity caveat that counts the target peptide and pGlu form together.", "score": 20 }, { "slug": "medchemexpress", "name": "MedChemExpress", "url": "https://www.medchemexpress.com/", "kind": "Institutional supplier", "products": [ "Bioactive peptides", "Research reagents", "Semaglutide", "Liraglutide", "Thymosin alpha-1" ], "note": "MedChemExpress offers product-level analytical-document access; accessible specifications alone receive limited method credit.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "MedChemExpress — official source", "https://www.medchemexpress.com/" ], [ "Semaglutide research catalogue listing", "https://www.medchemexpress.com/Semaglutide.html" ], [ "Liraglutide research catalogue listing", "https://www.medchemexpress.com/us/en/Liraglutide.html" ], [ "Thymosin alpha-1 research catalogue listing", "https://www.medchemexpress.com/us/en/Thymalfasin.html" ], [ "Testing document — wrwyar nh2 tfa.html", "https://www.medchemexpress.com/wrwyar-nh2-tfa.html" ] ], "checked": "2026-09-10", "question": "No successfully inspected full batch certificate in this pass. Document availability varies by product and should be checked for the ordered lot.", "reviewSections": [ [ "Research scope", "MedChemExpress offers product-level analytical-document access; accessible specifications alone receive limited method credit." ], [ "Testing methods and purification", "A product page exposes batch-selectable COA, RP-HPLC, MS and elemental-analysis document categories. The attempted competence-stimulating-peptide PDF was inaccessible in the final retrieval." ], [ "How often is testing performed?", "Batch-selectable records are offered, but this pass did not establish a complete dated report series or retest interval." ], [ "What remains unverified", "No successfully inspected full batch certificate in this pass. Document availability varies by product and should be checked for the ordered lot." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "A product page exposes batch-selectable COA, RP-HPLC, MS and elemental-analysis document categories. The attempted competence-stimulating-peptide PDF was inaccessible in the final retrieval.", "frequency": "Batch-selectable records are offered, but this pass did not establish a complete dated report series or retest interval.", "scope": "MedChemExpress offers product-level analytical-document access; accessible specifications alone receive limited method credit.", "gaps": "No successfully inspected full batch certificate in this pass. Document availability varies by product and should be checked for the ordered lot.", "reportReviewed": false, "sources": [ "https://www.medchemexpress.com/wrwyar-nh2-tfa.html" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "MedChemExpress review: batch-selectable analytical documents, HPLC/MS specifications and the limits of accessible report evidence.", "score": 10 }, { "slug": "selleck-chemicals", "name": "Selleck Chemicals", "url": "https://www.selleckchem.com/", "kind": "Institutional supplier", "products": [ "Bioactive peptides", "Research reagents" ], "note": "Selleck publishes a broad batch-QC policy. The reviewed examples should not be generalized into a full contaminant panel for peptides.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Selleck Chemicals — official source", "https://www.selleckchem.com/" ], [ "Testing document — quality control.html", "https://www.selleckchem.com/quality-control.html" ] ], "checked": "2026-09-10", "question": "Request the chosen peptide lot COA and relevant chromatograms. Broad claims of no hidden impurities are not accepted as analytical proof.", "reviewSections": [ [ "Research scope", "Selleck publishes a broad batch-QC policy. The reviewed examples should not be generalized into a full contaminant panel for peptides." ], [ "Testing methods and purification", "The QC page describes HPLC, NMR and elemental analysis, with batch COA/MS downloads. Its displayed examples concern inhibitors; elemental composition alone does not rule out every solvent or contaminant." ], [ "How often is testing performed?", "Selleck claims testing every batch and comparison of each new batch with a reference. No peptide-specific lot series was inspected." ], [ "What remains unverified", "Request the chosen peptide lot COA and relevant chromatograms. Broad claims of no hidden impurities are not accepted as analytical proof." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The QC page describes HPLC, NMR and elemental analysis, with batch COA/MS downloads. Its displayed examples concern inhibitors; elemental composition alone does not rule out every solvent or contaminant.", "frequency": "Selleck claims testing every batch and comparison of each new batch with a reference. No peptide-specific lot series was inspected.", "scope": "Selleck publishes a broad batch-QC policy. The reviewed examples should not be generalized into a full contaminant panel for peptides.", "gaps": "Request the chosen peptide lot COA and relevant chromatograms. Broad claims of no hidden impurities are not accepted as analytical proof.", "reportReviewed": false, "sources": [ "https://www.selleckchem.com/quality-control.html" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Selleck Chemicals review: every-batch QC claims, analytical methods and the limits of applying inhibitor examples to peptides.", "score": 10 }, { "slug": "tocris-bioscience", "name": "Tocris Bioscience", "url": "https://www.rndsystems.com/about/tocris-bioscience", "kind": "Institutional supplier", "products": [ "Bioactive peptides", "Neuroscience reagents" ], "note": "Tocris provides a useful PYY (3-36) example distinguishing chromatographic purity from net peptide content.", "evidence": "Sample report inspected", "levels": [ 0.5, 0, 0, 0.5, 0.5 ], "lab": "Tocris / Bio-Techne in-house certificate", "flag": "", "sources": [ [ "Tocris Bioscience — official source", "https://www.rndsystems.com/about/tocris-bioscience" ], [ "Testing document — 1618 4 coa.pdf", "https://resources.rndsystems.com/pdfs/tocris_coa/1618_4_coa.pdf?1758474464=" ] ], "checked": "2026-09-10", "question": "No contaminant panel or external laboratory attribution. The sample does not establish results for other products or current lots.", "reviewSections": [ [ "Research scope", "Tocris provides a useful PYY (3-36) example distinguishing chromatographic purity from net peptide content." ], [ "Testing methods and purification", "The inspected in-house certificate includes HPLC, mass-spectrum consistency and amino-acid analysis with net peptide content." ], [ "How often is testing performed?", "One batch-specific certificate, printed August 2025, was inspected. Print date is not an analysis date or a retesting schedule." ], [ "What remains unverified", "No contaminant panel or external laboratory attribution. The sample does not establish results for other products or current lots." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The inspected in-house certificate includes HPLC, mass-spectrum consistency and amino-acid analysis with net peptide content.", "frequency": "One batch-specific certificate, printed August 2025, was inspected. Print date is not an analysis date or a retesting schedule.", "scope": "Tocris provides a useful PYY (3-36) example distinguishing chromatographic purity from net peptide content.", "gaps": "No contaminant panel or external laboratory attribution. The sample does not establish results for other products or current lots.", "reportReviewed": true, "sources": [ "https://resources.rndsystems.com/pdfs/tocris_coa/1618_4_coa.pdf?1758474464=" ] }, "scoreReasons": [ "A sample result with purity/identity data was inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "10/20: measured net content (5) plus an identifiable batch with a dated printed certificate (5). Print date is not the analysis date.", "Public business/contact and product-use context; no independent audit of the operator." ], "measurements": "Peptide YY (3-36), catalogue 1618, batch 4, certificate printed 27 August 2025: HPLC purity 95.10%; mass spectrum consistent with structure; net peptide content 66.4%, with an amino-acid analysis table. The balance is described as counterions and residual water; TFA is the counterion.", "metaDescription": "Tocris Bioscience review: a PYY batch certificate, HPLC purity, amino-acid analysis and measured net peptide content.", "score": 25 }, { "slug": "merck-sigma-aldrich", "name": "Merck / Sigma-Aldrich", "url": "https://www.sigmaaldrich.com/US/en", "kind": "Institutional supplier", "products": [ "Peptide reagents", "Custom synthesis" ], "note": "Merck / Sigma-Aldrich has product and lot documentation infrastructure, but the inspected peptide lookup did not yield a full batch certificate.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Merck / Sigma-Aldrich — official source", "https://www.sigmaaldrich.com/US/en" ], [ "Testing document — sml2967", "https://www.sigmaaldrich.com/US/en/product/sigma/sml2967" ], [ "Testing document — h2016", "https://www.sigmaaldrich.com/DK/en/product/sial/h2016" ] ], "checked": "2026-09-10", "question": "Specify catalogue and lot before assigning results. Do not transfer a general brand reputation or unrelated product COA to the peptide being purchased.", "reviewSections": [ [ "Research scope", "Merck / Sigma-Aldrich has product and lot documentation infrastructure, but the inspected peptide lookup did not yield a full batch certificate." ], [ "Testing methods and purification", "Product pages provide product-specific HPLC specifications and lot COA lookup. A purity specification is not a measured result for the selected bottle." ], [ "How often is testing performed?", "Lot documentation is offered. FAQ guidance distinguishes release dates from expiry/retest dates, which depend on available stability data. No universal annual retesting schedule is established." ], [ "What remains unverified", "Specify catalogue and lot before assigning results. Do not transfer a general brand reputation or unrelated product COA to the peptide being purchased." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Product pages provide product-specific HPLC specifications and lot COA lookup. A purity specification is not a measured result for the selected bottle.", "frequency": "Lot documentation is offered. FAQ guidance distinguishes release dates from expiry/retest dates, which depend on available stability data. No universal annual retesting schedule is established.", "scope": "Merck / Sigma-Aldrich has product and lot documentation infrastructure, but the inspected peptide lookup did not yield a full batch certificate.", "gaps": "Specify catalogue and lot before assigning results. Do not transfer a general brand reputation or unrelated product COA to the peptide being purchased.", "reportReviewed": false, "sources": [ "https://www.sigmaaldrich.com/US/en/product/sigma/sml2967", "https://www.sigmaaldrich.com/DK/en/product/sial/h2016" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Merck / Sigma-Aldrich review: peptide specifications, lot COA access and why release, expiry and retest dates mean different things.", "score": 5 }, { "slug": "thermo-fisher-scientific", "name": "Thermo Fisher Scientific", "url": "https://www.thermofisher.com/", "kind": "Institutional supplier", "products": [ "Peptide reagents", "Custom synthesis" ], "note": "Thermo Fisher publishes a useful grade comparison; standard, high-throughput and quantitative reference peptides have different QC packages.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Thermo Fisher Scientific — official source", "https://www.thermofisher.com/" ], [ "Testing document — custom peptide synthesis brochure.pdf", "https://documents.thermofisher.com/TFS-Assets/LSG/brochures/custom-peptide-synthesis-brochure.pdf" ] ], "checked": "2026-09-10", "question": "The brochure is a service specification, not an inspected lot COA. Instrument application notes are not evidence that each sold peptide passed those tests.", "reviewSections": [ [ "Research scope", "Thermo Fisher publishes a useful grade comparison; standard, high-throughput and quantitative reference peptides have different QC packages." ], [ "Testing methods and purification", "Custom-peptide QC differs by grade: standard services use MS/HPLC, Pepotec can use MS only, and AQUA grades include quantitative amino-acid analysis with grade-specific tolerances." ], [ "How often is testing performed?", "The brochure describes analytical data delivered with orders, not a universal calendar retesting frequency." ], [ "What remains unverified", "The brochure is a service specification, not an inspected lot COA. Instrument application notes are not evidence that each sold peptide passed those tests." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Custom-peptide QC differs by grade: standard services use MS/HPLC, Pepotec can use MS only, and AQUA grades include quantitative amino-acid analysis with grade-specific tolerances.", "frequency": "The brochure describes analytical data delivered with orders, not a universal calendar retesting frequency.", "scope": "Thermo Fisher publishes a useful grade comparison; standard, high-throughput and quantitative reference peptides have different QC packages.", "gaps": "The brochure is a service specification, not an inspected lot COA. Instrument application notes are not evidence that each sold peptide passed those tests.", "reportReviewed": false, "sources": [ "https://documents.thermofisher.com/TFS-Assets/LSG/brochures/custom-peptide-synthesis-brochure.pdf" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Thermo Fisher Scientific review: grade-specific peptide QC, HPLC/MS and AQUA content analysis, with documentation limits.", "score": 10 }, { "slug": "dn-research", "name": "DN Research", "url": "https://dnresearch.com/", "kind": "Unverified listing", "products": [ "Catalogue not verified" ], "note": "DNresearch.com remains an unverified requested listing. A numeric rating is withheld until its identity and evidence can be established.", "evidence": "Testing policy / evidence gaps", "levels": null, "lab": "Not verified", "flag": "Verification pending", "sources": [ [ "Official source / access checked", "https://dnresearch.com/" ] ], "checked": "2026-09-10", "question": "An accessible official site, operator details and laboratory documents are required. Absence of access is not a finding of poor product quality.", "reviewSections": [ [ "Research scope", "DNresearch.com remains an unverified requested listing. A numeric rating is withheld until its identity and evidence can be established." ], [ "Testing methods and purification", "The requested domain did not yield verifiable supplier or laboratory documents. Unrelated businesses using similar names were excluded." ], [ "How often is testing performed?", "Unknown; no testing records established." ], [ "What remains unverified", "An accessible official site, operator details and laboratory documents are required. Absence of access is not a finding of poor product quality." ] ], "previousScore": 0, "research": { "reviewed": "2026-09-10", "methods": "The requested domain did not yield verifiable supplier or laboratory documents. Unrelated businesses using similar names were excluded.", "frequency": "Unknown; no testing records established.", "scope": "DNresearch.com remains an unverified requested listing. A numeric rating is withheld until its identity and evidence can be established.", "gaps": "An accessible official site, operator details and laboratory documents are required. Absence of access is not a finding of poor product quality.", "reportReviewed": false, "sources": [ "https://dnresearch.com/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Operator evidence remains limited or inaccessible." ], "metaDescription": "DN Research review: the requested domain, unresolved supplier identity and missing testing documents behind its unscored listing.", "score": null }, { "slug": "cordenpharma", "name": "CordenPharma", "url": "https://cordenpharma.com/how-we-deliver/technology-platforms/peptides-platform/", "kind": "Institutional supplier", "products": [ "Peptide APIs", "Clinical manufacturing", "Commercial manufacturing" ], "note": "CordenPharma documents clinical/GMP manufacturing services rather than public retail peptide certificates.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://cordenpharma.com/how-we-deliver/technology-platforms/peptides-platform/" ], [ "Testing document — pepcellerate first in human peptide injectable clinical trial development", "https://cordenpharma.com/what-you-need/apis/pepcellerate-first-in-human-peptide-injectable-clinical-trial-development/" ] ], "checked": "2026-09-10", "question": "No current lot COA inspected. API and finished drug-product release panels must be distinguished and agreed for the actual clinical programme.", "reviewSections": [ [ "Research scope", "CordenPharma documents clinical/GMP manufacturing services rather than public retail peptide certificates." ], [ "Testing methods and purification", "The integrated clinical peptide service describes in-process controls, phase-appropriate analytical release and stability testing for APIs and injectable drug products." ], [ "How often is testing performed?", "Release testing is described for manufactured materials/batches; stability schedules are programme-specific, not publicly quantified for every product." ], [ "What remains unverified", "No current lot COA inspected. API and finished drug-product release panels must be distinguished and agreed for the actual clinical programme." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The integrated clinical peptide service describes in-process controls, phase-appropriate analytical release and stability testing for APIs and injectable drug products.", "frequency": "Release testing is described for manufactured materials/batches; stability schedules are programme-specific, not publicly quantified for every product.", "scope": "CordenPharma documents clinical/GMP manufacturing services rather than public retail peptide certificates.", "gaps": "No current lot COA inspected. API and finished drug-product release panels must be distinguished and agreed for the actual clinical programme.", "reportReviewed": false, "sources": [ "https://cordenpharma.com/what-you-need/apis/pepcellerate-first-in-human-peptide-injectable-clinical-trial-development/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "CordenPharma review: clinical peptide release testing, stability services and the distinction between API and drug-product evidence.", "score": 5 }, { "slug": "ambiopharm", "name": "AmbioPharm", "url": "https://www.ambiopharm.com/about-us/", "kind": "Institutional supplier", "products": [ "Custom peptides", "GMP APIs", "Non-GMP synthesis" ], "note": "AmbioPharm explicitly distinguishes non-GMP and GMP COA scope, making the order specification central to any quality comparison.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "Parent: CordenPharma", "sources": [ [ "Official source / access checked", "https://www.ambiopharm.com/about-us/" ], [ "Testing document — data provided on certificate of analysis", "https://www.ambiopharm.com/faq/data-provided-on-certificate-of-analysis/" ], [ "Testing document — CommercialManufacturingPeptides.pdf", "https://www.ambiopharm.com/wp-content/uploads/2021/09/CommercialManufacturingPeptides.pdf" ] ], "checked": "2026-09-10", "question": "Do not assign GMP contaminant results to a non-GMP custom peptide. No independent-lab certificate was inspected.", "reviewSections": [ [ "Research scope", "AmbioPharm explicitly distinguishes non-GMP and GMP COA scope, making the order specification central to any quality comparison." ], [ "Testing methods and purification", "Non-GMP standard documents cover sequence, MS and RP-HPLC; content, water, counterions, bioburden/endotoxins are extras. GMP programmes describe broader release analysis." ], [ "How often is testing performed?", "QA reviews production and analytical records before batch release and COA issuance. No customer lot series or fixed retest interval was inspected." ], [ "What remains unverified", "Do not assign GMP contaminant results to a non-GMP custom peptide. No independent-lab certificate was inspected." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Non-GMP standard documents cover sequence, MS and RP-HPLC; content, water, counterions, bioburden/endotoxins are extras. GMP programmes describe broader release analysis.", "frequency": "QA reviews production and analytical records before batch release and COA issuance. No customer lot series or fixed retest interval was inspected.", "scope": "AmbioPharm explicitly distinguishes non-GMP and GMP COA scope, making the order specification central to any quality comparison.", "gaps": "Do not assign GMP contaminant results to a non-GMP custom peptide. No independent-lab certificate was inspected.", "reportReviewed": false, "sources": [ "https://www.ambiopharm.com/faq/data-provided-on-certificate-of-analysis/", "https://www.ambiopharm.com/wp-content/uploads/2021/09/CommercialManufacturingPeptides.pdf" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "AmbioPharm review: standard non-GMP peptide COAs, broader GMP analysis and which tests require an order-specific agreement.", "score": 10 }, { "slug": "cpc-scientific", "name": "CPC Scientific", "url": "https://cpcscientific.com/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Catalogue peptides", "Peptide CMC" ], "note": "CPC documents both routine custom analytics and a broader GMP release toolkit, with additional testing scope depending on the contract.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://cpcscientific.com/" ], [ "Testing document — custom peptide synthesis", "https://cpcscientific.com/custom-peptide-synthesis/" ], [ "Testing document — quality", "https://cpcscientific.com/custom-peptide-synthesis/cgmp-peptide-manufacturing/quality/" ] ], "checked": "2026-09-10", "question": "Audited contract laboratories are mentioned as additional support; no inspected external report or product-specific contaminant result earns points here.", "reviewSections": [ [ "Research scope", "CPC documents both routine custom analytics and a broader GMP release toolkit, with additional testing scope depending on the contract." ], [ "Testing methods and purification", "Custom synthesis includes COA, RP-HPLC, ESI-MS and solubility data. GMP services additionally describe content, Karl Fischer water, counterions, GC-MS solvents, LAL, bioburden and ICP-MS metals." ], [ "How often is testing performed?", "CPC says every custom peptide receives analytical documentation; GMP release is batch-based. Annual product reviews are not annual testing of every vial." ], [ "What remains unverified", "Audited contract laboratories are mentioned as additional support; no inspected external report or product-specific contaminant result earns points here." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Custom synthesis includes COA, RP-HPLC, ESI-MS and solubility data. GMP services additionally describe content, Karl Fischer water, counterions, GC-MS solvents, LAL, bioburden and ICP-MS metals.", "frequency": "CPC says every custom peptide receives analytical documentation; GMP release is batch-based. Annual product reviews are not annual testing of every vial.", "scope": "CPC documents both routine custom analytics and a broader GMP release toolkit, with additional testing scope depending on the contract.", "gaps": "Audited contract laboratories are mentioned as additional support; no inspected external report or product-specific contaminant result earns points here.", "reportReviewed": false, "sources": [ "https://cpcscientific.com/custom-peptide-synthesis/", "https://cpcscientific.com/custom-peptide-synthesis/cgmp-peptide-manufacturing/quality/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "CPC Scientific review: custom HPLC/MS deliverables, GMP contaminant-test capabilities and unverified batch-result coverage.", "score": 10 }, { "slug": "csbio", "name": "CSBio", "url": "https://www.csbio.com/", "kind": "Institutional supplier", "products": [ "Peptide synthesizers", "Custom peptide enquiries" ], "note": "CSBio provides a concrete purification case study, but it does not establish routine release results for other peptide orders.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.csbio.com/" ], [ "Testing document — longpeptide", "https://www.csbio.com/blog/longpeptide" ] ], "checked": "2026-09-10", "question": "Request product-specific identity, purity, content and residual analysis. Process yield and high chromatographic purity alone do not establish a contaminant-free product.", "reviewSections": [ [ "Research scope", "CSBio provides a concrete purification case study, but it does not establish routine release results for other peptide orders." ], [ "Testing methods and purification", "A public long-peptide case study describes C18 HPLC purification from 75% crude to 98.7% purified material, with yield information. This is a process example, not a current commercial lot COA." ], [ "How often is testing performed?", "No catalogue-wide batch testing or fixed retest schedule established from the inspected case study." ], [ "What remains unverified", "Request product-specific identity, purity, content and residual analysis. Process yield and high chromatographic purity alone do not establish a contaminant-free product." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "A public long-peptide case study describes C18 HPLC purification from 75% crude to 98.7% purified material, with yield information. This is a process example, not a current commercial lot COA.", "frequency": "No catalogue-wide batch testing or fixed retest schedule established from the inspected case study.", "scope": "CSBio provides a concrete purification case study, but it does not establish routine release results for other peptide orders.", "gaps": "Request product-specific identity, purity, content and residual analysis. Process yield and high chromatographic purity alone do not establish a contaminant-free product.", "reportReviewed": false, "sources": [ "https://www.csbio.com/blog/longpeptide" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "CSBio review: a long-peptide purification case study, HPLC results and the limits of applying process examples to current lots.", "score": 5 }, { "slug": "aapptec", "name": "AAPPTec", "url": "https://www.peptide.com/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Synthesis reagents", "Peptide synthesizers" ], "note": "AAPPTec provides a route to request lot documentation, but a complete product certificate was not inspected.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.peptide.com/" ], [ "Testing document — certificate of analysis", "https://www.peptide.com/resources/certificate-of-analysis/" ] ], "checked": "2026-09-10", "question": "Obtain the actual COA and raw methods before assessing purity, quantity or contaminant coverage.", "reviewSections": [ [ "Research scope", "AAPPTec provides a route to request lot documentation, but a complete product certificate was not inspected." ], [ "Testing methods and purification", "The public COA page asks customers to email a lot number from the product label. A published HPLC purification protocol is technical guidance, not a certificate for an ordered peptide." ], [ "How often is testing performed?", "Lot-linked COAs are available on request; no dated report sequence or retesting interval was established." ], [ "What remains unverified", "Obtain the actual COA and raw methods before assessing purity, quantity or contaminant coverage." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The public COA page asks customers to email a lot number from the product label. A published HPLC purification protocol is technical guidance, not a certificate for an ordered peptide.", "frequency": "Lot-linked COAs are available on request; no dated report sequence or retesting interval was established.", "scope": "AAPPTec provides a route to request lot documentation, but a complete product certificate was not inspected.", "gaps": "Obtain the actual COA and raw methods before assessing purity, quantity or contaminant coverage.", "reportReviewed": false, "sources": [ "https://www.peptide.com/resources/certificate-of-analysis/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "AAPPTec review: lot-number COA requests, public documentation access and the analytical evidence still needed for a full assessment.", "score": 5 }, { "slug": "gl-biochem", "name": "GL Biochem", "url": "https://www.glschina.com/en/news.htm", "kind": "Institutional supplier", "products": [ "Custom peptides", "Amino acids", "Synthesis reagents" ], "note": "GL Biochem remains a manufacturer listing with limited accessible testing evidence in this review.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.25 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.glschina.com/en/news.htm" ], [ "Testing document — www.glschina.com", "https://www.glschina.com/" ] ], "checked": "2026-09-10", "question": "A current official QC specification and representative dated certificates are needed. The limited score describes evidence access, not manufacturing quality.", "reviewSections": [ [ "Research scope", "GL Biochem remains a manufacturer listing with limited accessible testing evidence in this review." ], [ "Testing methods and purification", "The official site and an older catalogue could not be reliably retrieved for analytical review. Directory listings and similar domains were not used as substitutes for current QC documents." ], [ "How often is testing performed?", "Unknown in this review; no current testing log established." ], [ "What remains unverified", "A current official QC specification and representative dated certificates are needed. The limited score describes evidence access, not manufacturing quality." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The official site and an older catalogue could not be reliably retrieved for analytical review. Directory listings and similar domains were not used as substitutes for current QC documents.", "frequency": "Unknown in this review; no current testing log established.", "scope": "GL Biochem remains a manufacturer listing with limited accessible testing evidence in this review.", "gaps": "A current official QC specification and representative dated certificates are needed. The limited score describes evidence access, not manufacturing quality.", "reportReviewed": false, "sources": [ "https://www.glschina.com/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Operator evidence remains limited or inaccessible." ], "metaDescription": "GL Biochem review: limited access to current official QC documents, unresolved testing frequency and the next evidence needed.", "score": 3 }, { "slug": "chinapeptides", "name": "ChinaPeptides", "url": "https://chinapeptides.net/english/list.pdf", "kind": "Institutional supplier", "products": [ "Bioactive catalogue peptides", "Custom synthesis enquiries" ], "note": "ChinaPeptides publishes analytical examples and grade-dependent QC descriptions. Example chromatograms are not current product-release results.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://chinapeptides.net/english/list.pdf" ], [ "Testing document — qualitycfuben.php", "https://www.chinapeptides.net/qualitycfuben.php" ], [ "Testing document — peptide book.aspx", "https://www.chinapeptides.net/english/peptide_book.aspx" ] ], "checked": "2026-09-10", "question": "The example lacks a current order/lot link. Historical ISO 9001:2008 wording is not treated as proof of current certification.", "reviewSections": [ [ "Research scope", "ChinaPeptides publishes analytical examples and grade-dependent QC descriptions. Example chromatograms are not current product-release results." ], [ "Testing methods and purification", "The official quality page shows example C18 HPLC at 220 nm and ESI-MS. Service grades distinguish crude material with MS from purified peptides with HPLC/MS." ], [ "How often is testing performed?", "Purified peptides are described as individually checked; crude-grade analysis differs. No current dated lot series inspected." ], [ "What remains unverified", "The example lacks a current order/lot link. Historical ISO 9001:2008 wording is not treated as proof of current certification." ] ], "previousScore": 0, "research": { "reviewed": "2026-09-10", "methods": "The official quality page shows example C18 HPLC at 220 nm and ESI-MS. Service grades distinguish crude material with MS from purified peptides with HPLC/MS.", "frequency": "Purified peptides are described as individually checked; crude-grade analysis differs. No current dated lot series inspected.", "scope": "ChinaPeptides publishes analytical examples and grade-dependent QC descriptions. Example chromatograms are not current product-release results.", "gaps": "The example lacks a current order/lot link. Historical ISO 9001:2008 wording is not treated as proof of current certification.", "reportReviewed": false, "sources": [ "https://www.chinapeptides.net/qualitycfuben.php", "https://www.chinapeptides.net/english/peptide_book.aspx" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "ChinaPeptides review: example HPLC/MS data, crude-versus-purified QC rules and the lack of a current inspected batch certificate.", "score": 10 }, { "slug": "hybio-pharmaceutical", "name": "Hybio Pharmaceutical", "url": "https://www.hybio.com/", "kind": "Institutional supplier", "products": [ "Peptide APIs", "Peptide drug development", "Formulation development" ], "note": "Hybio documents analytical development capability for peptide drugs; public service descriptions do not reveal customer batch results.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.hybio.com/" ], [ "Testing document — peptide drug development", "https://www.hybio.com/peptide-drug-development/" ] ], "checked": "2026-09-10", "question": "Request method validation, actual release specifications and same-lot results. No routine contaminant panel is inferred from development capability.", "reviewSections": [ [ "Research scope", "Hybio documents analytical development capability for peptide drugs; public service descriptions do not reveal customer batch results." ], [ "Testing methods and purification", "Development services describe two-dimensional HPLC, high-resolution MS, impurity/chiral characterization, stability and packaging compatibility." ], [ "How often is testing performed?", "No public per-lot cadence or repeat-testing interval established from the service description." ], [ "What remains unverified", "Request method validation, actual release specifications and same-lot results. No routine contaminant panel is inferred from development capability." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Development services describe two-dimensional HPLC, high-resolution MS, impurity/chiral characterization, stability and packaging compatibility.", "frequency": "No public per-lot cadence or repeat-testing interval established from the service description.", "scope": "Hybio documents analytical development capability for peptide drugs; public service descriptions do not reveal customer batch results.", "gaps": "Request method validation, actual release specifications and same-lot results. No routine contaminant panel is inferred from development capability.", "reportReviewed": false, "sources": [ "https://www.hybio.com/peptide-drug-development/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Hybio Pharmaceutical review: peptide analytical development, impurity methods and the limits of public batch-testing evidence.", "score": 10 }, { "slug": "sinopep-biopharma", "name": "Sinopep Biopharma", "url": "https://www.sinopep.com/", "kind": "Institutional supplier", "products": [ "GMP peptides", "Custom peptides", "Peptide conjugates" ], "note": "Sinopep explains standard custom testing and broader GMP analytical services, which must be distinguished in procurement.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.sinopep.com/" ], [ "Testing document — peptide synthesis", "https://www.sinopep.com/discovery/peptide-synthesis/" ], [ "Testing document — quality", "https://www.sinopep.com/cdmo-services/quality/" ] ], "checked": "2026-09-10", "question": "Published acceptance limits are not measured results. No batch COA or independent external laboratory report was inspected.", "reviewSections": [ [ "Research scope", "Sinopep explains standard custom testing and broader GMP analytical services, which must be distinguished in procurement." ], [ "Testing methods and purification", "Custom peptide analytics include LC-MS/MALDI and HPLC; extra tests include amino-acid analysis, moisture/solvents and microbiology. GMP scope includes content, counterions, ICP-MS, LAL and GC-MS." ], [ "How often is testing performed?", "Each custom peptide is described as accompanied by analytical data; GMP batches receive QA release. Annual quality review is not a calendar retest commitment." ], [ "What remains unverified", "Published acceptance limits are not measured results. No batch COA or independent external laboratory report was inspected." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Custom peptide analytics include LC-MS/MALDI and HPLC; extra tests include amino-acid analysis, moisture/solvents and microbiology. GMP scope includes content, counterions, ICP-MS, LAL and GC-MS.", "frequency": "Each custom peptide is described as accompanied by analytical data; GMP batches receive QA release. Annual quality review is not a calendar retest commitment.", "scope": "Sinopep explains standard custom testing and broader GMP analytical services, which must be distinguished in procurement.", "gaps": "Published acceptance limits are not measured results. No batch COA or independent external laboratory report was inspected.", "reportReviewed": false, "sources": [ "https://www.sinopep.com/discovery/peptide-synthesis/", "https://www.sinopep.com/cdmo-services/quality/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Sinopep Biopharma review: custom HPLC/MS documentation, GMP release capabilities and which analytical tests are optional.", "score": 10 }, { "slug": "asymchem", "name": "Asymchem", "url": "https://www.asymchem.com/assets/documents/Asymchem-peptide-cdmo-capabilities-one-pager%20website.pdf", "kind": "Institutional supplier", "products": [ "Peptide development", "Manufacturing", "Analytical services" ], "note": "Asymchem provides analytical-development and manufacturing capability information, not inspectable results for a retail peptide.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.asymchem.com/assets/documents/Asymchem-peptide-cdmo-capabilities-one-pager%20website.pdf" ], [ "Testing document — peptide cdmo", "https://www.asymchem.com/api-solutions/apis-and-intermediates/peptide-cdmo" ], [ "Testing document — quality control", "https://www.asymchem.com/global-facilities/uk-sandwich/quality-control" ] ], "checked": "2026-09-10", "question": "A site equipment list does not demonstrate use of every method on every peptide. Obtain the contracted panel and actual batch release data.", "reviewSections": [ [ "Research scope", "Asymchem provides analytical-development and manufacturing capability information, not inspectable results for a retail peptide." ], [ "Testing methods and purification", "Peptide services describe in-process testing, characterization, release and ICH stability. Site-level QC lists chromatography, MS, NMR, ICP-MS and Karl Fischer methods." ], [ "How often is testing performed?", "Release and stability testing are project-specific; no public peptide batch series or universal interval established." ], [ "What remains unverified", "A site equipment list does not demonstrate use of every method on every peptide. Obtain the contracted panel and actual batch release data." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Peptide services describe in-process testing, characterization, release and ICH stability. Site-level QC lists chromatography, MS, NMR, ICP-MS and Karl Fischer methods.", "frequency": "Release and stability testing are project-specific; no public peptide batch series or universal interval established.", "scope": "Asymchem provides analytical-development and manufacturing capability information, not inspectable results for a retail peptide.", "gaps": "A site equipment list does not demonstrate use of every method on every peptide. Obtain the contracted panel and actual batch release data.", "reportReviewed": false, "sources": [ "https://www.asymchem.com/api-solutions/apis-and-intermediates/peptide-cdmo", "https://www.asymchem.com/global-facilities/uk-sandwich/quality-control" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Asymchem review: peptide release and stability services, site analytical capabilities and the limits of product-level evidence.", "score": 10 }, { "slug": "wuxi-tides", "name": "WuXi TIDES", "url": "https://tides.wuxiapptec.com/", "kind": "Institutional supplier", "products": [ "Peptide discovery", "Peptide APIs", "Synthetic conjugates" ], "note": "WuXi TIDES publishes a broad peptide CMC analytical service scope. It is capability evidence, not a passed product panel.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://tides.wuxiapptec.com/" ], [ "Testing document — analytical", "https://tides.wuxiapptec.com/services-solutions/peptide/peptide-cmc/analytical/" ] ], "checked": "2026-09-10", "question": "No customer lot COA inspected. Specify the manufacturing stage and contracted tests before comparing against finished research-vial documentation.", "reviewSections": [ [ "Research scope", "WuXi TIDES publishes a broad peptide CMC analytical service scope. It is capability evidence, not a passed product panel." ], [ "Testing methods and purification", "Analytical services include UPLC/QTOF, sequencing, chiral amino-acid analysis, LAL/bioburden, ICP-MS elemental impurities, GC solvents and stability studies." ], [ "How often is testing performed?", "The service describes release testing across raw materials, intermediates, API and drug product; actual schedules depend on the project." ], [ "What remains unverified", "No customer lot COA inspected. Specify the manufacturing stage and contracted tests before comparing against finished research-vial documentation." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Analytical services include UPLC/QTOF, sequencing, chiral amino-acid analysis, LAL/bioburden, ICP-MS elemental impurities, GC solvents and stability studies.", "frequency": "The service describes release testing across raw materials, intermediates, API and drug product; actual schedules depend on the project.", "scope": "WuXi TIDES publishes a broad peptide CMC analytical service scope. It is capability evidence, not a passed product panel.", "gaps": "No customer lot COA inspected. Specify the manufacturing stage and contracted tests before comparing against finished research-vial documentation.", "reportReviewed": false, "sources": [ "https://tides.wuxiapptec.com/services-solutions/peptide/peptide-cmc/analytical/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "WuXi TIDES review: peptide CMC testing, impurity and microbial analysis capabilities, with no inferred batch-level test results.", "score": 10 }, { "slug": "peptide-2-0", "name": "Peptide 2.0", "url": "https://www.peptide2.com/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Peptide libraries", "High-throughput synthesis" ], "note": "Peptide 2.0 provides clear grade-dependent testing information for custom synthesis.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.peptide2.com/" ], [ "Testing document — peptide synthesis frequently asked questions.php", "https://www.peptide2.com/peptide_synthesis_frequently_asked_questions.php" ] ], "checked": "2026-09-10", "question": "No current lot certificate or contaminant results inspected. Confirm actual purity grade and optional quantitative testing.", "reviewSections": [ [ "Research scope", "Peptide 2.0 provides clear grade-dependent testing information for custom synthesis." ], [ "Testing methods and purification", "The FAQ distinguishes HPLC/MS for purified peptides from MS-only QC for crude peptides." ], [ "How often is testing performed?", "All purified peptides are described as receiving HPLC/MS; weekly project updates refer to communication, not weekly retesting." ], [ "What remains unverified", "No current lot certificate or contaminant results inspected. Confirm actual purity grade and optional quantitative testing." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The FAQ distinguishes HPLC/MS for purified peptides from MS-only QC for crude peptides.", "frequency": "All purified peptides are described as receiving HPLC/MS; weekly project updates refer to communication, not weekly retesting.", "scope": "Peptide 2.0 provides clear grade-dependent testing information for custom synthesis.", "gaps": "No current lot certificate or contaminant results inspected. Confirm actual purity grade and optional quantitative testing.", "reportReviewed": false, "sources": [ "https://www.peptide2.com/peptide_synthesis_frequently_asked_questions.php" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Peptide 2.0 review: purified-versus-crude peptide testing, HPLC/MS deliverables and why weekly updates are not weekly retests.", "score": 10 }, { "slug": "lifetein", "name": "LifeTein", "url": "https://www.lifetein.com/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Cyclic peptides", "Labeled peptides" ], "note": "LifeTein documents standard identity/purity checks and explicitly separates additional content analysis.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.lifetein.com/" ], [ "Testing document — What are QC standards for peptide synthesis.html", "https://www.lifetein.com/What-are-QC-standards-for-peptide-synthesis.html" ], [ "Testing document — peptide synthesis handling and storage of synthetic peptides", "https://www.lifetein.com/blog/docs/peptide-synthesis-handling-and-storage-of-synthetic-peptides/" ] ], "checked": "2026-09-10", "question": "Gross powder mass cannot substitute for net peptide content. No product-specific endotoxin, sterility or solvent results inspected.", "reviewSections": [ [ "Research scope", "LifeTein documents standard identity/purity checks and explicitly separates additional content analysis." ], [ "Testing methods and purification", "Standard QC is HPLC and MS; RP-HPLC purification is described. Net peptide content, amino-acid and elemental analysis are additional options." ], [ "How often is testing performed?", "HPLC/MS data are described as part of peptide orders. No dated batch series or calendar retesting interval established." ], [ "What remains unverified", "Gross powder mass cannot substitute for net peptide content. No product-specific endotoxin, sterility or solvent results inspected." ] ], "previousScore": 8, "research": { "reviewed": "2026-09-10", "methods": "Standard QC is HPLC and MS; RP-HPLC purification is described. Net peptide content, amino-acid and elemental analysis are additional options.", "frequency": "HPLC/MS data are described as part of peptide orders. No dated batch series or calendar retesting interval established.", "scope": "LifeTein documents standard identity/purity checks and explicitly separates additional content analysis.", "gaps": "Gross powder mass cannot substitute for net peptide content. No product-specific endotoxin, sterility or solvent results inspected.", "reportReviewed": false, "sources": [ "https://www.lifetein.com/What-are-QC-standards-for-peptide-synthesis.html", "https://www.lifetein.com/blog/docs/peptide-synthesis-handling-and-storage-of-synthetic-peptides/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "LifeTein review: standard HPLC/MS, optional net content analysis and the missing batch results behind its documentation score.", "score": 10 }, { "slug": "phoenix-pharmaceuticals", "name": "Phoenix Pharmaceuticals", "url": "https://phoenixpeptide.com/", "kind": "Institutional supplier", "products": [ "Research peptides", "Labeled peptides", "Peptide libraries" ], "note": "Phoenix documents standard custom-peptide identity and purity analysis with shipment-level paperwork.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://phoenixpeptide.com/" ], [ "Testing document — custom peptide protein synthesis", "https://phoenixpeptide.com/services/custom-peptide-protein-synthesis/" ] ], "checked": "2026-09-10", "question": "No actual shipment certificate inspected; purity grades are contractual specifications, not measured results or human-use approvals.", "reviewSections": [ [ "Research scope", "Phoenix documents standard custom-peptide identity and purity analysis with shipment-level paperwork." ], [ "Testing methods and purification", "Custom synthesis describes in-house HPLC and MS with selectable purity grades, including 75%, 95% and 98%." ], [ "How often is testing performed?", "The service promises QC for every custom peptide and a COA with every shipment. No retesting interval or lot series independently established." ], [ "What remains unverified", "No actual shipment certificate inspected; purity grades are contractual specifications, not measured results or human-use approvals." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Custom synthesis describes in-house HPLC and MS with selectable purity grades, including 75%, 95% and 98%.", "frequency": "The service promises QC for every custom peptide and a COA with every shipment. No retesting interval or lot series independently established.", "scope": "Phoenix documents standard custom-peptide identity and purity analysis with shipment-level paperwork.", "gaps": "No actual shipment certificate inspected; purity grades are contractual specifications, not measured results or human-use approvals.", "reportReviewed": false, "sources": [ "https://phoenixpeptide.com/services/custom-peptide-protein-synthesis/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Phoenix Pharmaceuticals review: custom peptide HPLC/MS, purity grades and shipment COA claims, with explicit evidence limits.", "score": 10 }, { "slug": "boc-sciences", "name": "BOC Sciences", "url": "https://www.bocsci.com/", "kind": "Institutional supplier", "products": [ "Research chemicals", "Peptide conjugates", "Analytical services" ], "note": "BOC Sciences offers substantial analytical services, but optional tests and service packages must not be mistaken for universal product testing.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.bocsci.com/" ], [ "Testing document — peptide quality control testing.html", "https://formulation.bocsci.com/aesthetic-medicine/peptide-quality-control-testing.html" ], [ "Testing document — biotin labeled peptides.html", "https://bioconjugation.bocsci.com/services/biotin-labeled-peptides.html" ] ], "checked": "2026-09-10", "question": "No current product COA or independent laboratory certificate inspected. Obtain the ordered panel, final sample identity and measured results.", "reviewSections": [ [ "Research scope", "BOC Sciences offers substantial analytical services, but optional tests and service packages must not be mistaken for universal product testing." ], [ "Testing methods and purification", "Service pages describe HPLC, MS, amino-acid analysis, stability and endotoxin testing. Biotin-labelled peptide packages describe LC-MS/HPLC identity and purity data." ], [ "How often is testing performed?", "Release documentation is described for specific services; a universal testing interval or catalogue batch series was not established." ], [ "What remains unverified", "No current product COA or independent laboratory certificate inspected. Obtain the ordered panel, final sample identity and measured results." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Service pages describe HPLC, MS, amino-acid analysis, stability and endotoxin testing. Biotin-labelled peptide packages describe LC-MS/HPLC identity and purity data.", "frequency": "Release documentation is described for specific services; a universal testing interval or catalogue batch series was not established.", "scope": "BOC Sciences offers substantial analytical services, but optional tests and service packages must not be mistaken for universal product testing.", "gaps": "No current product COA or independent laboratory certificate inspected. Obtain the ordered panel, final sample identity and measured results.", "reportReviewed": false, "sources": [ "https://formulation.bocsci.com/aesthetic-medicine/peptide-quality-control-testing.html", "https://bioconjugation.bocsci.com/services/biotin-labeled-peptides.html" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "BOC Sciences review: peptide analytical services, HPLC/MS packages and why optional testing does not establish every-lot coverage.", "score": 10 }, { "slug": "iris-biotech", "name": "Iris Biotech", "url": "https://iris-biotech.de/", "kind": "Institutional supplier", "products": [ "Peptide building blocks", "Linkers", "Custom synthesis" ], "note": "Iris Biotech explains chemical documentation and custom analytics, with a scope that differs from consumer research-peptide sellers.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://iris-biotech.de/" ], [ "Testing document — how to decipher a certificate of analysis coa.html", "https://iris-biotech.de/de/blog/how-to-decipher-a-certificate-of-analysis-coa.html" ] ], "checked": "2026-09-10", "question": "No finished-peptide batch report inspected. Do not transfer reagent analytical results or supplier audit claims to a finished formulation.", "reviewSections": [ [ "Research scope", "Iris Biotech explains chemical documentation and custom analytics, with a scope that differs from consumer research-peptide sellers." ], [ "Testing methods and purification", "COA guidance describes batch-dependent chemical tests, including FTIR, HPLC and enantiomer analysis. Much of this concerns building blocks and reagents rather than finished peptide vials." ], [ "How often is testing performed?", "The company describes COAs for chemical batches; no finished-peptide lot sequence or retesting interval established." ], [ "What remains unverified", "No finished-peptide batch report inspected. Do not transfer reagent analytical results or supplier audit claims to a finished formulation." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "COA guidance describes batch-dependent chemical tests, including FTIR, HPLC and enantiomer analysis. Much of this concerns building blocks and reagents rather than finished peptide vials.", "frequency": "The company describes COAs for chemical batches; no finished-peptide lot sequence or retesting interval established.", "scope": "Iris Biotech explains chemical documentation and custom analytics, with a scope that differs from consumer research-peptide sellers.", "gaps": "No finished-peptide batch report inspected. Do not transfer reagent analytical results or supplier audit claims to a finished formulation.", "reportReviewed": false, "sources": [ "https://iris-biotech.de/de/blog/how-to-decipher-a-certificate-of-analysis-coa.html" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Iris Biotech review: chemical batch COA guidance and the limits of applying reagent documentation to finished peptide products.", "score": 5 }, { "slug": "chempep", "name": "ChemPep", "url": "https://chempep.com/custom-peptide-synthesis/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Modified peptides", "Purification services" ], "note": "ChemPep describes analytical deliverables alongside custom synthesis and purification services.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://chempep.com/custom-peptide-synthesis/" ], [ "Testing document — custom peptide price estimation", "https://chempep.com/custom-peptide-price-estimation/" ], [ "Testing document — custom purification services", "https://chempep.com/custom-purification-services/" ] ], "checked": "2026-09-10", "question": "No lot-specific result or complete contaminant panel inspected. Additional purification services are not proof that every order underwent them.", "reviewSections": [ [ "Research scope", "ChemPep describes analytical deliverables alongside custom synthesis and purification services." ], [ "Testing methods and purification", "Custom pricing includes COA, HPLC and MS reports. Separate purification services describe preparative/chiral HPLC and optional characterization." ], [ "How often is testing performed?", "Documentation is included per custom order; no fixed calendar retest interval or series of dated certificates inspected." ], [ "What remains unverified", "No lot-specific result or complete contaminant panel inspected. Additional purification services are not proof that every order underwent them." ] ], "previousScore": 8, "research": { "reviewed": "2026-09-10", "methods": "Custom pricing includes COA, HPLC and MS reports. Separate purification services describe preparative/chiral HPLC and optional characterization.", "frequency": "Documentation is included per custom order; no fixed calendar retest interval or series of dated certificates inspected.", "scope": "ChemPep describes analytical deliverables alongside custom synthesis and purification services.", "gaps": "No lot-specific result or complete contaminant panel inspected. Additional purification services are not proof that every order underwent them.", "reportReviewed": false, "sources": [ "https://chempep.com/custom-peptide-price-estimation/", "https://chempep.com/custom-purification-services/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "ChemPep review: custom peptide COA deliverables, HPLC/MS and purification services, with unverified lot-specific results.", "score": 10 }, { "slug": "peptide-institute", "name": "Peptide Institute", "url": "https://www.peptide.co.jp/en/", "kind": "Institutional supplier", "products": [ "Research peptides", "Biochemical reagents", "Custom synthesis enquiries" ], "note": "Peptide Institute publishes detailed historical analytical sheets. The dated example demonstrates documentation format but has limited relevance to current stock.", "evidence": "Sample report inspected", "levels": [ 0.25, 0, 0, 0.25, 0.5 ], "lab": "Peptide Institute in-house QC", "flag": "", "sources": [ [ "Official source / access checked", "https://www.peptide.co.jp/en/" ], [ "Testing document — 4396 640615.pdf", "https://www.peptide.co.jp/pdf/ads/4396-640615.pdf" ] ], "checked": "2026-09-10", "question": "No current peptide lot certificate, measured net content or contaminant panel inspected. Historical data receive partial rather than current multi-lot credit.", "reviewSections": [ [ "Research scope", "Peptide Institute publishes detailed historical analytical sheets. The dated example demonstrates documentation format but has limited relevance to current stock." ], [ "Testing methods and purification", "The inspected historical KYT-36 analytical sheet includes elemental analysis, TLC and an HPLC chromatogram/method. It concerns a peptidic inhibitor and does not cover present-day catalogue lots." ], [ "How often is testing performed?", "One June 2014 lot record was inspected; this is historical evidence, not current batch coverage or an annual testing schedule." ], [ "What remains unverified", "No current peptide lot certificate, measured net content or contaminant panel inspected. Historical data receive partial rather than current multi-lot credit." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The inspected historical KYT-36 analytical sheet includes elemental analysis, TLC and an HPLC chromatogram/method. It concerns a peptidic inhibitor and does not cover present-day catalogue lots.", "frequency": "One June 2014 lot record was inspected; this is historical evidence, not current batch coverage or an annual testing schedule.", "scope": "Peptide Institute publishes detailed historical analytical sheets. The dated example demonstrates documentation format but has limited relevance to current stock.", "gaps": "No current peptide lot certificate, measured net content or contaminant panel inspected. Historical data receive partial rather than current multi-lot credit.", "reportReviewed": true, "sources": [ "https://www.peptide.co.jp/pdf/ads/4396-640615.pdf" ] }, "scoreReasons": [ "5/20: historical HPLC and elemental/TLC documentation for a peptidic inhibitor; incomplete current peptide purity/identity evidence.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "5/20: identifiable lot with a dated document (5); no measured peptide-content result earns quantity credit (0). A print or expiry date does not establish analysis timing.", "Public business/contact and product-use context; no independent audit of the operator." ], "measurements": "KYT-36, code 4396-v, lot 640615, record 140375 dated 11 June 2014. The sheet provides elemental results and an HPLC method using a YMC ODS-A column, a 20–60% acetonitrile gradient and 220 nm detection. It is a historical peptidic-inhibitor record; no numeric peptide-content assay is reported.", "metaDescription": "Peptide Institute review: a historical analytical sheet, HPLC method details and why old records cannot establish current stock quality.", "score": 15 }, { "slug": "jpt-peptide-technologies", "name": "JPT Peptide Technologies", "url": "https://www.jpt.com/", "kind": "Institutional supplier", "products": [ "Peptide pools", "Peptide microarrays", "Proteomics standards" ], "note": "JPT provides unusually specific grade-dependent testing rules. The FastGrade sampling exception matters when comparing prices and documentation.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.jpt.com/" ], [ "Testing document — about peptide quality purity", "https://www.jpt.com/support-contact/resources/about-peptide-quality-purity/" ], [ "Testing document — premium grade pepmix pools", "https://www.jpt.com/products-services/peptide-pools/pepmix-peptide-pools/premium-grade-pepmix-pools/" ] ], "checked": "2026-09-10", "question": "No actual Premium batch certificate inspected. Extra microbiological tests do not automatically apply to ordinary custom or FastGrade orders.", "reviewSections": [ [ "Research scope", "JPT provides unusually specific grade-dependent testing rules. The FastGrade sampling exception matters when comparing prices and documentation." ], [ "Testing methods and purification", "QC varies by grade: most peptides receive individual HPLC/MS, whereas FastGrade uses statistical 5% testing. Premium PepMix describes LAL/rFC endotoxins, pharmacopoeial sterility and cytotoxicity testing." ], [ "How often is testing performed?", "Most grades: each peptide. FastGrade: 5% sample. Premium PepMix: each batch, plus recurrent functional testing; no fixed interval is stated for recurrence." ], [ "What remains unverified", "No actual Premium batch certificate inspected. Extra microbiological tests do not automatically apply to ordinary custom or FastGrade orders." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "QC varies by grade: most peptides receive individual HPLC/MS, whereas FastGrade uses statistical 5% testing. Premium PepMix describes LAL/rFC endotoxins, pharmacopoeial sterility and cytotoxicity testing.", "frequency": "Most grades: each peptide. FastGrade: 5% sample. Premium PepMix: each batch, plus recurrent functional testing; no fixed interval is stated for recurrence.", "scope": "JPT provides unusually specific grade-dependent testing rules. The FastGrade sampling exception matters when comparing prices and documentation.", "gaps": "No actual Premium batch certificate inspected. Extra microbiological tests do not automatically apply to ordinary custom or FastGrade orders.", "reportReviewed": false, "sources": [ "https://www.jpt.com/support-contact/resources/about-peptide-quality-purity/", "https://www.jpt.com/products-services/peptide-pools/pepmix-peptide-pools/premium-grade-pepmix-pools/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "JPT Peptide Technologies review: grade-specific HPLC/MS, FastGrade sampling and Premium PepMix microbial testing policies.", "score": 10 }, { "slug": "proimmune", "name": "ProImmune", "url": "https://www.proimmune.com/custom-peptide-synthesis/", "kind": "Institutional supplier", "products": [ "thinkpeptides custom synthesis", "ProMix peptide pools", "Immunology reagents" ], "note": "ProImmune provides useful peptide purity/content interpretation through its custom-peptide resources. Educational guidance is not itself a batch certificate.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.proimmune.com/custom-peptide-synthesis/" ], [ "Testing document — custom peptides", "https://www.proimmune.com/custom-peptides" ] ], "checked": "2026-09-10", "question": "Request the actual thinkpeptides order specification and analytical documents; no product-specific impurity clearance or external lab evidence inspected.", "reviewSections": [ [ "Research scope", "ProImmune provides useful peptide purity/content interpretation through its custom-peptide resources. Educational guidance is not itself a batch certificate." ], [ "Testing methods and purification", "Technical guidance explains RP-HPLC at 210–220 nm and amino-acid analysis for net content. It distinguishes UV-visible peptide impurities from salts and water." ], [ "How often is testing performed?", "No per-order testing promise or fixed retesting interval established from the inspected technical guidance." ], [ "What remains unverified", "Request the actual thinkpeptides order specification and analytical documents; no product-specific impurity clearance or external lab evidence inspected." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Technical guidance explains RP-HPLC at 210–220 nm and amino-acid analysis for net content. It distinguishes UV-visible peptide impurities from salts and water.", "frequency": "No per-order testing promise or fixed retesting interval established from the inspected technical guidance.", "scope": "ProImmune provides useful peptide purity/content interpretation through its custom-peptide resources. Educational guidance is not itself a batch certificate.", "gaps": "Request the actual thinkpeptides order specification and analytical documents; no product-specific impurity clearance or external lab evidence inspected.", "reportReviewed": false, "sources": [ "https://www.proimmune.com/custom-peptides" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "ProImmune review: peptide purity and net-content guidance, testing-method context and the need for order-specific certificates.", "score": 5 }, { "slug": "innovagen", "name": "Innovagen", "url": "https://www.innovagen.com/", "kind": "Institutional supplier", "products": [ "Antibody development", "Peptide enquiries" ], "note": "Innovagen describes custom-peptide services, but the accessible material does not support a detailed result-based score.", "evidence": "Testing policy / evidence gaps", "levels": [ 0, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.innovagen.com/" ], [ "Testing document — custom peptide synthesis", "https://www.innovagen.com/services/peptides-proteins/custom-peptide-synthesis/" ] ], "checked": "2026-09-10", "question": "Obtain the actual HPLC/identity methods, content assay and any contaminant tests specified for the order.", "reviewSections": [ [ "Research scope", "Innovagen describes custom-peptide services, but the accessible material does not support a detailed result-based score." ], [ "Testing methods and purification", "The custom synthesis page describes purification and analysis, with net peptide content available as an additional service. A sufficiently specific routine analytical method pair was not established in this pass." ], [ "How often is testing performed?", "No public fixed testing interval or dated lot series established." ], [ "What remains unverified", "Obtain the actual HPLC/identity methods, content assay and any contaminant tests specified for the order." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The custom synthesis page describes purification and analysis, with net peptide content available as an additional service. A sufficiently specific routine analytical method pair was not established in this pass.", "frequency": "No public fixed testing interval or dated lot series established.", "scope": "Innovagen describes custom-peptide services, but the accessible material does not support a detailed result-based score.", "gaps": "Obtain the actual HPLC/identity methods, content assay and any contaminant tests specified for the order.", "reportReviewed": false, "sources": [ "https://www.innovagen.com/services/peptides-proteins/custom-peptide-synthesis/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "No qualifying purity and identity evidence established.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Innovagen review: custom synthesis documentation, optional content analysis and unresolved methods and testing frequency.", "score": 5 }, { "slug": "smartox-biotechnology", "name": "Smartox Biotechnology", "url": "https://www.smartox-biotech.com/company/about-smartox", "kind": "Institutional supplier", "products": [ "Venom-derived peptides", "Cyclic peptides", "Custom peptide synthesis" ], "note": "Smartox publishes peptide analytical and purification capabilities; this review did not inspect a current client or catalogue lot certificate.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.smartox-biotech.com/company/about-smartox" ], [ "Testing document — analytical services", "https://www.smartox-biotech.com/service/analytical-services" ] ], "checked": "2026-09-10", "question": "Request the exact release panel and batch report. Biological activity and structural complexity do not establish contaminant clearance.", "reviewSections": [ [ "Research scope", "Smartox publishes peptide analytical and purification capabilities; this review did not inspect a current client or catalogue lot certificate." ], [ "Testing methods and purification", "Analytical services include mass spectrometry, purity, net content, sequencing and solubility, with HPLC examples. These are service capabilities." ], [ "How often is testing performed?", "No standard per-batch cadence or calendar retest interval established." ], [ "What remains unverified", "Request the exact release panel and batch report. Biological activity and structural complexity do not establish contaminant clearance." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Analytical services include mass spectrometry, purity, net content, sequencing and solubility, with HPLC examples. These are service capabilities.", "frequency": "No standard per-batch cadence or calendar retest interval established.", "scope": "Smartox publishes peptide analytical and purification capabilities; this review did not inspect a current client or catalogue lot certificate.", "gaps": "Request the exact release panel and batch report. Biological activity and structural complexity do not establish contaminant clearance.", "reportReviewed": false, "sources": [ "https://www.smartox-biotech.com/service/analytical-services" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Smartox Biotechnology review: peptide analytics, HPLC/MS capabilities and the current batch documents still needed for verification.", "score": 10 }, { "slug": "cayman-chemical", "name": "Cayman Chemical", "url": "https://www.caymanchem.com/", "kind": "Institutional supplier", "products": [ "Research reagent catalogue" ], "note": "Cayman provides a public RGDS peptide certificate with multiple orthogonal identity methods.", "evidence": "Sample report inspected", "levels": [ 0.5, 0, 0, 0.25, 0.5 ], "lab": "Cayman Chemical in-house certificate", "flag": "", "sources": [ [ "Official source / access checked", "https://www.caymanchem.com/" ], [ "Testing document — Cayman CofA 15359 0675573.pdf", "https://cdn.caymanchem.com/cdn/downloadCofa/Cayman-CofA-15359-0675573.pdf" ] ], "checked": "2026-09-10", "question": "No quantitative peptide content, endotoxin, sterility, solvent or metal results in this example. TLC purity is not a universal mass-purity result.", "reviewSections": [ [ "Research scope", "Cayman provides a public RGDS peptide certificate with multiple orthogonal identity methods." ], [ "Testing methods and purification", "The RGDS certificate contains HPLC, MS, IR, NMR and TLC results with a batch identifier and expiry date. It is an in-house supplier certificate." ], [ "How often is testing performed?", "One identifiable lot certificate was inspected. Expiration in 2028 is not an analysis date or proof of a scheduled retest programme." ], [ "What remains unverified", "No quantitative peptide content, endotoxin, sterility, solvent or metal results in this example. TLC purity is not a universal mass-purity result." ] ], "previousScore": 0, "research": { "reviewed": "2026-09-10", "methods": "The RGDS certificate contains HPLC, MS, IR, NMR and TLC results with a batch identifier and expiry date. It is an in-house supplier certificate.", "frequency": "One identifiable lot certificate was inspected. Expiration in 2028 is not an analysis date or proof of a scheduled retest programme.", "scope": "Cayman provides a public RGDS peptide certificate with multiple orthogonal identity methods.", "gaps": "No quantitative peptide content, endotoxin, sterility, solvent or metal results in this example. TLC purity is not a universal mass-purity result.", "reportReviewed": true, "sources": [ "https://cdn.caymanchem.com/cdn/downloadCofa/Cayman-CofA-15359-0675573.pdf" ] }, "scoreReasons": [ "A sample result with purity/identity data was inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "5/20: identifiable lot with a dated document (5); no measured peptide-content result earns quantity credit (0). A print or expiry date does not establish analysis timing.", "Public business/contact and product-use context; no independent audit of the operator." ], "measurements": "RGDS peptide, item 15359, batch 0675573: HPLC purity 97.9% against a ≥95% specification; MS MH+ 434.4; IR and NMR conform; TLC purity 100%. Expiration date 15 November 2028. No analytical date or measured peptide content is stated.", "metaDescription": "Cayman Chemical review: an RGDS batch certificate with HPLC, MS and structural tests, plus the contaminant checks it does not include.", "score": 20 }, { "slug": "peptx", "name": "Peptx", "url": "https://peptx.co.uk/testing", "kind": "Research retailer", "products": [ "PT-141", "Ipamorelin", "Retatrutide", "Tirzepatide" ], "note": "Peptx links to laboratory verification, and one Janoshik record was inspected directly. The record identifies the client as PX but lists the batch and manufacturer as unknown.", "evidence": "Lab-hosted report inspected", "levels": [ 0.25, 0.75, 0, 0.25, 0.5 ], "lab": "Janoshik (lab-hosted report inspected)", "flag": "", "sources": [ [ "Official source / access checked", "https://peptx.co.uk/testing" ], [ "Testing document — coa library", "https://peptx.co.uk/coa-library" ], [ "Testing document — peptide supplier uk", "https://peptx.co.uk/peptide-supplier-uk" ], [ "Testing document — 211038 IPA 5 TI3KF4EKTYKS", "https://verify.janoshik.com/tests/211038-IPA_5_TI3KF4EKTYKS" ] ], "checked": "2026-09-10", "question": "No batch-to-vial link or independent purchase chain established. Separate cartridge sterility/endotoxin/residue tests concern hardware, not peptide contents, and earn no peptide contaminant points.", "reviewSections": [ [ "Research scope", "Peptx links to laboratory verification, and one Janoshik record was inspected directly. The record identifies the client as PX but lists the batch and manufacturer as unknown." ], [ "Testing methods and purification", "The COA library mixes supplier-submitted tests, random stock checks and group testing. A Janoshik-hosted Ipamorelin report was opened directly. Its summary gives purity and quantity but not the full method/chromatogram." ], [ "How often is testing performed?", "Peptx describes rolling/random QC rather than every-batch testing. Library publication is ongoing, but inconsistent summary totals prevent treating its counts as a complete audit log." ], [ "What remains unverified", "No batch-to-vial link or independent purchase chain established. Separate cartridge sterility/endotoxin/residue tests concern hardware, not peptide contents, and earn no peptide contaminant points." ] ], "previousScore": 8, "research": { "reviewed": "2026-09-10", "methods": "The COA library mixes supplier-submitted tests, random stock checks and group testing. A Janoshik-hosted Ipamorelin report was opened directly. Its summary gives purity and quantity but not the full method/chromatogram.", "frequency": "Peptx describes rolling/random QC rather than every-batch testing. Library publication is ongoing, but inconsistent summary totals prevent treating its counts as a complete audit log.", "scope": "Peptx links to laboratory verification, and one Janoshik record was inspected directly. The record identifies the client as PX but lists the batch and manufacturer as unknown.", "gaps": "No batch-to-vial link or independent purchase chain established. Separate cartridge sterility/endotoxin/residue tests concern hardware, not peptide contents, and earn no peptide contaminant points.", "reportReviewed": true, "sources": [ "https://peptx.co.uk/coa-library", "https://peptx.co.uk/peptide-supplier-uk", "https://verify.janoshik.com/tests/211038-IPA_5_TI3KF4EKTYKS" ] }, "scoreReasons": [ "5/20: partial analytical documentation gives purity and peptide identity, but the inspected portal summary does not include methods or chromatograms.", "Report inspected on the laboratory portal; sample custody is not audited.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "5/20: measured Ipamorelin content (5); the laboratory record explicitly says the batch is unknown, so batch traceability earns zero.", "Public business/contact and product-use context; no independent audit of the operator." ], "measurements": "Janoshik task 211038, sample IPA 5, client PX: ordered 21 July, received 7 August and analysed 11 August 2026. Ipamorelin 4.81 mg; purity 99.653%. Batch and manufacturer fields say Unknown. The laboratory-hosted record supports provenance of this report, not the identity or quality of every Peptx lot.", "metaDescription": "Peptx review: a Janoshik-hosted report, measured Ipamorelin content, rolling QC claims and an unknown batch identifier.", "score": 30 }, { "slug": "uk-peptides", "name": "UK Peptides", "url": "https://www.uk-peptides.com/", "kind": "Research retailer", "products": [ "BPC-157", "Research peptide catalogue" ], "note": "UK Peptides clearly discloses an important limitation: its public COAs do not correspond to individual production batches.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.uk-peptides.com/" ], [ "Testing document — faq", "https://www.uk-peptides.com/faq" ] ], "checked": "2026-09-10", "question": "No independent or current-batch certificate inspected. A reference identity/purity document cannot establish the contents of the delivered vial.", "reviewSections": [ [ "Research scope", "UK Peptides clearly discloses an important limitation: its public COAs do not correspond to individual production batches." ], [ "Testing methods and purification", "The FAQ states in-house HPLC/MS COAs are reference documents and explicitly not batch-specific. They are not included with orders." ], [ "How often is testing performed?", "No batch-specific release-testing cadence is evidenced by these reference COAs. The supplier encourages independent testing of the customer’s own batch." ], [ "What remains unverified", "No independent or current-batch certificate inspected. A reference identity/purity document cannot establish the contents of the delivered vial." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "The FAQ states in-house HPLC/MS COAs are reference documents and explicitly not batch-specific. They are not included with orders.", "frequency": "No batch-specific release-testing cadence is evidenced by these reference COAs. The supplier encourages independent testing of the customer’s own batch.", "scope": "UK Peptides clearly discloses an important limitation: its public COAs do not correspond to individual production batches.", "gaps": "No independent or current-batch certificate inspected. A reference identity/purity document cannot establish the contents of the delivered vial.", "reportReviewed": false, "sources": [ "https://www.uk-peptides.com/faq" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "UK Peptides review: in-house HPLC/MS references and the supplier’s explicit disclosure that its COAs are not batch-specific.", "score": 10 }, { "slug": "bio-synthesis", "name": "Bio-Synthesis", "url": "https://www.biosyn.com/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Peptide conjugation", "Peptide analytics" ], "note": "Bio-Synthesis describes substantial release QC but explicitly different service scales and scopes.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.biosyn.com/" ], [ "Testing document — peptide release qc services.aspx", "https://www.biosyn.com/peptide-release-qc-services.aspx" ], [ "Testing document — peptide tech bsi.aspx", "https://www.biosyn.com/peptide-tech-bsi.aspx" ] ], "checked": "2026-09-10", "question": "No actual lot certificate inspected. Sterile filtration is a process step, not proof of a passed sterility test, and midscale endotoxin coverage is not universal catalogue coverage.", "reviewSections": [ [ "Research scope", "Bio-Synthesis describes substantial release QC but explicitly different service scales and scopes." ], [ "Testing methods and purification", "Standard peptide pages describe HPLC/MS; release services offer content/AAA, GC solvents, ICP-MS, water, counterions, LAL and bioburden. Endotoxin testing is specifically described as standard for the 1–100 g midscale service." ], [ "How often is testing performed?", "Each peptide is described as receiving HPLC/MS and batch documentation; additional coverage is service-specific. No calendar retest interval established." ], [ "What remains unverified", "No actual lot certificate inspected. Sterile filtration is a process step, not proof of a passed sterility test, and midscale endotoxin coverage is not universal catalogue coverage." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Standard peptide pages describe HPLC/MS; release services offer content/AAA, GC solvents, ICP-MS, water, counterions, LAL and bioburden. Endotoxin testing is specifically described as standard for the 1–100 g midscale service.", "frequency": "Each peptide is described as receiving HPLC/MS and batch documentation; additional coverage is service-specific. No calendar retest interval established.", "scope": "Bio-Synthesis describes substantial release QC but explicitly different service scales and scopes.", "gaps": "No actual lot certificate inspected. Sterile filtration is a process step, not proof of a passed sterility test, and midscale endotoxin coverage is not universal catalogue coverage.", "reportReviewed": false, "sources": [ "https://www.biosyn.com/peptide-release-qc-services.aspx", "https://www.biosyn.com/peptide-tech-bsi.aspx" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Bio-Synthesis review: peptide release analytics, scale-specific endotoxin testing and the distinction between standard and extra QC.", "score": 10 }, { "slug": "creative-peptides", "name": "Creative Peptides", "url": "https://www.creative-peptides.com/services/peptide-purity-analysis.html", "kind": "Institutional supplier", "products": [ "Custom peptides", "Peptide analysis", "Purification services" ], "note": "Creative Peptides describes standard analytical QC and optional biological testing. Those options must be tied to the actual order.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://www.creative-peptides.com/services/peptide-purity-analysis.html" ], [ "Testing document — biological testing.html", "https://www.creative-peptides.com/services/biological-testing.html" ], [ "Testing document — targeting peptide quality testing and purification.html", "https://www.creative-peptides.com/services/targeting-peptide-quality-testing-and-purification.html" ] ], "checked": "2026-09-10", "question": "No product-specific external report or contaminant result inspected. Endotoxin-removal capability is not a measured result on every peptide.", "reviewSections": [ [ "Research scope", "Creative Peptides describes standard analytical QC and optional biological testing. Those options must be tied to the actual order." ], [ "Testing methods and purification", "HPLC/MS are described during synthesis and purification. Additional services include endotoxin removal, sterility, bioburden and cytotoxicity testing; low-endotoxin limits are service specifications." ], [ "How often is testing performed?", "The targeting-peptide service describes batch QC records; no public sequence of dated certificates or fixed retest interval inspected." ], [ "What remains unverified", "No product-specific external report or contaminant result inspected. Endotoxin-removal capability is not a measured result on every peptide." ] ], "previousScore": 8, "research": { "reviewed": "2026-09-10", "methods": "HPLC/MS are described during synthesis and purification. Additional services include endotoxin removal, sterility, bioburden and cytotoxicity testing; low-endotoxin limits are service specifications.", "frequency": "The targeting-peptide service describes batch QC records; no public sequence of dated certificates or fixed retest interval inspected.", "scope": "Creative Peptides describes standard analytical QC and optional biological testing. Those options must be tied to the actual order.", "gaps": "No product-specific external report or contaminant result inspected. Endotoxin-removal capability is not a measured result on every peptide.", "reportReviewed": false, "sources": [ "https://www.creative-peptides.com/services/biological-testing.html", "https://www.creative-peptides.com/services/targeting-peptide-quality-testing-and-purification.html" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Creative Peptides review: HPLC/MS policies, optional biological tests and why endotoxin-removal services are not batch results.", "score": 10 }, { "slug": "proteogenix", "name": "ProteoGenix", "url": "https://us.proteogenix.science/custom-peptide-synthesis/", "kind": "Institutional supplier", "products": [ "Custom peptides", "Modified peptides", "Peptide analysis" ], "note": "ProteoGenix clearly separates standard custom-peptide analytics from optional quantitative and contaminant tests.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "", "sources": [ [ "Official source / access checked", "https://us.proteogenix.science/custom-peptide-synthesis/" ] ], "checked": "2026-09-10", "question": "Do not transfer antibody quality-charter tests to peptides. No actual peptide lot COA or independent laboratory result inspected.", "reviewSections": [ [ "Research scope", "ProteoGenix clearly separates standard custom-peptide analytics from optional quantitative and contaminant tests." ], [ "Testing methods and purification", "Standard custom COAs include HPLC/MS except crude/desalted grades. Gross weight is distinguished from optional net content; additional options cover AAA, water, counterions, solvents and endotoxins." ], [ "How often is testing performed?", "Standard orders receive analytical documentation with stated grade exceptions; no dated lot series or fixed retest interval inspected." ], [ "What remains unverified", "Do not transfer antibody quality-charter tests to peptides. No actual peptide lot COA or independent laboratory result inspected." ] ], "previousScore": 8, "research": { "reviewed": "2026-09-10", "methods": "Standard custom COAs include HPLC/MS except crude/desalted grades. Gross weight is distinguished from optional net content; additional options cover AAA, water, counterions, solvents and endotoxins.", "frequency": "Standard orders receive analytical documentation with stated grade exceptions; no dated lot series or fixed retest interval inspected.", "scope": "ProteoGenix clearly separates standard custom-peptide analytics from optional quantitative and contaminant tests.", "gaps": "Do not transfer antibody quality-charter tests to peptides. No actual peptide lot COA or independent laboratory result inspected.", "reportReviewed": false, "sources": [ "https://us.proteogenix.science/custom-peptide-synthesis/" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "ProteoGenix review: grade-specific HPLC/MS, optional content and contaminant tests, with crude and desalted exceptions.", "score": 10 }, { "slug": "pepscan-biosynth", "name": "Pepscan / Biosynth", "url": "https://www.biosynth.com/peptides", "kind": "Institutional supplier", "products": [ "Custom peptides", "Peptide discovery services" ], "note": "Pepscan is reviewed in its Biosynth group context. The two directory entries are not independent laboratories or independent corroborating sources.", "evidence": "Testing policy / evidence gaps", "levels": [ 0.25, 0, 0, 0, 0.5 ], "lab": "Not verified", "flag": "Parent: Biosynth", "sources": [ [ "Official source / access checked", "https://www.biosynth.com/peptides" ], [ "Testing document — gmp peptides", "https://www.biosynth.com/peptides/gmp-peptides" ] ], "checked": "2026-09-10", "question": "No separate Pepscan lot certificate inspected. A parent-company research COA is not automatically evidence for every Pepscan product or site.", "reviewSections": [ [ "Research scope", "Pepscan is reviewed in its Biosynth group context. The two directory entries are not independent laboratories or independent corroborating sources." ], [ "Testing methods and purification", "Biosynth’s GMP peptide services describe identity, purity, net content, chirality, water/counterions, solvents and microbiological testing. This is parent-group service capability." ], [ "How often is testing performed?", "Release schedules are product/contract-specific; no Pepscan-specific public lot sequence or fixed retest interval inspected." ], [ "What remains unverified", "No separate Pepscan lot certificate inspected. A parent-company research COA is not automatically evidence for every Pepscan product or site." ] ], "previousScore": 2, "research": { "reviewed": "2026-09-10", "methods": "Biosynth’s GMP peptide services describe identity, purity, net content, chirality, water/counterions, solvents and microbiological testing. This is parent-group service capability.", "frequency": "Release schedules are product/contract-specific; no Pepscan-specific public lot sequence or fixed retest interval inspected.", "scope": "Pepscan is reviewed in its Biosynth group context. The two directory entries are not independent laboratories or independent corroborating sources.", "gaps": "No separate Pepscan lot certificate inspected. A parent-company research COA is not automatically evidence for every Pepscan product or site.", "reportReviewed": false, "sources": [ "https://www.biosynth.com/peptides/gmp-peptides" ] }, "measurements": "No product-specific laboratory result was inspected in this research pass. Published methods and service specifications are described below; they are not measured batch results.", "scoreReasons": [ "Named analytical methods are described; no qualifying batch result inspected.", "No inspected external-laboratory report earns credit; in-house QC is not independent testing.", "No qualifying, product-specific contaminant result inspected. Optional capabilities do not earn result points.", "No qualifying measured content or batch-level record inspected.", "Public business/contact and product-use context; no independent audit of the operator." ], "metaDescription": "Pepscan / Biosynth review: Biosynth group analytical services and why parent-company evidence is not independent batch verification.", "score": 10 } ], "articles": [ { "slug": "semaglutide", "title": "Semaglutide", "category": "Metabolic health", "level": "Established clinical evidence", "summary": "A GLP-1 medicine with substantial human evidence. Product and indication matter.", "sections": [ [ "What is Semaglutide?", "GLP-1 receptor agonism links appetite regulation with glucose-dependent insulin signalling. The name identifies an active ingredient; different branded products, formulations and indications have their own evidence and instructions. A research-labelled powder is not the same evaluated product as a prescription medicine." ], [ "What the science shows", "The STEP 1 randomized trial enrolled 1,961 adults with overweight or obesity without diabetes. Over 68 weeks, semaglutide plus lifestyle support produced greater average weight reduction than placebo plus lifestyle support. This is human clinical evidence for the studied population and formulation, not a laboratory-only hypothesis." ], [ "Potential advantages and evidence limits", "The established advantage is a clinically demonstrated effect on weight management in eligible patients. Whether that benefit is worthwhile for an individual depends on their health conditions, treatment goals, tolerability and access to continuing care. Trial averages conceal substantial variation between people." ], [ "Risks, side effects and uncertainty", "Gastrointestinal symptoms, including nausea, vomiting, diarrhoea and constipation, feature in product safety information. Important precautions extend beyond these common symptoms. Read the current product information with a clinician, particularly when other medicines, pregnancy planning or significant gastrointestinal problems are relevant." ], [ "What people report experiencing", "Reports about feeling less hungry or thinking less about food are experiences rather than proof of a particular mechanism in an individual. Structured patient outcomes and adverse-event data are more useful than a selected before-and-after post. A person who stopped treatment because of side effects still belongs in the overall assessment." ], [ "How to evaluate a claim", "Ask which approved product and indication are being discussed, what benefit would count as meaningful, and how response and adverse effects will be reviewed.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "EMA: Wegovy assessment and product information", "https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy" ], [ "FDA: concerns with unapproved GLP-1 drugs", "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" ], [ "Primary study: Semaglutide", "https://pubmed.ncbi.nlm.nih.gov/33567185/" ] ], "checked": "2026-09-10", "faq": [ [ "Does Semaglutide have proven benefits?", "The established advantage is a clinically demonstrated effect on weight management in eligible patients. Whether that benefit is worthwhile for an individual depends on their health conditions, treatment goals, tolerability and access to continuing care. Trial averages conceal substantial variation between people." ], [ "Are user experiences reliable evidence?", "Reports about feeling less hungry or thinking less about food are experiences rather than proof of a particular mechanism in an individual. Structured patient outcomes and adverse-event data are more useful than a selected before-and-after post. A person who stopped treatment because of side effects still belongs in the overall assessment." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "tirzepatide", "title": "Tirzepatide", "category": "Metabolic health", "level": "Established clinical evidence", "summary": "One molecule, two receptor targets: GIP and GLP-1.", "sections": [ [ "What is Tirzepatide?", "Tirzepatide activates GIP and GLP-1 receptors. It is an active ingredient used in prescription products with specific indications. Dual-receptor activity is a pharmacological description, not a guarantee that it is the best option for every person." ], [ "What the science shows", "SURMOUNT-1 randomized 2,539 adults with obesity, or overweight with a weight-related complication, without diabetes. At 72 weeks, the study reported substantially greater average weight reduction with tirzepatide than placebo. The trial included dose escalation and lifestyle support; the result should be interpreted within that treatment programme." ], [ "Potential advantages and evidence limits", "The useful clinical question is whether treatment improves outcomes important to the eligible patient. Weight, glucose regulation, symptoms and tolerability can all matter. Comparing two drugs using unrelated trials is less reliable than a direct head-to-head comparison with matching participants and follow-up." ], [ "Risks, side effects and uncertainty", "Gastrointestinal adverse effects are common in the studied treatment setting. Current product information should be checked for other warnings, contraindications and interactions. Product authenticity, formulation and proper clinical assessment are separate issues from whether the active ingredient has good trial evidence." ], [ "What people report experiencing", "Personal accounts may describe appetite changes, digestive discomfort or differences in daily functioning. Such accounts cannot estimate how often an effect occurs: satisfied users, disappointed users and people who never post are not sampled equally. Do not treat community ratings of a seller as clinical outcomes for tirzepatide." ], [ "How to evaluate a claim", "Ask how the proposed product matches the evidence, what monitoring is needed and what the plan is if treatment is not tolerated.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "EMA: Mounjaro assessment and product information", "https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro" ], [ "FDA: concerns with unapproved GLP-1 drugs", "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" ], [ "Primary study: Tirzepatide", "https://pubmed.ncbi.nlm.nih.gov/35658024/" ] ], "checked": "2026-09-10", "faq": [ [ "Does Tirzepatide have proven benefits?", "The useful clinical question is whether treatment improves outcomes important to the eligible patient. Weight, glucose regulation, symptoms and tolerability can all matter. Comparing two drugs using unrelated trials is less reliable than a direct head-to-head comparison with matching participants and follow-up." ], [ "Are user experiences reliable evidence?", "Personal accounts may describe appetite changes, digestive discomfort or differences in daily functioning. Such accounts cannot estimate how often an effect occurs: satisfied users, disappointed users and people who never post are not sampled equally. Do not treat community ratings of a seller as clinical outcomes for tirzepatide." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "retatrutide", "title": "Retatrutide", "category": "Metabolic health", "level": "Investigational", "summary": "A triple-receptor agonist with promising trial results and unresolved clinical questions.", "sections": [ [ "What is Retatrutide?", "Retatrutide is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. Its three-target mechanism has made it a prominent metabolic research programme. A receptor count does not by itself establish superior long-term health outcomes." ], [ "What the science shows", "The published phase 2 obesity trial provides randomized human evidence of weight reduction over the studied period. Development has since advanced: Lilly reported phase 3 topline results from the TRIUMPH programme in 2026. Topline sponsor announcements should be distinguished from complete peer-reviewed results and regulatory decisions." ], [ "Potential advantages and evidence limits", "The potential advantage is a substantial metabolic effect in the populations under investigation. Questions about durability, cardiovascular outcomes, tolerability, discontinuation and comparison with existing treatments require the relevant trials. Promising development results do not authenticate products advertised by unrelated sellers." ], [ "Risks, side effects and uncertainty", "The clinical programme has reported gastrointestinal adverse events, and the phase 2 work also examined heart-rate changes. Long-term benefit–risk assessment is still an essential part of development. The current sponsor source describes retatrutide as investigational; retail availability does not establish authorization." ], [ "What people report experiencing", "Online descriptions of research-vial experiences cannot confirm that the vial contained trial-grade retatrutide or that an observed change was caused by it. These stories are unsuitable for estimating a safe dose or predicting a personal result. We do not publish invented testimonials or a synthesized community consensus." ], [ "How to evaluate a claim", "Ask whether a claim comes from a trial publication, a sponsor announcement or an unrelated vendor, and check the date.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "Jastreboff et al.: phase 2 retatrutide trial", "https://pubmed.ncbi.nlm.nih.gov/37366315/" ], [ "FDA: concerns with unapproved GLP-1 drugs", "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" ], [ "Primary study: Retatrutide", "https://pubmed.ncbi.nlm.nih.gov/37366315/" ], [ "Lilly: current retatrutide development status (sponsor source)", "https://www.lilly.com/news/stories/what-to-know-about-retatrutide" ] ], "checked": "2026-09-10", "faq": [ [ "Does Retatrutide have proven benefits?", "The potential advantage is a substantial metabolic effect in the populations under investigation. Questions about durability, cardiovascular outcomes, tolerability, discontinuation and comparison with existing treatments require the relevant trials. Promising development results do not authenticate products advertised by unrelated sellers." ], [ "Are user experiences reliable evidence?", "Online descriptions of research-vial experiences cannot confirm that the vial contained trial-grade retatrutide or that an observed change was caused by it. These stories are unsuitable for estimating a safe dose or predicting a personal result. We do not publish invented testimonials or a synthesized community consensus." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "liraglutide", "title": "Liraglutide", "category": "Metabolic health", "level": "Established clinical evidence", "summary": "A GLP-1 analogue used in approved prescription medicines.", "sections": [ [ "What is Liraglutide?", "Liraglutide is a GLP-1 receptor agonist used in prescription medicines. It affects glucose regulation and appetite-related signalling. Indications and product formulations matter when interpreting the same ingredient name across diabetes and weight-management discussions." ], [ "What the science shows", "The SCALE Obesity and Prediabetes randomized trial evaluated liraglutide alongside diet and activity support. It found greater weight loss and improvements in metabolic measures than placebo in its study population. This is a controlled treatment comparison, rather than evidence derived from customer reviews." ], [ "Potential advantages and evidence limits", "Its advantage is an established clinical evidence base for specific uses. An older medicine may still be appropriate when treatment needs, tolerability, availability and patient preference are considered. Ranking medicines only by the largest weight-loss percentage ignores these practical differences." ], [ "Risks, side effects and uncertainty", "Current product information describes gastrointestinal side effects and additional precautions. Suitability requires attention to the actual patient and other treatments. A brief guide cannot reproduce every contraindication, and a seller’s purity certificate has no role in replacing a prescribing assessment." ], [ "What people report experiencing", "Individual stories about hunger, eating patterns or digestive symptoms may help people describe questions to a clinician. They do not establish the expected response for another person. Useful accounts mention duration, formulation, other changes and why treatment was continued or stopped." ], [ "How to evaluate a claim", "Ask what outcome is being targeted and how the proposed medicine compares with alternatives for that specific goal.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "EMA: Saxenda assessment and product information", "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda" ], [ "Primary study: Liraglutide", "https://pubmed.ncbi.nlm.nih.gov/26132939/" ] ], "checked": "2026-09-10", "faq": [ [ "Does Liraglutide have proven benefits?", "Its advantage is an established clinical evidence base for specific uses. An older medicine may still be appropriate when treatment needs, tolerability, availability and patient preference are considered. Ranking medicines only by the largest weight-loss percentage ignores these practical differences." ], [ "Are user experiences reliable evidence?", "Individual stories about hunger, eating patterns or digestive symptoms may help people describe questions to a clinician. They do not establish the expected response for another person. Useful accounts mention duration, formulation, other changes and why treatment was continued or stopped." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "bpc-157", "title": "BPC-157", "category": "Repair research", "level": "Limited human evidence", "summary": "A repair-research peptide whose popularity exceeds the strength of its clinical evidence.", "sections": [ [ "What is BPC-157?", "BPC-157 is a synthetic peptide investigated in experimental models of tissue injury and repair. Its popular reputation extends well beyond the scope of the human evidence. References to a biological pathway or animal recovery should be read as research findings with a defined model." ], [ "What the science shows", "A published 2025 intravenous pilot is a very small human safety investigation, not a randomized demonstration of tendon, gut or joint healing. Other early human reports and extensive preclinical work do not together provide the same certainty as adequately powered controlled clinical trials." ], [ "Potential advantages and evidence limits", "Tissue-repair and gastrointestinal claims are hypotheses worth studying. The relevant advantage has not been established for routine self-treatment by the sources assessed here. A convincing study would specify the injury, comparator, outcome measurement and follow-up before looking at the results." ], [ "Risks, side effects and uncertainty", "The absence of a well-characterized adverse-event rate is an uncertainty, not a zero-risk finding. Small and short studies cannot reliably detect uncommon or delayed harms. Route, formulation, peptide-related impurities and product quality also limit transfer of findings between research settings." ], [ "What people report experiencing", "A person may sincerely report less pain after BPC-157 while natural recovery, rehabilitation, other treatment and changing activity explain part or all of the improvement. Without a comparison group, the counterfactual remains unknown. Pain relief also does not automatically establish structural healing." ], [ "How to evaluate a claim", "Ask for controlled human evidence for the exact injury claim, rather than a list of animal studies or customer success stories.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "BPC-157: effects in isolated human artery tissue", "https://pubmed.ncbi.nlm.nih.gov/42123221/" ], [ "FDA: peptide compounding safety concerns", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ], [ "Primary study: BPC-157", "https://pubmed.ncbi.nlm.nih.gov/40131143/" ] ], "checked": "2026-09-10", "faq": [ [ "Does BPC-157 have proven benefits?", "Tissue-repair and gastrointestinal claims are hypotheses worth studying. The relevant advantage has not been established for routine self-treatment by the sources assessed here. A convincing study would specify the injury, comparator, outcome measurement and follow-up before looking at the results." ], [ "Are user experiences reliable evidence?", "A person may sincerely report less pain after BPC-157 while natural recovery, rehabilitation, other treatment and changing activity explain part or all of the improvement. Without a comparison group, the counterfactual remains unknown. Pain relief also does not automatically establish structural healing." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "tb-500", "title": "TB-500 / thymosin beta-4", "category": "Repair research", "level": "Preclinical / limited", "summary": "Names that are often used interchangeably can refer to different materials.", "sections": [ [ "What is TB-500 / thymosin beta-4?", "TB-500 is a marketing and research label that is often linked to thymosin beta-4. The exact sequence matters: full-length thymosin beta-4 and a fragment are not interchangeable research materials. A name on a vial is insufficient to determine which molecule a study investigated." ], [ "What the science shows", "A randomized phase 2 trial studied thymosin beta-4 eye drops for severe dry eye. That is a specific ophthalmic formulation and indication. It does not demonstrate that an injectable product sold as TB-500 repairs a tendon or improves athletic recovery." ], [ "Potential advantages and evidence limits", "Thymosin-related biology creates legitimate research questions around tissue responses. The practical advantage claimed in sports and recovery marketing requires direct human evidence for the same sequence and route. Evidence cannot be transferred solely because two names are associated online." ], [ "Risks, side effects and uncertainty", "Human safety data for one preparation do not establish the safety profile of every fragment, blend or route. Long-term and systemic effects require their own investigation. Supplier reports should identify the actual sequence and mass rather than relying only on the label TB-500." ], [ "What people report experiencing", "Recovery stories commonly involve several simultaneous changes. Training load, rest, rehabilitation and symptom fluctuation all need consideration. We have not assembled a verified, representative dataset of TB-500 user outcomes, so no frequency or typical benefit is claimed here." ], [ "How to evaluate a claim", "Ask whether the cited paper studied the exact peptide, formulation and outcome being advertised.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "FDA: peptide compounding safety concerns", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ], [ "Primary study: TB-500 / thymosin beta-4", "https://pubmed.ncbi.nlm.nih.gov/25826322/" ] ], "checked": "2026-09-10", "faq": [ [ "Does TB-500 / thymosin beta-4 have proven benefits?", "Thymosin-related biology creates legitimate research questions around tissue responses. The practical advantage claimed in sports and recovery marketing requires direct human evidence for the same sequence and route. Evidence cannot be transferred solely because two names are associated online." ], [ "Are user experiences reliable evidence?", "Recovery stories commonly involve several simultaneous changes. Training load, rest, rehabilitation and symptom fluctuation all need consideration. We have not assembled a verified, representative dataset of TB-500 user outcomes, so no frequency or typical benefit is claimed here." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "ghk-cu", "title": "GHK-Cu", "category": "Skin research", "level": "Route-dependent evidence", "summary": "A copper-binding tripeptide studied in skin and tissue biology.", "sections": [ [ "What is GHK-Cu?", "GHK-Cu is a copper complex of the tripeptide glycyl-histidyl-lysine. It appears in skin-related research and cosmetic discussions. The copper complex, uncomplexed GHK and a complete cosmetic formulation are distinct things to evaluate." ], [ "What the science shows", "A primary study examined delivery of copper peptide through human skin using microneedles. This was a delivery experiment, not a trial proving anti-ageing benefit in people. It illustrates why route and formulation affect what a molecule can reach and why laboratory findings need careful translation." ], [ "Potential advantages and evidence limits", "The plausible research interest concerns skin biology and formulation development. Claims about visible cosmetic improvement should be supported by controlled studies of the actual finished product. Findings for topical formulations cannot establish benefits from systemic administration." ], [ "Risks, side effects and uncertainty", "A short ingredient label does not reveal the full formulation, exposure or tolerability profile. Local skin reactions and systemic questions belong to different assessments. We do not infer that copper-related biology makes every GHK-Cu product beneficial or harmless." ], [ "What people report experiencing", "Before-and-after photographs depend on lighting, camera processing, skincare changes and time. A more informative cosmetic study standardizes photography and uses blinded assessment and a comparator. Personal satisfaction is worth describing but should not be presented as proof of collagen change." ], [ "How to evaluate a claim", "Ask whether the evidence concerns intact skin, a delivery device, cultured cells or a finished cosmetic product tested in people.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "FDA: peptide compounding safety concerns", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ], [ "Primary study: GHK-Cu", "https://pubmed.ncbi.nlm.nih.gov/25690343/" ] ], "checked": "2026-09-10", "faq": [ [ "Does GHK-Cu have proven benefits?", "The plausible research interest concerns skin biology and formulation development. Claims about visible cosmetic improvement should be supported by controlled studies of the actual finished product. Findings for topical formulations cannot establish benefits from systemic administration." ], [ "Are user experiences reliable evidence?", "Before-and-after photographs depend on lighting, camera processing, skincare changes and time. A more informative cosmetic study standardizes photography and uses blinded assessment and a comparator. Personal satisfaction is worth describing but should not be presented as proof of collagen change." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "cjc-1295", "title": "CJC-1295", "category": "Hormone research", "level": "Early human trials", "summary": "A growth-hormone-releasing hormone analogue with important naming differences.", "sections": [ [ "What is CJC-1295?", "CJC-1295 is a growth-hormone-releasing hormone analogue. The long-acting compound studied in early trials must be distinguished from products labelled no-DAC or combined with other peptides. Similar commercial naming does not establish identical pharmacology." ], [ "What the science shows", "A randomized study in healthy adults found prolonged increases in growth hormone and IGF-I after the long-acting compound. These were endocrine measurements. They do not by themselves demonstrate better strength, sleep, recovery, longevity or clinical health." ], [ "Potential advantages and evidence limits", "The demonstrated signal is stimulation of the GH/IGF-I axis under study conditions. Whether changing that signal produces a worthwhile benefit requires a separate trial with patient-relevant outcomes. Higher hormone measurements should not automatically be interpreted as improvement." ], [ "Risks, side effects and uncertainty", "Early studies cannot settle long-term safety or the effects of repeated unregulated combinations. The studied preparation, participant selection and monitoring matter. A result for CJC-1295 alone cannot be assumed to describe a blend with ipamorelin." ], [ "What people report experiencing", "Accounts of improved sleep or recovery are subjective and can be influenced by training, expectations and other treatments. Tracking an experience more carefully can improve its description, but it still does not recreate randomization or establish causality." ], [ "How to evaluate a claim", "Ask which exact CJC-1295 formulation was studied and whether the reported endpoint was a hormone measurement or a meaningful health outcome.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "CJC-1295: human GH pulsatility study", "https://pubmed.ncbi.nlm.nih.gov/17018654/" ], [ "Primary study: CJC-1295", "https://pubmed.ncbi.nlm.nih.gov/16352683/" ] ], "checked": "2026-09-10", "faq": [ [ "Does CJC-1295 have proven benefits?", "The demonstrated signal is stimulation of the GH/IGF-I axis under study conditions. Whether changing that signal produces a worthwhile benefit requires a separate trial with patient-relevant outcomes. Higher hormone measurements should not automatically be interpreted as improvement." ], [ "Are user experiences reliable evidence?", "Accounts of improved sleep or recovery are subjective and can be influenced by training, expectations and other treatments. Tracking an experience more carefully can improve its description, but it still does not recreate randomization or establish causality." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "ipamorelin", "title": "Ipamorelin", "category": "Hormone research", "level": "Limited human evidence", "summary": "A growth-hormone secretagogue studied through the ghrelin receptor pathway.", "sections": [ [ "What is Ipamorelin?", "Ipamorelin acts at the ghrelin receptor and is commonly described as a growth-hormone secretagogue. That mechanism has led to research in gastrointestinal motility as well as interest in endocrine effects. A mechanistic description does not establish a wellness indication." ], [ "What the science shows", "A phase 2 randomized proof-of-concept study investigated ipamorelin for postoperative ileus after bowel resection. This is evidence from a surgical population and a specific route. It should not be represented as a trial of muscle gain, sleep improvement or anti-ageing use in healthy people." ], [ "Potential advantages and evidence limits", "The appropriate scientific advantage to investigate depends on the target condition. A programme aimed at postoperative bowel function asks different questions from a consumer recovery claim. Demonstrating receptor activity is only an early step in that chain." ], [ "Risks, side effects and uncertainty", "Adverse events in surgical patients require careful assessment because the underlying illness and operation also carry risks. Conversely, describing a trial as tolerated cannot establish safety for long-term use in another population. Full study tables and the product context matter." ], [ "What people report experiencing", "People may describe appetite, sleep or recovery changes while using combinations. Such reports cannot isolate ipamorelin from another peptide or a change in routine. Our supplier comments concern customer experience and are not treated as an efficacy database." ], [ "How to evaluate a claim", "Ask whether the human study supports the advertised purpose and whether the preparation and route match.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "FDA: peptide compounding safety concerns", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ], [ "Primary study: Ipamorelin", "https://pubmed.ncbi.nlm.nih.gov/25331030/" ] ], "checked": "2026-09-10", "faq": [ [ "Does Ipamorelin have proven benefits?", "The appropriate scientific advantage to investigate depends on the target condition. A programme aimed at postoperative bowel function asks different questions from a consumer recovery claim. Demonstrating receptor activity is only an early step in that chain." ], [ "Are user experiences reliable evidence?", "People may describe appetite, sleep or recovery changes while using combinations. Such reports cannot isolate ipamorelin from another peptide or a change in routine. Our supplier comments concern customer experience and are not treated as an efficacy database." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "tesamorelin", "title": "Tesamorelin", "category": "Hormone research", "level": "Clinical, specific population", "summary": "Human evidence concerns specific medical populations, not general fat-loss promises.", "sections": [ [ "What is Tesamorelin?", "Tesamorelin is a growth-hormone-releasing hormone analogue with a specific clinical context in HIV-associated excess abdominal fat. Its name frequently appears in general body-composition marketing, where the population distinction can disappear." ], [ "What the science shows", "A randomized trial assessed visceral and liver fat in people with HIV and abdominal fat accumulation. It supports discussion of the studied outcomes in that population. It does not establish an unrestricted fat-loss or longevity indication for healthy adults." ], [ "Potential advantages and evidence limits", "The important distinction is between a defined clinical problem and a generic desire to reduce body fat. A treatment can have useful evidence for the first without being justified for the second. Visceral fat, liver fat and total body weight are also different measurements." ], [ "Risks, side effects and uncertainty", "Changes in the GH/IGF-I axis require clinical context and monitoring. Current prescribing information, including metabolic precautions and contraindications, should guide assessment of an approved medicine. Research retail preparations do not inherit the quality assurance of the clinical product." ], [ "What people report experiencing", "Anecdotes about a smaller waist do not identify whether visceral fat changed, whether body weight changed or what other factors contributed. Objective measurement and a comparator make a clinical study more informative than a single self-report." ], [ "How to evaluate a claim", "Ask whether the individual and target outcome match the studied indication and how the relevant outcome would be measured.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "Stanley et al.: randomized tesamorelin trial", "https://pubmed.ncbi.nlm.nih.gov/25038357/" ], [ "Primary study: Tesamorelin", "https://pubmed.ncbi.nlm.nih.gov/25038357/" ] ], "checked": "2026-09-10", "faq": [ [ "Does Tesamorelin have proven benefits?", "The important distinction is between a defined clinical problem and a generic desire to reduce body fat. A treatment can have useful evidence for the first without being justified for the second. Visceral fat, liver fat and total body weight are also different measurements." ], [ "Are user experiences reliable evidence?", "Anecdotes about a smaller waist do not identify whether visceral fat changed, whether body weight changed or what other factors contributed. Objective measurement and a comparator make a clinical study more informative than a single self-report." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "mots-c", "title": "MOTS-c", "category": "Longevity research", "level": "Mostly preclinical", "summary": "A mitochondrial-derived peptide at the intersection of metabolism and exercise.", "sections": [ [ "What is MOTS-c?", "MOTS-c is a mitochondrial-derived peptide studied in metabolic signalling and responses to stress and exercise. A naturally occurring molecule can be biologically interesting without external administration being an established treatment." ], [ "What the science shows", "Reynolds and colleagues reported effects on physical performance in mice and studied exercise-associated changes in humans. Measuring an endogenous peptide after exercise in people is not the same experiment as giving the peptide to people and demonstrating clinical benefit." ], [ "Potential advantages and evidence limits", "The potential research advantage is insight into muscle and metabolic adaptation. Claims of an exercise replacement, predictable fat loss or human rejuvenation exceed what the cited experimental work establishes. Translation requires appropriate human intervention trials." ], [ "Risks, side effects and uncertainty", "Without a mature human intervention evidence base, reliable frequencies of adverse effects and long-term outcomes are not established. Analogue studies, endogenous blood measurements and mouse dosing should not be merged into a single human safety claim." ], [ "What people report experiencing", "Energy and exercise-performance stories are especially sensitive to training, sleep, motivation, nutrition and measurement conditions. A controlled performance test is more informative than a perceived energetic day. We do not infer a typical user experience from selected posts." ], [ "How to evaluate a claim", "Ask whether a source administered MOTS-c to humans or merely measured the peptide in human samples.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "Reynolds et al.: MOTS-c, exercise and muscle homeostasis", "https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689/" ] ], "checked": "2026-09-10", "faq": [ [ "Does MOTS-c have proven benefits?", "The potential research advantage is insight into muscle and metabolic adaptation. Claims of an exercise replacement, predictable fat loss or human rejuvenation exceed what the cited experimental work establishes. Translation requires appropriate human intervention trials." ], [ "Are user experiences reliable evidence?", "Energy and exercise-performance stories are especially sensitive to training, sleep, motivation, nutrition and measurement conditions. A controlled performance test is more informative than a perceived energetic day. We do not infer a typical user experience from selected posts." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "thymosin-alpha-1", "title": "Thymosin alpha-1", "category": "Immune research", "level": "Clinical, context-specific", "summary": "An immune-modulating peptide whose evidence depends on the disease being studied.", "sections": [ [ "What is Thymosin alpha-1?", "Thymosin alpha-1 is an immune-modulating peptide investigated in several disease settings. Immunity is not a single dial that should always be turned upward. The relevant question is the clinical condition, immune state and measured outcome." ], [ "What the science shows", "The 2025 TESTS study was a multicentre, double-blind, randomized phase 3 sepsis trial. It did not establish a significant reduction in the primary 28-day mortality outcome overall. A large controlled result deserves attention even when earlier or smaller studies looked promising." ], [ "Potential advantages and evidence limits", "Potential benefits must be assessed separately for each indication and jurisdiction. Evidence in critically ill patients does not establish routine infection prevention or general immune enhancement in healthy people. Subgroup findings need a different level of confidence from a prespecified primary result." ], [ "Risks, side effects and uncertainty", "Sepsis trial safety information belongs to a medically supervised, severely ill population. It cannot define the long-term effects of elective use in another setting. Regulatory status and prescribing practice also differ across countries and should be checked locally." ], [ "What people report experiencing", "Reports of fewer infections are difficult to interpret without comparable observation time and exposure. A mild winter or changed work routine can alter infection frequency. Community experience is useful for identifying questions, not for replacing controlled prevention studies." ], [ "How to evaluate a claim", "Ask for the primary outcome and the exact population, and check whether a favourable claim is based on a post-hoc subgroup.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "TESTS: phase 3 thymosin alpha-1 sepsis trial", "https://pubmed.ncbi.nlm.nih.gov/39814420/" ], [ "Primary study: Thymosin alpha-1", "https://pubmed.ncbi.nlm.nih.gov/39814420/" ] ], "checked": "2026-09-10", "faq": [ [ "Does Thymosin alpha-1 have proven benefits?", "Potential benefits must be assessed separately for each indication and jurisdiction. Evidence in critically ill patients does not establish routine infection prevention or general immune enhancement in healthy people. Subgroup findings need a different level of confidence from a prespecified primary result." ], [ "Are user experiences reliable evidence?", "Reports of fewer infections are difficult to interpret without comparable observation time and exposure. A mild winter or changed work routine can alter infection frequency. Community experience is useful for identifying questions, not for replacing controlled prevention studies." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "pt-141", "title": "PT-141 / bremelanotide", "category": "Sexual health", "level": "Clinical, specific population", "summary": "A melanocortin receptor agonist studied for a defined sexual-health indication.", "sections": [ [ "What is PT-141 / bremelanotide?", "PT-141 is another name for bremelanotide, a melanocortin-receptor agonist. Clinical evidence concerns specific sexual-health indications and populations. Sexual desire, distress and erectile function are related but distinct outcomes." ], [ "What the science shows", "The RECONNECT programme included two randomized phase 3 trials in premenopausal women with acquired, generalized hypoactive sexual desire disorder. The studies evaluated desire and associated distress. Those findings should not be converted into a universal sexual-performance claim for everyone." ], [ "Potential advantages and evidence limits", "The clinical question is whether the treatment improves the defined condition in an eligible person. Patient-reported outcomes are particularly relevant here, but they are collected using structured instruments within controlled trials rather than selected online testimonials." ], [ "Risks, side effects and uncertainty", "Nausea, flushing and headache were prominent in the clinical programme. Product information includes additional considerations, including cardiovascular suitability. A research vial with the same ingredient name is not an interchangeable approved treatment." ], [ "What people report experiencing", "Experiences of desire or satisfaction are personal and contextual. Trial questionnaires can capture meaningful experience while still using a comparator. A seller rating cannot tell whether a sexual-health intervention is appropriate or likely to help a particular individual." ], [ "How to evaluate a claim", "Ask which symptom is being treated, how it has been assessed and whether the evidence applies to that person.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "RECONNECT: bremelanotide phase 3 studies", "https://www.acog.org/education-and-events/creog/curriculum-resources/-/media/a290a66be12d44aba1954ce4ad508bd7.ashx" ], [ "RECONNECT randomized phase 3 trials", "https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/" ] ], "checked": "2026-09-10", "faq": [ [ "Does PT-141 / bremelanotide have proven benefits?", "The clinical question is whether the treatment improves the defined condition in an eligible person. Patient-reported outcomes are particularly relevant here, but they are collected using structured instruments within controlled trials rather than selected online testimonials." ], [ "Are user experiences reliable evidence?", "Experiences of desire or satisfaction are personal and contextual. Trial questionnaires can capture meaningful experience while still using a comparator. A seller rating cannot tell whether a sexual-health intervention is appropriate or likely to help a particular individual." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "epitalon", "title": "Epitalon", "category": "Longevity research", "level": "Insufficient clinical evidence", "summary": "Telomere-related claims should not be mistaken for demonstrated life extension.", "sections": [ [ "What is Epitalon?", "Epitalon, also spelled epithalon, is a synthetic tetrapeptide studied in ageing-related biology. The name is sometimes used alongside different pineal preparations; evidence should remain attached to the actual tested substance." ], [ "What the science shows", "A 2025 laboratory paper examined telomere-related changes in normal and cancer cell lines. It provides cell-level findings, not evidence that people live longer or develop fewer age-related diseases. The publication record includes a correction, which should be read with the original paper." ], [ "Potential advantages and evidence limits", "Telomere biology is a legitimate research area, but a change in one cellular measurement is not equivalent to improved healthspan. A useful longevity claim would require outcomes such as function, disease burden or survival in an appropriate human study." ], [ "Risks, side effects and uncertainty", "Long-term safety is not established by cell survival or a favourable biomarker. Telomere-maintenance mechanisms are relevant to both normal cells and cancer biology, making simplistic good-or-bad conclusions inappropriate. The cited work does not prove either human cancer prevention or human cancer causation." ], [ "What people report experiencing", "Claims of better sleep, energy or a younger biological age need independent evaluation. Commercial biological-age outputs are not interchangeable with demonstrated lifespan extension. We have no verified representative sample from which to estimate a typical epitalon experience." ], [ "How to evaluate a claim", "Ask whether the outcome was measured in cultured cells, animals or treated people, and whether it predicts an actual health benefit.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "FDA: peptide compounding safety concerns", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ], [ "Primary study: Epitalon", "https://pubmed.ncbi.nlm.nih.gov/40908429/" ] ], "checked": "2026-09-10", "faq": [ [ "Does Epitalon have proven benefits?", "Telomere biology is a legitimate research area, but a change in one cellular measurement is not equivalent to improved healthspan. A useful longevity claim would require outcomes such as function, disease burden or survival in an appropriate human study." ], [ "Are user experiences reliable evidence?", "Claims of better sleep, energy or a younger biological age need independent evaluation. Commercial biological-age outputs are not interchangeable with demonstrated lifespan extension. We have no verified representative sample from which to estimate a typical epitalon experience." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "kpv", "title": "KPV", "category": "Immune research", "level": "Preclinical", "summary": "A three-amino-acid fragment studied in inflammation models.", "sections": [ [ "What is KPV?", "KPV is the tripeptide lysine-proline-valine, associated with the C-terminal sequence of alpha-melanocyte-stimulating hormone. Research has investigated its anti-inflammatory activity and transport through peptide transport systems." ], [ "What the science shows", "A 2008 study investigated PepT1-mediated uptake in cell experiments and tested KPV in mouse colitis models. These results support a preclinical research hypothesis. They do not establish an effective treatment for inflammatory bowel disease in humans." ], [ "Potential advantages and evidence limits", "The potential advantage is a targeted research approach to inflammatory pathways. The distance from a cell response to a useful medicine includes delivery, exposure, dose finding, safety and controlled clinical outcomes. Those steps cannot be replaced by a mechanistic diagram." ], [ "Risks, side effects and uncertainty", "Human adverse-event frequencies and long-term outcomes are not adequately characterized by the cited preclinical work. The absence of published complications in a small or nonhuman dataset should not be interpreted as an established safety profile." ], [ "What people report experiencing", "Gastrointestinal symptoms fluctuate and can change with diet, stress, infection and existing treatments. A report of improvement after KPV does not establish which factor caused it. Community anecdotes are not a substitute for clinical diagnosis or a controlled treatment comparison." ], [ "How to evaluate a claim", "Ask for human intervention evidence with a defined diagnosis and validated outcome before treating a gut-health claim as established.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "FDA: peptide compounding safety concerns", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ], [ "Primary study: KPV", "https://pubmed.ncbi.nlm.nih.gov/18061177/" ] ], "checked": "2026-09-10", "faq": [ [ "Does KPV have proven benefits?", "The potential advantage is a targeted research approach to inflammatory pathways. The distance from a cell response to a useful medicine includes delivery, exposure, dose finding, safety and controlled clinical outcomes. Those steps cannot be replaced by a mechanistic diagram." ], [ "Are user experiences reliable evidence?", "Gastrointestinal symptoms fluctuate and can change with diet, stress, infection and existing treatments. A report of improvement after KPV does not establish which factor caused it. Community anecdotes are not a substitute for clinical diagnosis or a controlled treatment comparison." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "aod-9604", "title": "AOD-9604", "category": "Metabolic health", "level": "Insufficient clinical evidence", "summary": "A modified growth-hormone fragment marketed well beyond what is established.", "sections": [ [ "What is AOD-9604?", "AOD-9604 is a modified fragment related to human growth hormone, investigated for metabolic effects. Being a fragment does not establish that it retains only desirable effects or that it has no meaningful risks." ], [ "What the science shows", "FDA advisory-committee briefing material reviews the clinical development record, including obesity studies. The existence of early studies should not be confused with a proven, approved weight-loss treatment. Full trial outcomes matter more than selecting one favourable experimental result.\n\nAn original 2001 study investigated lipid metabolism in obese and receptor-knockout mice. It supports a preclinical mechanism discussion, not a demonstrated human weight-loss benefit." ], [ "Potential advantages and evidence limits", "The proposed advantage is an effect on fat metabolism without simply administering full-length growth hormone. That is a development hypothesis. It requires persuasive clinical outcome data and does not follow automatically from how the molecule was designed." ], [ "Risks, side effects and uncertainty", "Safety depends on the exact material, route, exposure and population. Claims such as side-effect-free or safe because it is a fragment are not justified by the sources assessed here. Incomplete characterization should remain visible instead of being replaced with a reassuring percentage." ], [ "What people report experiencing", "Weight-change accounts are particularly vulnerable to concurrent dietary changes and regression to the mean. They rarely provide a reliable comparator or a denominator that includes people who experienced no benefit. We do not present these stories as trial evidence." ], [ "How to evaluate a claim", "Ask whether the cited study demonstrated a meaningful clinical difference and whether its result was confirmed in later development.\n\nStart with the original publication below. Check the participants, comparator, formulation, outcome and follow-up. Separate what the authors measured from what a seller or social post says the finding means. A result can be statistically significant while its practical importance remains limited." ], [ "Product quality is a separate question", "Clinical evidence concerns a defined intervention. Supplier evidence concerns a defined sample. Neither replaces the other. A purity percentage is not a clinical endorsement; an interesting study does not authenticate a product. Use the supplier reviews below to examine documentation, then read the methodology to understand what a documentary score can and cannot establish." ] ], "sources": [ [ "FDA: peptide compounding safety concerns", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ], [ "FDA advisory committee briefing: AOD-9604 evidence", "https://www.fda.gov/media/183584/download" ], [ "Primary AOD-9604 mouse metabolism study (not a human trial)", "https://pubmed.ncbi.nlm.nih.gov/11713213/" ] ], "checked": "2026-09-10", "faq": [ [ "Does AOD-9604 have proven benefits?", "The proposed advantage is an effect on fat metabolism without simply administering full-length growth hormone. That is a development hypothesis. It requires persuasive clinical outcome data and does not follow automatically from how the molecule was designed." ], [ "Are user experiences reliable evidence?", "Weight-change accounts are particularly vulnerable to concurrent dietary changes and regression to the mean. They rarely provide a reliable comparator or a denominator that includes people who experienced no benefit. We do not present these stories as trial evidence." ], [ "Does a high-purity certificate prove safety?", "No. A sample certificate and clinical safety answer different questions. Identity, quantity, contaminants, formulation and clinical evidence must be assessed separately." ] ] }, { "slug": "purity-is-not-safety", "title": "99% pure. But pure of what?", "category": "Quality guide", "level": "Start here", "summary": "The number on the label is only one part of the evidence.", "sections": [ [ "What it is", "HPLC separates compounds under a particular method. A peak-area percentage describes the detected signal assigned to a component; it is not the percentage of the vial that is safe." ], [ "What the evidence tells us", "Water, counterions and some contaminants may not be captured by the same measurement. Identity needs complementary analysis, and net peptide content is a separate quantity." ], [ "What remains uncertain", "Ask for the chromatogram, method, identity data, quantity, lot and separate contaminant panels. A high number does not demonstrate sterility or the absence of every harmful impurity." ] ], "sources": [ [ "GenScript: peptide quality control", "https://www.genscript.com/peptide_quality.html" ], [ "FDA: pyrogen and endotoxin testing", "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers" ] ], "checked": "2026-09-10" }, { "slug": "read-a-coa", "title": "How to read a peptide COA", "category": "Quality guide", "level": "Practical checklist", "summary": "Follow the sample, the method and the evidence back to their source.", "sections": [ [ "What it is", "Start with the exact molecule, sequence or salt, sample ID, lot, stated quantity, report date and laboratory. A logo and signature alone do not authenticate a document." ], [ "What the evidence tells us", "Find the test method, result, units, specification and reporting limit. Check whether a report concerns raw powder, a final vial or a different submitted sample. Prefer laboratory-side verification." ], [ "What remains uncertain", "Vendor-selected samples can be unrepresentative. A verified report proves what was reported about the tested sample, not every vial shipped. Record discrepancies and request clarification before drawing a conclusion." ] ], "sources": [ [ "GenScript: peptide quality control", "https://www.genscript.com/peptide_quality.html" ] ], "checked": "2026-09-10" }, { "slug": "endotoxins-and-sterility", "title": "Endotoxins ≠ sterility", "category": "Quality guide", "level": "Two different questions", "summary": "A product can pass one test and fail the other.", "sections": [ [ "What it is", "Sterility testing looks for viable organisms under defined conditions. Endotoxin testing measures bacterial components capable of causing pyrogenic reactions. Bioburden is another distinct test." ], [ "What the evidence tells us", "The tests use different methods and acceptance criteria. Results need units, sample preparation, detection limits and evidence that the sample did not interfere with the method." ], [ "What remains uncertain", "“Not detected” means below that method’s reporting limit. It does not mean zero. Neither a purity percentage nor a single negative microbial result certifies a product’s overall safety." ] ], "sources": [ [ "FDA: pyrogen and endotoxin testing", "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers" ] ], "checked": "2026-09-10" }, { "slug": "purification-and-residues", "title": "What better purification should prove", "category": "Quality guide", "level": "Beyond marketing", "summary": "Reward measured outcomes, not an expensive-sounding manufacturing story.", "sections": [ [ "What it is", "Peptide synthesis can leave related sequences, reagents, solvents and counterions. Purification separates the desired material, but each process has specific capabilities and limitations." ], [ "What the evidence tells us", "Preparative chromatography is a manufacturing step; analytical chromatography evaluates a sample. Evidence of solvent control, elemental impurities and related-species characterization adds information a purity headline misses." ], [ "What remains uncertain", "Price and claims of multiple purification rounds are not proof of a cleaner product. Residual-solvent limits depend on the substance and exposure. Use the applicable specification and validated method." ] ], "sources": [ [ "FDA / ICH: residual solvents", "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-tables-and-list-rev-4" ], [ "GenScript: peptide quality control", "https://www.genscript.com/peptide_quality.html" ] ], "checked": "2026-09-10" }, { "slug": "research-vs-medicine", "title": "Research peptide or approved medicine?", "category": "Evidence guide", "level": "Know the difference", "summary": "The molecule’s name does not establish the product’s medical status.", "sections": [ [ "What it is", "A research chemical, an active pharmaceutical ingredient and a finished prescription medicine are different products. A COA cannot substitute for clinical evaluation and regulated manufacturing." ], [ "What the evidence tells us", "An approved medicine has a defined formulation, intended use and product information. A research supplier can sell a molecule with the same name without establishing equivalence." ], [ "What remains uncertain", "For Cyprus and the EU, consult EMA product information and the relevant national authority. US FDA statements describe the US context. A directory listing is not confirmation of local legality, import eligibility or medical suitability." ] ], "sources": [ [ "EMA: Wegovy assessment and product information", "https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy" ], [ "FDA: concerns with unapproved GLP-1 drugs", "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" ] ], "checked": "2026-09-10" }, { "slug": "evidence-ladder", "title": "From a promising molecule to a proven benefit", "category": "Evidence guide", "level": "Read research better", "summary": "Mechanisms, biomarkers and patient outcomes answer different questions.", "sections": [ [ "What it is", "A cell experiment can reveal a mechanism. An animal study can test a hypothesis in a living system. Observational human data can find associations. Randomized trials can help determine treatment effects." ], [ "What the evidence tells us", "Read the population, comparator, sample size, endpoint, follow-up and adverse events. An improvement in a biomarker may not improve symptoms, function or survival." ], [ "What remains uncertain", "A small positive trial needs replication. Negative results matter. Avoid transferring findings between species, routes, sequences or formulations without supporting evidence." ] ], "sources": [ [ "Reynolds et al.: MOTS-c, exercise and muscle homeostasis", "https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689/" ], [ "CJC-1295: human GH pulsatility study", "https://pubmed.ncbi.nlm.nih.gov/17018654/" ], [ "Jastreboff et al.: phase 2 retatrutide trial", "https://pubmed.ncbi.nlm.nih.gov/37366315/" ] ], "checked": "2026-09-10" }, { "slug": "bpc-157-evidence-and-recovery-claims", "title": "BPC-157 and Recovery Claims: What the Evidence Can Actually Tell You", "summary": "BPC-157 attracts strong interest in injury recovery. The central question is how far experimental findings support the claims made about people.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "Begin with the exact recovery claim", "Recovery is a broad word. It can mean less pain, greater range of motion, a return to training, structural repair or simply feeling better. These outcomes are related but not identical. A claim that BPC-157 improves recovery should specify which outcome changed and how it was measured. Without that definition, almost any favourable experience can be presented as confirmation, even if the underlying injury was never assessed.\n\nConsider a hypothetical runner whose discomfort improves while taking time away from training. The improvement matters to that person, but it does not identify which biological process caused it. If several treatments and a peptide were started together, attribution becomes even harder. A useful evidence review begins by narrowing the question: a defined injury, a defined intervention, a meaningful comparator and an outcome measured over a suitable period. This is the standard needed to evaluate the claim, not an assumption that the claim must be false." ], [ "Understand why preclinical findings are interesting", "Experimental work can reveal biological responses, identify pathways and suggest where a potential treatment deserves further investigation. These are important contributions. A peptide that changes a response in a model may help researchers understand the underlying biology even if it never becomes a medicine. The value of preclinical research does not depend on pretending that it already proves a clinical benefit.\n\nThe problem arises when the model disappears from the summary. A sentence about an animal injury experiment can become a general statement that the peptide heals human injuries. That transformation skips questions about exposure, formulation, species differences, outcome measurement and safety. A fair guide should describe the experimental level every time it matters. Readers can be interested in promising biology while recognizing that a controlled clinical demonstration is still a different achievement. Curiosity and precision are compatible; neither requires exaggerating what the experiment established." ], [ "Put early human reports in perspective", "The BPC-157 literature includes early human reports, including a published intravenous safety pilot in 2025. Such work can contribute preliminary observations, but a very small pilot is not a definitive safety programme or an efficacy trial for tendon repair. Its design and scope should remain visible. The word human is not enough to establish a high level of certainty.\n\nWhen evaluating an early report, ask how many people were included, how they were selected, what was measured and how long they were followed. Was there a comparison group? Were outcomes planned before treatment? Were participants using other therapies? A report may provide useful descriptive information while leaving causal questions unresolved. Avoid two opposite mistakes: saying no human work exists when small reports are available, and treating the existence of those reports as proof that a popular use is established. The accurate position depends on the actual design and findings." ], [ "Pain improvement is not the same as tissue repair", "Pain is a real and important outcome. It affects sleep, activity and quality of life. However, a reduction in pain does not automatically demonstrate structural healing of a tendon, ligament or other tissue. A claim about repair requires an appropriate way to assess repair. A claim about symptom relief requires a suitable symptom outcome and comparator. The two questions should not be mixed simply because both can be described as recovery.\n\nThis distinction changes how a study should be read. If the paper records a symptom score, summarize the symptom score. If it uses imaging, explain what the imaging measured and whether the finding connects to function. If it reports return to sport, consider the criteria for that return. Each endpoint can be valuable, but none should silently stand in for all the others. A careful page gives readers the actual outcome rather than a larger claim assembled from the emotional meaning of the word healing." ], [ "Look for the missing counterfactual", "The counterfactual is what would have happened without the intervention. In everyday experience, it cannot be observed directly for the same person at the same time. That is why comparison groups matter. Many symptoms change naturally, and people often try a new intervention when symptoms are unusually bad. Improvement afterward may partly reflect a return toward their usual level, even when the experience feels dramatic.\n\nA randomized controlled design helps estimate the intervention's contribution by comparing groups. It does not remove every source of uncertainty, but it is far more informative than selecting only people who say they improved. A collection of sincere testimonials can still omit people who had no benefit, stopped early or never posted. The point is not to dismiss lived experience. It is to avoid asking an anecdote to answer a causal question that its design cannot resolve. Good research starts with observations and then tests competing explanations." ], [ "Safety needs more than a short observation period", "A small study can report what happened during its observation window. It cannot reliably exclude uncommon events or establish effects after years of exposure. This is especially important when a popular discussion turns “no serious events observed” into “safe.” The first statement describes a dataset. The second implies a broader conclusion that may require much more information.\n\nSafety assessment also depends on the exact material and context. Different routes, formulations and combinations are separate questions. If a report concerns a specified research preparation, it does not establish the quality of a product sold elsewhere under the same name. A guide should therefore distinguish uncertainty about the molecule from uncertainty about the supplied material. These uncertainties can coexist. Solving one does not automatically solve the other, and a purity certificate cannot provide the missing long-term clinical evidence." ], [ "Why a COA cannot validate a healing claim", "A certificate of analysis can help describe an identified sample. Depending on its contents, it may report identity, purity, quantity or selected contaminants. It does not measure whether a person's injury will heal faster. The laboratory report and the clinical claim belong to different evidence chains. Linking both on the same product page does not create a scientific connection between them.\n\nSuppose a hypothetical supplier publishes a well-documented BPC-157 sample report. That can strengthen a statement about the tested sample. It does not convert an animal study into a human recovery trial. Conversely, even if future clinical work establishes a benefit for a defined preparation, unrelated retail products would still require their own quality and provenance assessment. This is why Peptide.cy separates supplier evidence scores from peptide evidence summaries. Combining them into one reassuring badge would make both kinds of evidence harder to understand." ], [ "Read combinations with extra care", "BPC-157 is sometimes discussed alongside other peptides or recovery interventions. A combination creates an additional attribution problem: if an outcome changes, which component contributed, and did the combination behave differently from the components separately? Evidence for one ingredient cannot automatically be transferred to the mixture. Adding several promising mechanisms does not amount to testing a treatment programme.\n\nWhen reading a combination claim, ask whether the exact combination was studied, whether there was a suitable comparator and whether outcomes and adverse events were systematically collected. If the evidence consists of separate papers on separate ingredients, say so. That may justify further research, but it does not establish the combined claim. The same reasoning applies when a person combines a peptide with rehabilitation, dietary changes or other therapies. A clear account lists the concurrent changes rather than attributing every favourable result to the newest ingredient." ], [ "What would stronger evidence look like?", "A more informative clinical programme would define a specific condition and recruit an appropriate population. It would use a clearly characterized intervention, a meaningful comparator and outcomes that matter to patients. It would prespecify the analysis, document adverse events and include enough follow-up to evaluate the intended claim. Independent replication would add confidence that the result is not a one-off finding.\n\nThe exact design depends on the question. A trial about tendon function needs different endpoints from a study about gastrointestinal symptoms. A safety study has a different purpose from an efficacy trial. Readers should not expect one paper to answer every possible use. Instead, ask whether each advertised claim has its own relevant evidence. This approach supports productive experimentation because it identifies what must be learned next. It also prevents promising early findings from being stretched into a catalogue of unsupported benefits." ], [ "How to use personal experiences responsibly", "A detailed personal account can help identify questions for future research or describe the burden of a condition. Useful accounts explain the diagnosis, timing, other interventions and what changed. They also include uncertainty. Someone can honestly say that symptoms improved after an intervention without claiming to know that the intervention caused the improvement. That distinction makes the report more credible, not less valuable.\n\nIf you read supplier reviews, focus on what the reviewer could directly observe: communication, the documentation received, packaging or complaint handling. Treat claims about biological effectiveness separately. Our community system does not verify medical outcomes and should not be used to estimate BPC-157 efficacy. The strongest current reading habit is simple: preserve the model, population and outcome whenever you repeat a finding. BPC-157 can remain an interesting research subject while broad recovery promises remain unestablished. Better evidence may change that assessment; marketing confidence cannot substitute for it." ], [ "Avoid treating an unexplained improvement as a product assay", "A perceived effect cannot confirm what a vial contained. Even a striking change in symptoms does not identify the molecule, quantify its amount or measure contaminants. The opposite is also true: an absence of a perceived effect does not establish that the sample was fake. Product analysis and clinical interpretation require different evidence. If a dispute concerns the contents, the appropriate route is a traceable analytical test with the sample and method documented. If it concerns whether an intervention helps an injury, the appropriate evidence is a relevant clinical comparison. Keeping the questions separate prevents customer enthusiasm or disappointment from being mistaken for chemistry." ] ], "sources": [ [ "BPC-157 intravenous human pilot", "https://pubmed.ncbi.nlm.nih.gov/40131143/" ], [ "BPC-157 human-artery experimental study", "https://pubmed.ncbi.nlm.nih.gov/42123221/" ], [ "FDA compounding safety information", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ] ], "checked": "2026-09-10", "wordCount": 1575 }, { "slug": "endotoxins-sterility-and-peptide-testing", "title": "Endotoxins, Sterility and Peptide Testing: A Clear Guide to the Differences", "summary": "A chemical purity report does not answer every contamination question. This guide explains how to read microbial and endotoxin evidence without overstating it.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "Why separate tests deserve separate labels", "People often use clean, sterile and pure as though they mean the same thing. In analytical and manufacturing discussions, they do not. Different tests are designed to investigate different properties. A supplier comparison becomes more useful when it preserves those distinctions instead of compressing everything into one reassuring badge.\n\nStart by asking what the report actually names. Does it describe chromatographic purity, a microbial count, a sterility test or an endotoxin result? Then identify the sample, method and units for each. This sounds basic, but it prevents a common error: assuming that one favourable test fills the gaps left by another. The goal is not to make every reader a laboratory specialist. It is to help readers recognize when the evidence answers a narrow question and when the language surrounding it has become broader than the measurement." ], [ "Chemical purity has a different purpose", "A chromatographic purity result concerns the analytical signals measured under its method. It is useful for characterizing a chemical sample, but it does not automatically demonstrate the absence of microorganisms or endotoxins. Those questions require relevant methods of their own. A high main-peak percentage cannot be converted into a universal contamination assessment.\n\nImagine a hypothetical product page showing a ninety-nine-percent result beside the word sterile. Unless the report includes evidence supporting sterility, the two statements should remain separate. The purity result may be genuine while the sterility claim remains unestablished in the reviewed material. A fair reviewer should say exactly that. There is no need to accuse the sample of contamination, and no basis for granting an unsupported assurance. Precision allows the favourable result to retain its value without being used to prove something it did not measure." ], [ "Bioburden and sterility are not interchangeable", "A microbial count and a sterility assessment have different purposes and procedures. The report's terminology should be retained rather than rewritten into whichever word sounds clearest to a consumer. A result described as bioburden should not automatically be labelled a sterility certificate. If the distinction is unclear, ask the laboratory or supplier to explain the scope of the method.\n\nFor a public evidence table, create separate fields. Record the method name as given, the units, the reporting limit and the sample identifier. This approach may produce more empty cells, but those cells are informative. They show which questions have not been addressed in the available documents. Filling them with assumptions creates a more attractive table at the cost of accuracy. A comparison should help readers see the boundary of the evidence rather than conceal it beneath a broad statement that testing was performed." ], [ "Endotoxin testing asks another question", "Endotoxin testing is distinct from assessing viable microorganisms. The FDA's guidance on pyrogen and endotoxin testing provides a primary reference for the regulatory context and method considerations. A reader comparing supplier documents should not treat an endotoxin panel as redundant simply because another microbial test appears on the report. The tests answer different questions.\n\nThe practical reading task is to identify what was measured and what the result means under the stated method. Avoid turning a result into a general statement that all pyrogen-related concerns have been eliminated. Avoid assuming that the absence of an endotoxin result proves a problem. The correct public description is narrower: the result was provided, was not provided or could not be interpreted confidently. Those categories preserve the distinction between a finding and a gap in the evidence, which is essential for a fair supplier review." ], [ "Units are part of the result", "A number without a unit is incomplete. The unit tells you the basis on which a result is expressed, and that basis matters when comparing reports. A concentration in a prepared sample is not automatically equivalent to an amount per vial or per mass of peptide. Converting between them requires the relevant quantities and a valid understanding of the preparation.\n\nSuppose a hypothetical document uses one unit in the summary and another in a detailed table. Do not assume the values are equivalent merely because they appear on the same page. Check whether the report supplies the information needed to connect them. If it does not, preserve the original values and request clarification. A confident but unsupported conversion can be more misleading than leaving the comparison incomplete. The purpose of a public guide is to make the evidence understandable, not to manufacture a common unit when the necessary basis is missing." ], [ "Reporting limits define what can be concluded", "Tests have limits of detection, quantitation or reporting, depending on the method and how the laboratory presents the result. A statement below a threshold should be read as a bounded statement. It does not establish an exact zero at every possible level. This is a normal feature of measurement, not a reason to dismiss testing.\n\nThe key is to keep the threshold attached to the result whenever it is repeated. A summary that says not detected but omits the method's limit can create an impression of absolute absence. A better summary records the laboratory's wording and the relevant threshold. If an acceptance criterion is included, distinguish it from the measurement limit. One concerns what the method reports; the other concerns how the result is judged for a defined purpose. They may appear together, but they are not the same concept." ], [ "A pass statement needs a specification", "Pass is a conclusion relative to a criterion. To interpret it, a reader needs to know what criterion was used and for what application. A pass statement without that context can be difficult to compare with another report. Different specifications may address different materials or uses, so identical words do not necessarily imply identical analytical findings.\n\nWhen a report gives only a pass result, ask whether a numerical result, method and acceptance limit are available. The answer may improve the evidence record even if the overall conclusion remains unchanged. If detailed information is unavailable, record that limit rather than inventing it. A public supplier score should reward the evidence that was actually inspected, not an assumed laboratory process hidden behind a one-word result. This approach is demanding about documentation while avoiding unsupported conclusions about the quality of an uncharacterized sample." ], [ "Keep sample identities connected", "A comprehensive-looking bundle can contain results from different samples. Sometimes the relationship is legitimate and documented; sometimes it is unclear. The reviewer should compare sample identifiers, batches and dates before treating the bundle as one panel. A shared peptide name alone is not enough to establish that all tests describe the same material.\n\nIf the identifiers differ, ask how the samples relate. Were they separate units from the same documented lot, separate submissions or unrelated production batches? The answer determines what can be concluded. Do not merge the reports merely because their combined coverage looks stronger. Do not assume the difference proves misconduct. The useful action is to preserve the discrepancy and request an explanation. Traceability is what allows individual test results to form a coherent account of a product. Without it, the bundle may contain valuable measurements but support a narrower conclusion than its cover page suggests." ], [ "Storage and handling create additional questions", "A report describes the tested material at a particular point in its history. Subsequent packaging, storage and handling can raise separate questions that the report may not address. This does not mean a historical result is useless. It means that dates and the relationship to current inventory matter when interpreting the evidence.\n\nA supplier claiming ongoing quality should explain how its testing relates to production and release. Is each lot covered? How is the tested sample connected to the items supplied? What documentation supports relevant stability claims? Public readers may not obtain every detail, but they can record which questions were answered. Avoid treating one old favourable result as a permanent certificate for a brand. Consistency is a pattern across appropriate observations, not a property established by repeatedly displaying the same document on every product page." ], [ "How to report an unclear finding fairly", "Use neutral, specific language. Instead of saying a supplier has unsafe products because a panel is missing, say that the panel was not available in the reviewed evidence. Instead of saying a product is sterile because a general microbial result was favourable, describe the actual test. If two fields conflict, state the conflict and explain that clarification is needed.\n\nThis style is not evasive. It is what makes a review useful to both readers and suppliers who want to correct the record. A precise question can be answered with a precise document. An exaggerated accusation or reassurance is harder to evaluate because it mixes evidence with assumptions. Peptide.cy's scoring approach treats missing information as an evidence gap and keeps clinical suitability separate. That allows the site to place substantial weight on contaminant documentation without pretending that every untested field represents either a failure or a pass." ], [ "A practical reading checklist in prose", "Before relying on a report, identify the sample and date, read the method names, preserve the units and thresholds, and separate each test's purpose. Check whether the laboratory attribution can be authenticated and whether the sample can be connected to the relevant lot. Then write what the evidence supports and what remains outside it. That final step often reveals where a broad marketing claim has outrun the data.\n\nThe strongest result is not necessarily the shortest answer. It may be a clear account showing good evidence for some properties and unresolved questions for others. Chemical purity, microbial assessment and endotoxin testing each contribute useful information when interpreted within their scope. None should be used to erase the need for the others, and no analytical panel alone establishes that a research product is a suitable treatment. Better comparisons keep the measurements distinct, traceable and connected to the question they were designed to answer." ] ], "sources": [ [ "FDA pyrogen and endotoxin testing guidance", "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers" ], [ "Particle Peptides sample report bundle", "https://particlepeptides.com/img/cms/test-results/GHRP-2-5mg.pdf" ], [ "Peptidology sample report bundle", "https://peptidology.co/wp-content/uploads/2025/04/BPC-157-10mg-February-2025-Final.pdf" ] ], "checked": "2026-09-10", "wordCount": 1572 }, { "slug": "how-to-compare-peptide-suppliers", "title": "How to Compare Peptide Suppliers Without Falling for Marketing", "summary": "A useful supplier review follows the evidence from the business identity to the actual sample. This guide explains how to build that comparison step by step.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "Decide what kind of supplier you need to compare", "The peptide supply chain contains businesses with very different roles. A contract manufacturer may make active ingredients for pharmaceutical development. A custom synthesis company may produce sequences for laboratory experiments. A research retailer may sell small labelled vials. A catalogue distributor may source products from several manufacturers. Comparing these businesses without acknowledging their roles can produce a ranking that looks comprehensive but answers no clear question.\n\nStart by defining the comparison. Are you evaluating public documentation for a research catalogue, assessing a custom synthesis proposal or investigating a pharmaceutical manufacturing partner? Each requires different evidence. A retailer's convenient checkout is irrelevant to a complex manufacturing programme. A manufacturer's large facility is not proof that an unrelated retail vial came from that facility. Keep the business role visible throughout the review. This also helps explain why a company with substantial technical capability might publish fewer batch documents than a retailer running a public certificate library." ], [ "Confirm the business and the domain", "A familiar brand name is not enough to establish the identity of a website. Similar spellings, old domains, redirects and unauthorized references to manufacturers can confuse the supply chain. Record the exact official domain and the legal or operating entity described there. If the site redirects, preserve that observation. If the company has been acquired, distinguish the brand from the parent company rather than counting both as unrelated businesses.\n\nAn inaccessible site creates an evidence gap. It does not prove that the business is illegitimate, and it does not justify borrowing facts from a similarly named company. DN Research is an example of how our directory handles this problem: the requested domain is listed, but unverified identity and catalogue details remain unverified. The next step is to obtain an authoritative source, not to fill the page with plausible assumptions. A useful review should make uncertainty discoverable before a reader follows an external link." ], [ "Look beyond the quality slogan", "Statements such as premium quality, research grade and trusted worldwide are broad marketing language. They are not a substitute for defined specifications or identifiable test results. More useful statements name the analytical method, the sample, the laboratory or the specific quality process. Even then, a statement that a process exists should be distinguished from evidence that it was applied to the material being evaluated.\n\nCreate two columns in your notes: claims made and evidence inspected. In the first, record what the business says. In the second, record the document or source that supports the claim. If a supplier says every batch is tested but you inspected one historical certificate, those are two different entries. The review can report both accurately. Problems arise when the broader claim silently acquires the evidential status of the narrower document. Keeping them separate is one of the simplest ways to make a supplier review more trustworthy." ], [ "Examine the laboratory relationship", "Third-party testing is valuable when its scope and provenance are clear. Identify the named laboratory and check whether the report can be confirmed through a laboratory-controlled channel. Then determine who selected and submitted the sample. Laboratory independence and sampling independence are separate attributes. A manufacturer can commission a genuine external test without the sample representing a blind purchase from the retail market.\n\nDo not award the same confidence to every use of the phrase independently tested. A supplier statement, an inspected vendor-hosted report and a report authenticated with its issuer represent different levels of evidence. The distinction should be visible in the score. Similarly, an ISO quality-management statement concerns a management system and scope; it does not automatically mean an outside laboratory chemically tested every peptide lot. Ask what the certificate actually covers before using it as a shortcut for product quality." ], [ "Read the contaminant coverage", "A supplier comparison that rewards only chromatographic purity can overlook important unanswered questions. Record whether separate information is available on microbial testing, endotoxins, residual solvents, relevant elemental impurities, counterions and other specified contaminants. The appropriate panel depends on the material and application. The public review should describe the panel, not pretend that one universal checklist can make every product suitable for every purpose.\n\nFor each result, look for the method, units, sample identity and reporting limit. If no result is available, mark it unestablished in the reviewed evidence. That wording matters. It avoids accusing a business of contamination merely because its public documentation is incomplete. At the same time, it prevents an undocumented clean-product claim from earning the same confidence as an inspectable result. A fair system can be demanding about evidence while remaining precise about what it has and has not found." ], [ "Evaluate quantity and traceability together", "A purity figure does not tell you how much peptide is in a vial. Quantity results should be assessed separately and linked to the correct sample. Traceability connects the report to the product identifier, batch and relevant dates. Without that connection, a technically sophisticated report may have limited value for the item being compared. The analytical result and the chain of identity both matter.\n\nLook for consistency across documents. A label, invoice and COA should not contradict one another about the product or lot. Differences can have ordinary explanations, such as a separate laboratory identifier, but the relationship needs to be documented. Do not assume that every discrepancy is fraud. Do not ignore it because the reported percentage is attractive. The appropriate response is a specific clarification request. A supplier's ability to answer that request with coherent evidence is more informative than a generic reassurance that quality is its top priority." ], [ "Treat customer service as its own dimension", "Communication, delivery and complaint handling are legitimate parts of a customer experience. They should not be confused with chemical analysis. A supplier can answer messages quickly without providing adequate laboratory evidence. Another can have excellent technical documentation but slow support. Combining these attributes into one unexplained star rating makes it difficult to understand what the reviewer actually valued.\n\nWhen reading customer comments, look for concrete details: the date, the question asked, the document requested and how the business responded. A review that says support supplied a batch-specific certificate is more informative than a statement that the product felt strong. Neither proves the contents of every order. On Peptide.cy, community ratings remain separate from editorial documentary scores. That separation allows people to describe service experiences without turning subjective opinions into a laboratory-quality ranking. It also gives critical reviews space without exaggerating their scientific meaning." ], [ "Understand why size is difficult to rank", "The biggest peptide businesses cannot reliably be ordered using one public metric. Revenue may include non-peptide products. Manufacturing capacity can refer to reactor volume, annual output or planned facilities. Retail traffic does not equal production scale. A global manufacturer and a specialist catalogue brand may both be prominent while occupying entirely different parts of the market.\n\nA directory should therefore explain its inclusion criteria. Our collection covers prominent manufacturers, research suppliers and requested brands, not a verified global league table by revenue or market share. Parent relationships and archived brands are identified where known. This is more useful than inventing a precise size ranking from incomparable claims. If a future report ranks capacity, it should define the metric, separate operating from planned capacity and use dated primary sources. The title of a ranking should describe what was actually measured, rather than what attracts the largest number of clicks." ], [ "Read scores as an evidence map", "A score becomes useful when its components and limitations are visible. Ask whether the system measures the quality of public documentation, laboratory findings, customer service or some combination. Then check what missing data does to the result. If unknown fields receive zero points, a low score can mean that the reviewer lacked evidence, not that a test failed. That distinction should appear near the number, not only in a distant disclaimer.\n\nAlso consider coverage. A score based on one peptide and one historical sample should not imply a complete audit of a large catalogue. Repeated lots, independent sampling and current verification can strengthen a comparison, but those activities must actually have occurred. The score should not award imaginary confidence for work planned in the future. A transparent ranking is allowed to have ties, low-confidence records and unscored entries. Those outcomes are often more honest than forcing every brand into a unique position." ], [ "Ask a focused set of questions", "A practical enquiry can be short. Identify the product and ask for its current lot-specific report, the laboratory verification route, measured quantity, contaminant panels and any relevant stability or handling documentation. For custom synthesis, ask which tests are included in the quote and which are optional. For a manufacturer, ask which site and quality agreement apply. Tailor the questions to the supplier's role rather than sending the same consumer checklist to every business.\n\nWhen a response arrives, update the evidence record rather than simply changing your impression. Note what was supplied, what remains unanswered and whether the new document changes the score under the published rules. This makes corrections reproducible. Another reader should be able to follow the same sources and understand the conclusion even if they disagree with the weighting. A good supplier review is not a declaration that trust has been solved. It is a clear account of what supports confidence, what limits it and what evidence would meaningfully change the assessment." ], [ "Date the conclusion as carefully as the source", "A supplier review is a snapshot. Ownership, catalogues and documentation can change after publication. Show the access date and explain what would trigger an update, such as a new authenticated report, a corrected sample identifier or an official closure notice. A current-looking page should not hide that its decisive evidence is historical. Readers can then judge both the finding and its freshness." ] ], "sources": [ [ "Sinopep official business and domain notice", "https://www.sinopep.com/" ], [ "CordenPharma peptide platform", "https://cordenpharma.com/how-we-deliver/technology-platforms/peptides-platform/" ], [ "JPT quality-management description", "https://www.jpt.com/" ], [ "GL Biochem official news and impersonation notice", "https://www.glschina.com/en/news.htm" ], [ "ProteoGenix custom peptide specifications", "https://us.proteogenix.science/custom-peptide-synthesis/" ] ], "checked": "2026-09-10", "wordCount": 1563 }, { "slug": "how-to-read-peptide-coa", "title": "How to Read a Peptide COA: A Practical Evidence Guide", "summary": "A certificate of analysis can answer useful questions—if you know exactly what was tested, how it was measured and which sample the result belongs to.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "Start with the sample, not the percentage", "A peptide certificate of analysis, usually shortened to COA, is a document about a sample. That sounds obvious, but it is the distinction most easily lost when a certificate becomes a marketing badge. A report does not automatically describe every vial sold under the same product name. It does not establish the current contents of a warehouse. It does not tell you whether a person should use the substance. Before reading the largest number on the page, identify the object to which every number refers.\n\nWrite down the product name, stated sequence or identifier, batch number, sample identifier, test date and report date. Keep those fields separate. A batch number identifies a production group; a laboratory sample number identifies the submitted material. They can be linked, but the connection should be explicit. If a seller shows several documents, compare these fields across all of them. A purity report and a sterility report with different sample identifiers should not silently become a single comprehensive certificate." ], [ "Find out who submitted the material", "An independent laboratory can test a sample selected and submitted by the supplier. That is useful, but it answers a different question from testing a sample purchased without the supplier knowing which item would be selected. The laboratory's independence concerns who performed the measurement. Sampling independence concerns how the material reached the laboratory. A good review describes both rather than compressing them into a single third-party badge.\n\nAsk whether the sample was supplied by the manufacturer, selected by a retailer, purchased by a customer or obtained through a documented independent sampling programme. Then ask what evidence supports that account. A photograph, invoice or chain-of-custody record may improve traceability, but each has limitations. Do not infer that an attractive report layout proves a blind purchase. Equally, do not dismiss a supplier-submitted test as worthless. Its value is real but narrower than an independently sampled market survey." ], [ "Separate identity from purity", "Identity asks whether the target substance is the expected molecule. Purity asks how much of the measured analytical signal is assigned to that substance under a particular method. Those questions overlap in practice but are not interchangeable. A report should make clear which method supports identity and which supports the purity result. HPLC and mass spectrometry are commonly discussed together because their information can complement one another.\n\nSuppose a hypothetical certificate says only “purity: 99%” without naming the analyte or method. That statement leaves substantial ambiguity. Now imagine a report that specifies a peptide identifier, an expected molecular mass, an observed mass and a chromatographic method. The second document gives the reviewer more to inspect, even before considering whether its results are favourable. Documentation quality begins with making a claim precise enough to challenge. Precision does not guarantee correctness, but vagueness makes meaningful verification much harder." ], [ "Understand the denominator", "A percentage is a fraction with a denominator. When people discuss a peptide's HPLC purity, the denominator may concern integrated chromatographic peak area under the reported conditions. It is not necessarily the total mass inside the vial. Water, counterions, residual solvents or components not captured by that analytical method can make the relationship between a purity percentage and total material more complicated.\n\nUse a hypothetical example: a sample could have a strong main peptide peak while its total powder mass includes material that is not counted in that peak-area calculation. Multiplying the vial's nominal powder weight by the purity percentage would then be an unsupported shortcut for calculating peptide content. The practical response is to request a separate quantitative determination with units and method details. The question is not whether percentages are useful. It is whether the percentage answers the question you are asking." ], [ "Read quantity as its own result", "A useful quantity result identifies the measured amount, the units and the basis of calculation. It might refer to material per vial, concentration in a prepared solution or net peptide content. Those are not the same quantity. A reviewer should be able to tell which one is reported and how it relates to the product label. If that connection is unclear, record the uncertainty rather than inventing a conversion.\n\nImagine a nominal ten-milligram product with a measured result that differs from ten milligrams. Before describing it as underfilled or overfilled, examine the measurement uncertainty, sampling procedure and definition of the label claim. The result may still deserve attention, but the wording should fit the evidence. One unusual sample cannot establish an average for an entire supplier. A single favourable sample also cannot establish consistency. Quantity accuracy becomes a stronger finding when multiple independently selected lots are measured comparably over time." ], [ "Look for methods and reporting limits", "A contaminant result needs more than the words pass or not detected. The relevant method, units, reporting limit and acceptance criterion should be identifiable. A method can report no detection while still being unable to rule out lower concentrations. That is not a defect unique to peptide testing; it is a normal feature of measurement. The mistake is turning a bounded result into a claim of absolute absence.\n\nA hypothetical “less than X” result should be read literally. It establishes an upper reporting statement under the method, not an exact zero. If the summary says one thing and the detailed table appears to say another, stop and request clarification. Do not resolve the inconsistency by choosing the more reassuring interpretation. Do not choose the more alarming interpretation either. A transparent review can state that the fields are inconsistent and withhold the relevant conclusion until the issuing laboratory explains them." ], [ "Keep sterility and endotoxins distinct", "Sterility-related testing and endotoxin testing address different questions. They should appear as separate evidence fields with their own methods and sample references. A certificate that includes one does not automatically include the other. Similarly, a general microbial count is not simply another spelling of a sterility test. The report's actual terminology matters because different tests support different conclusions.\n\nThe FDA's guidance on pyrogen and endotoxin testing is a useful primary reference for understanding the regulatory context. For a reader comparing public reports, the immediate task is more modest: identify exactly which panel was performed and avoid filling empty cells from assumptions. If endotoxin information is absent, mark it absent from the reviewed evidence. Do not mark the sample contaminated. If a seller describes a broad testing programme but provides only a purity certificate, separate the programme claim from the document you could inspect." ], [ "Authenticate through an independent route", "A laboratory name printed on a PDF is an attribution. Authentication means checking that attribution through a channel controlled by the laboratory. A report-verification portal can help if the domain itself is authentic and the retrieved record matches the document. A QR code is a convenient link, not an independent guarantee. Check where it leads before trusting what it displays.\n\nIf a report cannot be verified publicly, the appropriate next step may be direct confirmation from the laboratory. Record what was confirmed: document existence, report contents, sample identity or something else. These are different levels of assurance. A laboratory may confirm that it issued a report without being able to confirm what a retailer subsequently shipped. Keep the chain of reasoning intact. Authentication strengthens confidence in the report; it does not magically extend the report to untested material or answer clinical questions." ], [ "Review the whole chromatogram cautiously", "A chromatogram can provide context that a single percentage hides, including the timing and appearance of separated signals. However, a screenshot without method details is not an invitation to diagnose every small feature by eye. Integration settings, detector response and separation conditions affect interpretation. A non-specialist should be especially careful about assigning chemical identities to peaks without supporting analysis.\n\nUseful questions include whether the full run is shown, whether the main peak is identified, whether the integration is documented and whether the report explains relevant impurities. A cropped image might simply be a poor presentation choice, or it might omit important information; the image alone cannot determine which. Request the complete report before escalating the claim. The strongest public review is often a carefully bounded description of what the document contains and what additional material would allow a more confident interpretation." ], [ "Make a one-page evidence record", "You do not need an elaborate spreadsheet to improve your reading. Create a short record with the supplier, product, sample identifier, batch, date, laboratory, identity method, purity method, quantity result and contaminant panels. Add a separate column for what you actually inspected and another for what the supplier merely states. This prevents a general quality claim from quietly becoming a verified result when you revisit the information later.\n\nFinish with three sentences: what the report supports, what it does not support and what would resolve the most important uncertainty. For example, a historical sample report may support a statement about that sample's measured identity and content while leaving current inventory, additional contaminants and clinical suitability unanswered. That is a useful conclusion. A COA becomes valuable when it makes the evidence more specific, not when it removes every question. Keep the original source link and access date so another reader can check your interpretation." ], [ "Keep an audit trail when the report changes", "A supplier may replace a document after a correction or publish a newer batch result. Record which version you read and when you accessed it. If a numerical field changes, distinguish a corrected report from a new sample rather than assuming they are interchangeable. The reason for a revision can matter as much as the revised number. Preserve enough context for another reviewer to follow the change, while respecting any private information in the document. A transparent correction improves the evidence record; silently combining old and new fields makes the record harder to reconstruct and can create conclusions that neither version actually supports." ] ], "sources": [ [ "GenScript peptide quality information", "https://www.genscript.com/peptide_quality.html" ], [ "FDA pyrogen and endotoxin testing guidance", "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers" ], [ "ProteoGenix peptide analysis", "https://us.proteogenix.science/custom-peptide-synthesis/peptide-analysis/" ] ], "checked": "2026-09-10", "wordCount": 1580 }, { "slug": "how-to-read-peptide-studies", "title": "How to Read Peptide Studies: From Cell Experiments to Clinical Evidence", "summary": "A study link is the beginning of an assessment. Learn how to decide whether the experiment actually supports the health claim attached to it.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "Translate the claim into a question", "Peptide discussions often start with a broad promise: healing, longevity, fat loss, better sleep or improved immunity. Those words can describe many different outcomes. Before opening a paper, turn the promise into a question that could be tested. Which people, with which condition, receiving which intervention, compared with what, and measured over what period? A precise question makes it easier to see whether the study is relevant.\n\nFor example, faster closure of an experimental wound is not the same outcome as less pain after a sports injury. A change in a hormone concentration is not the same as improved strength. A patient reporting less distress is not the same as a laboratory marker changing. None of these outcomes is automatically unimportant. They simply answer different questions. Much misleading science communication occurs when an interesting answer to one question is presented as a definitive answer to another, broader question." ], [ "Identify the experimental level", "First determine whether the work involved a chemical assay, cultured cells, an animal model, human samples or an intervention given to people. These categories should not be hidden behind the phrase scientifically studied. A paper using human cells is not necessarily a human clinical trial. A study measuring an endogenous peptide after exercise is not necessarily a trial of administering that peptide as a treatment.\n\nThe MOTS-c literature provides a useful example of why this matters. Work can combine animal intervention experiments with observations in human exercise samples. Both may be scientifically valuable, but they support different conclusions. A reader should map each headline to the corresponding part of the experiment. Do not let the presence of human material in one section upgrade every result in the paper to demonstrated human treatment benefit. The path from mechanism to medicine contains several distinct steps, each with its own uncertainties." ], [ "Match the exact intervention", "The intervention includes more than the molecule's popular name. Sequence, modification, formulation, route, schedule and co-interventions can all matter. A study of full-length thymosin beta-4 eye drops does not automatically support a claim about a product sold as injectable TB-500. A trial of a long-acting CJC-1295 analogue does not establish identical effects for every product using a similar label.\n\nWrite down the intervention as the paper describes it. If a seller's product cannot be matched confidently to that description, state the mismatch. Do not fill the gap by assuming all versions behave alike. This is particularly important for blends, where results from each ingredient separately are sometimes combined into an implied trial of the mixture. The mixture is a separate intervention. Its effects cannot be calculated by adding the most favourable findings from unrelated studies with different participants, routes and outcomes." ], [ "Find the comparator", "A comparator helps estimate what would have happened without the intervention or with an alternative. Depending on the question, it may be placebo, usual care, another treatment or a defined control condition. A before-and-after observation without a comparison group is much harder to interpret because time itself can change symptoms. Natural recovery, altered behaviour and expectations may all contribute.\n\nImagine a person begins a peptide during rehabilitation and reports less pain six weeks later. The improvement may be real, but its cause is uncertain. A randomized trial attempts to separate the intervention's contribution from other explanations by comparing groups under a planned design. Randomization is not magic, and trials can still have weaknesses. It is nevertheless a major difference from collecting only positive stories after treatment. When a claim says a peptide worked, ask what happened in the group used to judge that statement." ], [ "Check the population", "Study participants define the population to which a finding most directly applies. Adults without diabetes, people with a specific HIV-associated condition, critically ill patients and healthy volunteers are not interchangeable groups. A treatment may have a different balance of benefit and harm across them. Inclusion and exclusion criteria often explain why a result should not be generalized casually.\n\nRead who was eligible and who was left out. Consider age, diagnosis, disease severity, background treatment and other relevant characteristics. If your question concerns a group excluded from the study, the paper may still inform the discussion, but it does not directly answer it. This is why a tesamorelin trial in people with HIV and abdominal fat accumulation cannot simply be relabelled a universal fat-loss trial. The population is part of the evidence, not a footnote that can be removed to make the result more marketable." ], [ "Distinguish endpoints from interpretations", "An endpoint is a measured outcome. The interpretation is what the authors or commentators think that outcome means. Keep them separate. Changes in GH or IGF-I show an endocrine response under the study conditions. Whether that response produces better daily function or longer life requires additional evidence. Similarly, telomere-related changes in cultured cells do not establish that treated people experience healthy ageing.\n\nRead the primary endpoint before the discussion section. Then identify secondary and exploratory outcomes. A study may produce several interesting signals while failing to establish a benefit on its main planned question. That does not make the work worthless. It changes the strength and scope of the conclusion. A fair summary should not lead with the most flattering secondary result while omitting the primary finding. Readers deserve to know what the experiment was designed to test before being asked to interpret what else it happened to observe." ], [ "Put effect size beside uncertainty", "A statistically significant result does not tell you everything about practical importance. Look at the size of the difference, its uncertainty and the outcome's meaning. A small numerical change can matter greatly for one endpoint and very little for another. The same percentage can also describe a relative difference or an absolute difference, which are not interchangeable.\n\nUse a hypothetical example: reducing an event from two in a hundred to one in a hundred is a fifty-percent relative reduction and a one-percentage-point absolute reduction. Both statements can be mathematically correct, but they feel different when presented alone. A useful report includes enough context to understand the scale. Avoid copying a large relative number without the baseline. For continuous outcomes, examine the units and whether the observed difference is likely to be meaningful to the people in the study, not merely detectable by the analysis." ], [ "Read adverse events and discontinuation", "Benefits should be considered alongside adverse events and the number of people who stopped treatment. A result based only on people who completed the study can look different from an analysis that accounts for everyone assigned to treatment. Missing data and discontinuation are not administrative details; they can affect how the result should be understood in practice.\n\nDistinguish an adverse event from an adverse reaction judged related to treatment. Not every event after treatment is caused by treatment, especially in severely ill populations. Conversely, a study reporting few events may be too small or too short to detect uncommon or delayed harm. The appropriate conclusion depends on the design and observation period. Avoid translating no serious events observed into no serious risks exist. The first describes the dataset. The second claims knowledge beyond it. Good summaries preserve the difference even when a short headline would be easier." ], [ "Check publication status and timing", "A trial registration, conference abstract, sponsor press release and full peer-reviewed article provide different amounts of information. A registration describes a plan; it does not establish a successful result. A topline announcement can be timely but may omit detailed methods and tables. A full publication can support a more complete assessment, although peer review does not guarantee that every interpretation is correct.\n\nRetatrutide development illustrates why dates matter. Published phase 2 evidence and later phase 3 sponsor announcements should be identified separately. An older guide should not describe the programme as though no newer results exist, but a new announcement should not be treated as a regulatory approval. Check for corrections, updated analyses and changes in status. Keep the source date visible so readers can distinguish a historical finding from the current state of development. Scientific evidence accumulates, and an honest page should make its review date part of the story." ], [ "Build a short evidence summary", "A useful study note can fit in one paragraph: the design, participants, intervention, comparator, primary outcome, main finding and important limitation. Add the source link and publication status. If you cannot identify one of those elements from an abstract, record that rather than guessing. The exercise makes it much harder to use a citation merely as decoration beneath a broad health promise.\n\nFinally, compare the note with the original claim. Does the study directly support it, partly inform it or address a different question? Those are all legitimate outcomes of reading. A peptide can be biologically interesting while its popular use remains unproven. A well-established medicine can have strong evidence without being appropriate for every person. Scientific literacy is not a competition to be optimistic or sceptical. It is the habit of keeping conclusions connected to the experiment that supports them and leaving room for better evidence to change the answer." ], [ "Read funding and conflicts without using them as a shortcut", "Funding and declared relationships provide context for interpreting research. They do not automatically invalidate a result, and the absence of a commercial sponsor does not guarantee good methods. Read the design and reporting alongside the declarations. Ask whether the analysis was prespecified, whether relevant outcomes are presented and whether other groups have obtained compatible findings. This avoids two easy but unhelpful responses: accepting a study because it confirms your preference, or rejecting it solely because of who supported it. The evidence should remain open to methodological criticism regardless of whether the result is commercially convenient, surprising, positive or negative." ] ], "sources": [ [ "CJC-1295 randomized endocrine study", "https://pubmed.ncbi.nlm.nih.gov/16352683/" ], [ "Thymosin beta-4 dry-eye trial", "https://pubmed.ncbi.nlm.nih.gov/25826322/" ], [ "Tesamorelin randomized clinical trial", "https://pubmed.ncbi.nlm.nih.gov/25038357/" ], [ "MOTS-c original research", "https://doi.org/10.1038/s41467-020-20790-0" ], [ "Lilly retatrutide development update", "https://www.lilly.com/news/stories/what-to-know-about-retatrutide" ] ], "checked": "2026-09-10", "wordCount": 1566 }, { "slug": "longevity-peptides-biomarkers-and-evidence", "title": "Longevity Peptides: How to Judge Biomarkers, Mechanisms and Human Evidence", "summary": "Longevity claims often begin with an interesting cellular result. The challenge is determining whether that result supports a meaningful benefit in people.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "Define what longer and healthier mean", "Longevity can refer to lifespan, years lived without disease, physical function, independence or a laboratory estimate of biological age. These are not interchangeable outcomes. A claim that a peptide promotes longevity should identify which of them was actually studied. Without that definition, a change in almost any ageing-related marker can be presented as proof of a much broader benefit.\n\nStart with the endpoint. Did treated people live longer? Did they retain function? Did a disease outcome improve? Or did a measurement change in cells or animals? Each can be scientifically interesting, but the strength of the claim should fit the result. A useful guide does not dismiss mechanisms simply because they are early. It also does not allow the word longevity to hide the distance between a laboratory observation and a demonstrated improvement in human life. That distance is the central subject of the evidence assessment." ], [ "A biomarker is not automatically a benefit", "A biomarker is a measured biological characteristic. Some biomarkers can be useful indicators in particular settings, but a change in a marker is not automatically proof that an intervention improves health. The relationship between the marker and the outcome needs to be established for the relevant purpose. Otherwise, the intervention may change the measurement without delivering the hoped-for benefit.\n\nImagine a hypothetical test that assigns a biological-age score. A lower score after an intervention may be interesting, but it does not by itself establish that the person will live longer or develop fewer diseases. Measurement variation, the model used to calculate the score and concurrent changes all matter. Ask whether the marker has been validated as a substitute for the claimed outcome in that context. If not, describe it as a biomarker finding. This preserves its scientific value while avoiding a larger promise that the study did not test." ], [ "Epitalon illustrates the translation problem", "Epitalon has been investigated in telomere-related laboratory work. A 2025 study examined responses in normal and cancer cell lines, and the publication record includes a correction. That is a useful reason to read the original paper carefully. It is not evidence that administering epitalon extends human lifespan or establishes a general anti-ageing treatment.\n\nThe distinction is particularly important because telomeres are easily turned into a simple story: longer must mean younger, and younger must mean healthier. Biology is more complicated than that sequence of slogans. The study's actual cells, methods and endpoints should remain visible. A reader can acknowledge a cellular result without converting it into a prediction about treated people. Similarly, observations involving cancer cell lines should not be exaggerated into proof of human cancer causation or prevention. The appropriate conclusion remains attached to the experiment, with the human outcome question left open." ], [ "MOTS-c connects exercise biology with new questions", "MOTS-c research has examined metabolic stress, muscle biology and exercise-related responses. Original work reported intervention effects in mice and measured exercise-associated changes in humans. These are different experimental components. The presence of human measurements does not turn the animal intervention results into a demonstrated benefit from administering MOTS-c to people.\n\nThis distinction matters when a product is described as exercise in a vial. That phrase implies a practical substitute for a complex behaviour and its many effects. The cited experiments do not establish that claim. A more accurate question is whether a defined intervention can improve a defined outcome in an appropriate human trial. Mechanistic overlap with exercise can justify research without proving equivalence to exercise. The guide's job is to make that gap visible, not to deny the underlying biology or inflate it into a ready-made longevity programme." ], [ "Hormone changes need clinical interpretation", "Peptides that affect growth-hormone-related signalling are sometimes placed in longevity discussions. Early CJC-1295 studies, for example, demonstrated endocrine changes under their study conditions. A measurable increase in a hormone or related factor does not automatically establish better function, healthier ageing or longer survival. Those are separate outcomes that require their own evidence.\n\nA common reasoning error is to treat a measurement associated with youth as a target that should always be increased. Association does not establish that changing the measurement will recreate every benefit associated with a different age or health state. A treatment can affect several systems at once, and the overall result must be evaluated clinically. When reading a longevity claim, ask whether the cited work measured a downstream health outcome or only confirmed that the intervention changed the intended biological signal. Both findings can matter, but they belong at different stages of the argument." ], [ "Animal lifespan findings require careful translation", "Animal experiments can test hypotheses that would be difficult or slow to study in humans. They can reveal mechanisms and help prioritize research. However, results depend on the species, strain, environment, intervention and outcome. A favourable finding in one model is not a direct forecast of what will happen in a diverse human population.\n\nThe correct response is neither automatic dismissal nor automatic translation. Describe the model, look for replication and ask what would be required to test the hypothesis in people. If the claim concerns human healthspan, identify a meaningful human outcome and a feasible study design. A page that skips these questions may sound visionary while actually removing the information needed to evaluate the idea. Scientific ambition is better served by specifying the next test than by treating an early result as the final answer." ], [ "Long-term safety is part of a longevity claim", "An intervention intended for prolonged use raises questions that a short experiment cannot settle. Duration, cumulative exposure, interactions and uncommon outcomes matter. A brief study reporting few adverse events may be useful preliminary information, but it does not establish a favourable benefit–risk balance over years. The observation window is part of the result.\n\nThis point is especially relevant when the intended benefit is itself long term. A claim about extending healthy life should not rely on a safety assessment that ignores long-term outcomes. At the same time, uncertainty should not be presented as proof that harm will occur. The accurate statement is that the required evidence has not been established by the available study. A mature comparison can keep both potential benefit and unresolved risk visible without forcing every molecule into the categories miracle or danger." ], [ "Beware of stacking uncertain assumptions", "A longevity programme may combine several peptides, supplements, devices and behavioural changes. If an outcome changes, attribution becomes difficult. Each ingredient's separate evidence does not automatically establish the combination's effect. The programme can also create interactions that were not examined in the individual studies. A longer list of mechanisms is not the same as stronger clinical evidence.\n\nWhen evaluating a stack, ask whether the exact programme was studied and whether the outcome was measured against a suitable comparator. If the evidence is assembled from unrelated papers, identify that limitation. A hypothetical combination of three interventions with promising cell data does not become a proven human treatment because all three sound biologically compatible. The proper next step is a study of the combination, with clear outcomes and safety assessment. Until then, a guide should describe the rationale as a rationale rather than presenting it as an established result." ], [ "Personal tracking can help describe, not prove", "People interested in longevity often track sleep, exercise, laboratory values and subjective wellbeing. Consistent records can make an experience easier to describe and help identify questions. They do not recreate a randomized trial. Changes in routine, measurement noise and expectations can still influence the apparent result, especially when many outcomes are tracked and only the favourable ones are highlighted.\n\nA useful record specifies what was measured before starting, how often it was measured and what other factors changed. It also includes unfavourable or unchanged outcomes. Avoid selecting one improved score from a large set and treating it as decisive evidence. Personal tracking is most informative when it supports a careful conversation about uncertainty. It becomes misleading when it is used to claim that a peptide has extended lifespan, reversed ageing or produced a biological effect that the measurements cannot actually establish." ], [ "Ask what would change your conclusion", "A strong evidence review should identify the information that would increase or decrease confidence. For a longevity peptide, that might include a well-designed human trial with meaningful functional outcomes, adequate follow-up, transparent adverse-event reporting and independent replication. The exact requirements depend on the claim. A claim about sleep needs different evidence from a claim about survival.\n\nThis approach keeps the discussion open to discovery. It does not require assuming that every unproven intervention will fail. It requires a clear distinction between a promising hypothesis and a demonstrated result. Readers can then understand why confidence changes when new evidence arrives. A guide that cannot state what would change its conclusion may be defending a position rather than evaluating research. The most useful public resource makes its standards visible so both enthusiastic and sceptical readers can inspect the same path from experiment to claim." ], [ "Build an evidence hierarchy for the actual question", "For each longevity claim, record the molecule, exact intervention, experimental level, endpoint, comparator and follow-up. Add the publication date and whether the work has been corrected or independently replicated. Keep supplier documentation in a separate record. A well-characterized sample is valuable for research, but its purity does not establish human healthspan benefit.\n\nThe final question is simple: what did this study show, and what larger conclusion am I tempted to add? That pause can prevent a biomarker from becoming a promise, a mouse result from becoming a human forecast and a customer story from becoming a population estimate. Longevity research can be imaginative and ambitious while remaining precise. The best guide preserves that ambition by making the unanswered questions explicit and connecting every confident statement to evidence capable of supporting it." ] ], "sources": [ [ "Epitalon cell-line study and correction record", "https://pubmed.ncbi.nlm.nih.gov/40908429/" ], [ "MOTS-c original experimental research", "https://doi.org/10.1038/s41467-020-20790-0" ], [ "CJC-1295 endocrine study", "https://pubmed.ncbi.nlm.nih.gov/16352683/" ], [ "FDA peptide compounding safety information", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ] ], "checked": "2026-09-10", "wordCount": 1559 }, { "slug": "peptide-manufacturing-and-purification", "title": "Peptide Manufacturing and Purification: What Quality Claims Really Mean", "summary": "Understanding the steps between a chemical sequence and a finished research product helps you ask better questions about purity, residues and manufacturing claims.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "A sequence is a specification, not a finished product", "A peptide can be described as an ordered sequence of amino acids, sometimes with additional modifications. That description is the starting point for making and characterizing the material. It is not the same as demonstrating that a particular batch has the intended composition. Manufacturing must connect the written target to a physical product through a documented process and suitable analysis.\n\nFor a custom synthesis enquiry, clarity at the start prevents ambiguity later. Specify the sequence, terminal modifications, desired quantity, relevant purity requirement and any additional analytical needs. If the peptide has a label, conjugate or cyclic structure, those details belong in the specification. A quote based only on a familiar nickname may leave important assumptions unresolved. The resulting comparison should evaluate whether the supplier understood and documented the requested material, not simply whether its advertised price looked attractive." ], [ "Synthesis and purification answer different needs", "Synthesis aims to produce the target substance. Purification aims to separate desired material from other components. Analysis evaluates what was obtained. These activities are connected, but none should be used as a substitute for the others. A sophisticated synthesis platform does not remove the need to characterize the final material. A purification claim does not establish the result without measurement.\n\nMany peptide suppliers describe solid-phase synthesis, while some manufacturing programmes also use solution-phase or hybrid approaches. The appropriate process depends on the molecule and project. Public readers do not need to choose a production route themselves to evaluate the evidence. They do need to avoid assuming that the name of a process guarantees a universal quality level. Ask what specification was achieved and how it was verified. The process description can explain the approach, but the released material remains the object of the quality assessment." ], [ "Why difficult sequences can change the project", "Peptides differ in length, composition, modifications and structural requirements. A simple sequence and a complex cyclic or conjugated peptide may present very different manufacturing challenges. This is one reason a custom synthesis service offers several options rather than a single universal process. The quote should reflect the actual molecule and the required analytical deliverables.\n\nWhen comparing suppliers, ask how they handle the features that matter for the sequence. For a disulfide-containing peptide, the relevant structural questions may go beyond checking an expected mass. For a labelled peptide, the identity of the label and its attachment matter. For a library, composition and consistency across members may be central. These are examples of tailoring the specification, not a claim that one type of peptide is inherently better. A strong procurement discussion identifies the difficult part of the assignment instead of treating every sequence as the same product with a different name." ], [ "Purification cost is not a quality certificate", "Purification can require resources, time and material loss. That helps explain why a more demanding specification may cost more. However, the invoice amount is not an analytical result. An expensive service can still leave questions unanswered, and a competitively priced service may be well documented. Price is a commercial fact; quality must be evaluated through the relevant evidence.\n\nA supplier claiming extra purification should explain what the claim means for the identified batch. Was there an additional separation step? Was a specific impurity targeted? Were before-and-after results measured using comparable methods? What was the final specification? These questions turn a broad claim into something inspectable. Do not award points merely because a process sounds costly. Reward the documentation that demonstrates what the process achieved. That is the difference between recognizing real technical work and allowing expensive language to function as a substitute for proof." ], [ "Analytical purity is only one release attribute", "A final material can require several kinds of characterization. Identity, chromatographic purity, quantitative content and selected contaminants answer different questions. The appropriate package depends on the application and specification. A single purity percentage should not be treated as a complete description of the product, even when the number is high.\n\nFor a professional research order, ask which tests are standard and which are optional. A provider may include HPLC and MS while offering water content, counterion analysis or residual-solvent testing separately. That arrangement is not necessarily problematic, but it must be understood before comparing quotes. A cheaper quote with a smaller analytical package is not directly comparable with a more extensive one. Likewise, the availability of optional testing does not establish that those tests were performed on the material already listed for sale." ], [ "Counterion exchange should have a measurable endpoint", "A supplier may offer a change in counterion form as part of a custom project. The useful question is not just whether an exchange step was performed, but how the final composition was assessed. A process label cannot quantify the remaining counterion or establish that a target specification was met. The order should identify the desired form and any necessary analytical confirmation.\n\nAvoid turning counterion discussions into a simplistic ranking of good and bad products. The intended application, amount and specification matter. For research, a particular composition may affect how an experiment is planned or interpreted. For a clinical product, a different regulatory and formulation assessment applies. The public comparison should stay within its evidence: what was requested, what was reported and what remains unmeasured. Clear chemistry information helps readers understand the material without making unsupported claims about health effects from a name alone." ], [ "Drying and packaging do not settle every question", "A finished research product may be supplied as a dry material or in solution, with packaging and handling instructions appropriate to the product. Those features matter, but they do not replace analytical characterization. A neat vial, a sealed cap or a shipping insert can show how a product is presented without proving all of its chemical or microbial properties.\n\nRecord packaging observations separately from laboratory findings. If a supplier makes a stability claim, ask for the conditions and evidence supporting it. If a product is shipped under a particular temperature arrangement, distinguish the stated arrangement from actual monitoring records. Avoid assuming either that every temperature variation ruins a product or that a product is stable under any conditions. The right conclusion depends on the specific material and data. A useful review describes the evidence available rather than extrapolating from the appearance of the parcel." ], [ "GMP is a scope-dependent claim", "Good manufacturing practice belongs to a defined manufacturing and regulatory context. A company may operate different services, sites or grades of material. A broad statement about GMP capability does not automatically establish that a particular research catalogue item was manufactured and released under the same arrangements. The relevant scope should be identified before the claim contributes to a comparison.\n\nFor a manufacturing project, ask which site, quality agreement and product specification apply. For a retailer referring to a manufacturer, ask how the actual batch is traced to that source. These questions prevent a company's general capability from being transferred to unrelated material. They also allow a fairer comparison between professional manufacturers and research suppliers. The purpose is not to diminish regulated manufacturing. It is to make sure that its significance is attached to the correct product and documented chain of supply." ], [ "Repurification needs before-and-after evidence", "A claim that a peptide was cleaned more thoroughly can be evaluated more usefully when the starting and final samples are identified. The comparison should specify which property improved and how it was measured. If different methods were used before and after, a reviewer should consider whether the results are directly comparable. A better-looking number alone may not explain the whole change.\n\nImagine a hypothetical project targeting one related impurity. Successful reduction of that impurity would be valuable evidence for the stated goal. It would not automatically establish a result for residual solvents, endotoxins or every other possible component. Those require their own measurements when relevant. This is why a complete account of repurification includes both achievements and remaining limits. The more specific the evidence, the easier it is to recognize genuine quality work without allowing the word purified to become an unlimited assurance." ], [ "Compare deliverables before comparing prices", "A practical supplier comparison starts with a matched specification. List the desired material, quantity, purity requirement, analytical package, documentation and timeline. Ask each provider to identify exclusions and optional work. Then compare like with like. This is more informative than ranking a custom synthesis quote against a retail vial simply because both mention the same peptide name.\n\nWhen the product arrives, compare the delivered documentation with the agreed scope. Are the identifiers consistent? Are the methods and units clear? Are optional tests actually present? Record any questions and the supplier's response. This creates an evidence trail that can support a meaningful review. Good manufacturing is not demonstrated by a single adjective or an impressive factory photograph. It is supported by a coherent connection between the target specification, the process, the measured output and the documentation that allows another person to inspect the result." ], [ "A useful final distinction", "Manufacturing quality and clinical usefulness remain separate questions. A carefully made research peptide can be appropriate for a laboratory experiment without having an established benefit for a person. Conversely, a clinically useful ingredient does not authenticate an unrelated supplier's product. Keeping this distinction visible protects the meaning of both manufacturing evidence and clinical research.\n\nThe most valuable questions are therefore concrete: what material was made, what was measured, which specification was met and which claims remain outside the evidence? Those questions can recognize technical excellence when it is documented. They can also reveal when a polished description contains little inspectable information. A good comparison does not need to assume that expensive production is automatically superior or that every affordable supplier is cutting corners. It needs to follow the evidence from the written sequence to the identified final sample." ] ], "sources": [ [ "AAPPTec synthesis and purification discussion", "https://www.peptide.com/" ], [ "CordenPharma peptide manufacturing platform", "https://cordenpharma.com/how-we-deliver/technology-platforms/peptides-platform/" ], [ "ChemPep custom synthesis specifications", "https://chempep.com/custom-peptide-synthesis/" ], [ "ProteoGenix custom synthesis and optional analyses", "https://us.proteogenix.science/custom-peptide-synthesis/" ], [ "AmbioPharm manufacturing overview", "https://www.ambiopharm.com/about-us/" ] ], "checked": "2026-09-10", "wordCount": 1563 }, { "slug": "peptide-purity-vs-safety", "title": "Peptide Purity vs Safety: Why 99% Is Only One Part of the Story", "summary": "Purity, identity, quantity and contamination testing answer different questions. Understanding those differences makes supplier comparisons much more useful.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "Why the headline number attracts attention", "A purity percentage is easy to compare. It fits on a product card, looks scientific and suggests a simple ordering: a larger number appears better. The difficulty is that the number may represent only one part of the analytical picture. A useful comparison must first establish that the values were measured in comparable ways and refer to the same kind of result. Without that context, numerical precision can create more confidence than the evidence deserves.\n\nConsider two hypothetical suppliers. One displays a very high percentage without a report. The other publishes a slightly lower result with a named laboratory, identifiable sample and detailed methods. The first has the more impressive headline; the second may have the more inspectable evidence. Neither example establishes clinical safety. It illustrates why documentary transparency and measured purity should not be collapsed into the same score. A review should reward evidence that can be examined while describing the result itself accurately." ], [ "Identity comes before interpretation", "Before asking how pure a peptide is, ask whether the sample is the expected substance. Similar names, different fragments and modified sequences can create confusion. A report for one sequence cannot automatically support a claim about another. This is especially important when commercial shorthand is used across several products or when a blend is presented as though it were a single substance.\n\nA sensible evidence record preserves the exact product identifier and any reported sequence or molecular information. If the identity is ambiguous, the purity result remains attached to that ambiguity. Do not repair the problem by assuming the seller meant the most familiar version of the name. Ask for clarification. This is not an argument that every unclear label is fraudulent. It is an argument that the quality question cannot be answered until the material under discussion is defined well enough to evaluate." ], [ "Purity and content are different measurements", "Chromatographic purity and net peptide content should be treated separately. A chromatographic measurement can characterize the relative signals detected under a method, while a content determination addresses the amount of peptide. Powder weight, labelled amount and measured peptide quantity may each have a different basis. A complete comparison states which quantity is available rather than using the terms interchangeably.\n\nImagine that two hypothetical vials have identical reported chromatographic purity. One could still differ from the other in actual peptide amount, water content or counterion composition. The purity values would not necessarily reveal those differences. A reader who cares about quantity therefore needs a quantitative result, not simply another decimal place on the purity percentage. More decimals can make a result look precise without making it more relevant to the question being asked. Relevance begins with choosing the correct measurement." ], [ "What purification can and cannot prove", "Purification is a process used to separate desired material from other components. Its effectiveness must be evaluated through suitable analysis of the resulting material. A supplier's statement that a product was purified twice, repurified or produced using an expensive process is not the same as a demonstrated final result. Process descriptions can be informative, but they need an evidential connection to the actual batch.\n\nA meaningful repurification claim would ideally identify the starting sample, explain the process at an appropriate level and provide comparable before-and-after measurements. Even then, the result would concern the properties that were measured. Improving a chromatographic impurity profile does not automatically establish sterility, remove every possible contaminant or make a research product a medicine. The practical question is what changed, how that change was measured and which uncertainties remain. Cost can explain why a service is expensive; it cannot replace analytical evidence." ], [ "Residual solvents need their own context", "Peptide production and purification can involve solvents. Evaluating residues requires an appropriate analytical approach and a relevant specification. It is not enough to assume that drying or a high purity percentage settles the issue. Conversely, mentioning a solvent's name does not establish that a sample contains a harmful amount. A responsible comparison avoids both unsupported reassurance and unsupported alarm.\n\nThe FDA's ICH Q3C material provides a primary regulatory reference for residual-solvent assessment. A public supplier review is not a substitute for a qualified release decision, but it can record whether solvent testing was provided and whether the units and limits were clear. A missing panel should remain missing in the evidence table. If a vendor offers solvent testing as an optional service, note that distinction. Availability of a test is not proof that it was performed on the item being discussed." ], [ "Counterions are not a marketing shortcut", "Peptides can be supplied in different counterion forms, and those forms matter for interpreting composition and analytical results. Online discussions sometimes reduce this to a simple good-versus-bad story about one counterion. That framing is too crude. The relevant questions include what form is present, how much is present, the intended application and what the specification requires.\n\nFor professional research procurement, a request for counterion exchange should include a way to verify the final result. Merely renaming the product after an exchange process does not quantify the remaining material. A supplier may provide a method-specific analysis or offer it separately. Ask which applies. When writing a review, describe the test and finding without turning a chemistry detail into an unsupported clinical claim. An honest profile can say that counterion information was not available and explain why that limits the comparison." ], [ "Microbial questions are independent of peak area", "Microbial contamination is not assessed simply by reading the main peptide peak in an HPLC report. A chemical purity result and a microbial test belong in separate rows. Sterility, bioburden and endotoxin terminology should also remain distinct. Combining them into a single clean badge makes it harder for readers to see what was actually investigated.\n\nSuppose a hypothetical report contains a microbial result for sample A and an identity result for sample B. Unless the relationship between those samples is documented, the reports should not be treated as one complete panel. This is a traceability issue, not a claim that either sample failed. Public comparisons become more reliable when they preserve inconvenient details instead of smoothing them away. The reader should be able to reconstruct which conclusion came from which document, rather than being asked to trust a summary that hides the joins." ], [ "Not detected does not mean mathematically zero", "Analytical tests have limits. A result below a reporting threshold establishes a bounded statement under the method. It does not demonstrate absolute absence at every conceivable concentration. That distinction matters because a reassuring phrase can otherwise be repeated without the qualification that gives it scientific meaning. The qualification is part of the result, not optional small print.\n\nWhen reading a report, look for the unit, method and threshold together. If a summary says not detected but the detailed table uses different wording, record the inconsistency and request clarification. Avoid converting units unless the necessary quantities and assumptions are known. An elegant conversion based on an unknown sample amount can be less useful than leaving the original units intact. Clear uncertainty is preferable to a fabricated sense of comparability. The goal is a valid comparison, not a table in which every cell appears complete." ], [ "A clean sample is still not a clinical trial", "Even an excellent analytical package does not establish that administering the substance will benefit a person. Clinical safety and effectiveness depend on the molecule, formulation, route, exposure, population and treatment context. Those questions require the relevant clinical evidence. Supplier testing can address product identity and selected quality attributes; it cannot replace the development and evaluation of a medicine.\n\nThis distinction works in both directions. A medicine's strong clinical evidence does not authenticate an unrelated research vial bearing the ingredient's name. A well-documented research sample does not inherit the medicine's evidence merely because a name matches. Keep the two evidence chains separate until a justified connection can be established. Doing so makes the comparison more useful for researchers and more honest for readers interested in health. It prevents a certificate from being used as a shortcut around questions it was never designed to answer." ], [ "Build a comparison that rewards specificity", "A useful supplier table should distinguish identity, purity, quantity, independent verification, contaminants and traceability. The score should explain what earns points and what a zero means. Missing public documentation should not be labelled as a failed test. A favourable historical sample should not become a guarantee about current stock. These rules make a ranking less dramatic, but much more interpretable.\n\nBefore sharing a purity claim, try writing it as a complete sentence: this laboratory reported this result, using this method, for this identified sample, on this date. Then add what has not been established. If the sentence cannot be completed from the available evidence, the headline number is doing too much work. Better information does not always produce a confident winner. Sometimes it reveals that the available documents are not yet sufficient for a fair comparison—and identifies exactly which measurements would improve it." ], [ "Do not confuse a ranking with a release decision", "A public documentation score summarizes the evidence recorded by a reviewer. A professional release decision evaluates material against an agreed specification within a defined quality system. The two activities are not equivalent. A directory can help identify useful questions and missing documents, but its numerical score should not be used as a certificate authorizing an application. This distinction also explains why different business types need context. A pharmaceutical manufacturing partner, a custom research laboratory and a retail catalogue may publish different kinds of information. The comparison should describe those differences rather than assuming that the same public score settles every procurement or clinical question." ] ], "sources": [ [ "FDA ICH Q3C residual solvents", "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-tables-and-list-rev-4" ], [ "FDA pyrogen and endotoxin testing", "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers" ], [ "Creative Peptides chemical and physical analyses", "https://www.creative-peptides.com/services/chemical-physical-analyses.html" ], [ "ChemPep custom purification services", "https://chempep.com/custom-purification-services/" ] ], "checked": "2026-09-10", "wordCount": 1540 }, { "slug": "peptide-reviews-and-user-experiences", "title": "Peptide Reviews and User Experiences: How to Separate Useful Reports from Hype", "summary": "Customer stories can reveal service problems and unanswered questions. They become misleading when opinions are treated as laboratory findings or clinical proof.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "Ask what the reviewer actually observed", "A review is strongest when it describes something the writer could directly observe. A supplier answered a question, sent a document, delivered a parcel or handled a complaint. These are different kinds of observations from a claim that a peptide caused a biological effect. The first group can often be described concretely. The second requires a much more careful assessment of causality.\n\nStart by identifying the subject of the rating. Does five stars mean fast delivery, helpful support, convincing documentation or a perceived health effect? If the review does not say, the number has limited interpretive value. A useful platform should encourage reviewers to explain the basis of their opinion. That makes positive and negative feedback more informative and prevents a single star average from being mistaken for a scientific quality score. The review can still be valuable without answering every question about the supplier or product." ], [ "Specific details make an experience more useful", "Compare two hypothetical comments. One says a supplier is amazing. Another says the reviewer requested a current batch report on a particular date and received a document with a matching identifier two days later. The second provides a clearer account of what happened. It does not authenticate the document by itself, but it gives other readers a concrete observation they can understand and potentially investigate.\n\nUseful detail does not require publishing private information. Reviewers should avoid medical records, addresses, payment details and identifying information about other people. A public display name and a focused description are enough for most service feedback. If a document contains sensitive data, it should not be pasted into a comment. The aim is to make the experience inspectable without turning a public review page into a repository of personal records. Clear boundaries improve both the usefulness of the discussion and the quality of moderation." ], [ "A sincere experience can have an uncertain cause", "Someone may honestly report feeling better after using a substance. The experience itself can be real while its cause remains uncertain. Symptoms fluctuate, people change routines and several interventions may begin at once. Expectations can affect subjective outcomes, and natural recovery can occur over the same period. These possibilities do not imply that the reviewer is lying.\n\nThe distinction is between describing a sequence of events and proving causation. A personal account can establish that the writer noticed a change after an intervention. It cannot automatically establish what would have happened without it. That counterfactual is why controlled studies matter. A responsible platform allows people to describe experiences while preventing those descriptions from being repackaged as established efficacy. Respect for the person and precision about the evidence are compatible. Neither requires dismissing the report or accepting its strongest interpretation without question." ], [ "Online reviews do not provide a representative sample", "People choose whether to post reviews. Those choices can depend on how strong their experience was, whether they were invited to review and whether the platform makes feedback easy. A collection of comments therefore does not necessarily represent everyone who interacted with a supplier. Missing experiences can change the apparent picture even when every visible comment is genuine.\n\nThis matters especially when a site turns comments into percentages. If ten people report a benefit, the denominator is not automatically everyone who used the product. Without a defined sampling method, a platform cannot estimate the frequency of benefit or harm reliably. It can report what its users submitted and how many published reviews are present. Those are useful descriptive facts. They should not be presented as clinical incidence rates or proof that the same proportion of future users will have the same experience." ], [ "Incentives belong in the disclosure", "A reviewer may receive a discount, free product, referral benefit or other incentive. A reviewer may also work for a supplier or have a personal relationship with it. These facts can affect how readers interpret the account. Disclosure does not automatically make a review false, but hiding the relationship removes relevant context.\n\nA good review policy asks writers to disclose material connections in plain language. It should also prevent promotional links from turning the comment section into an advertising channel. Peptide.cy separates user opinions from editorial evidence scores and does not use affiliate links. The community form asks reviewers to identify supplier relationships. Moderation can examine whether a comment reads like promotion, but it cannot guarantee that every undisclosed relationship is detected. The platform should explain that limit rather than claiming that a CAPTCHA or manual review proves complete independence." ], [ "Star ratings need a clear denominator", "An average rating should be accompanied by the number of reviews used to calculate it. A perfect average based on one review means something different from a similar average based on hundreds. The platform should also state whether only published reviews contribute and whether the displayed average describes the whole dataset or a loaded page of results.\n\nAvoid treating small differences between averages as precise rankings. Reviews may concern different periods, products or aspects of service. A supplier with a broader customer base may attract a different mix of feedback from a specialist business. The average is a summary of submitted opinions under the platform's rules, not a measurement of chemical purity. A useful interface makes this distinction visible near the number. Readers should not need to search a policy page to discover that a customer rating and an editorial laboratory-evidence score answer different questions." ], [ "Moderation should preserve legitimate criticism", "A review system is not useful if it removes every negative comment or accepts every positive one. Moderation should assess relevance, personal information, promotional content and unsupported allegations consistently. A low rating based on a clearly described service experience can be legitimate. So can a positive rating that explains a specific helpful response.\n\nThe difficult cases often involve factual claims the platform cannot verify. A reviewer may say a product was contaminated without providing an authenticated result, or accuse a business of fraud based only on an unanswered message. A moderator should distinguish the observable experience from the broader allegation. The comment may need clarification or rejection if it cannot be published fairly in its current form. That is different from suppressing criticism because it is inconvenient. Transparent rules help readers understand what moderation does and why approval is not an endorsement of every statement in a review." ], [ "CAPTCHA is an abuse barrier, not identity verification", "A CAPTCHA can make automated submission more difficult. Server-side validation, expiration and replay prevention are important because a form-only check can be bypassed. Rate limits add another barrier. These controls improve the submission process, but they do not prove a reviewer's identity, purchase history or truthfulness. Human-generated spam and coordinated posting remain possible.\n\nA platform should therefore describe the protection accurately. On Peptide.cy, a visual code is required, verified on the server and usable once within a short validity period. Submissions are stored privately until moderation. Those are meaningful controls. They do not justify a verified-purchase badge, because the platform has not checked an order. The distinction matters: technical abuse prevention and evidential verification are different functions. Combining them under a vague verified label would give readers an assurance that the system has not actually earned." ], [ "Blocking links keeps the discussion focused", "A comment section with unrestricted links can attract referral spam, phishing and repeated promotional content. Blocking web addresses, email addresses and markup reduces that opportunity. The server should enforce the rule, and the browser should render approved comments as plain text rather than interpreting them as HTML. This prevents a review from becoming an executable or clickable content channel.\n\nNo automated filter can understand every possible obfuscated promotional message. Moderation remains useful for attempts to evade the rule or direct readers to an external sales channel through coded language. The policy should explain that links are prohibited without claiming that software can identify every imaginable reference to a website. For legitimate evidence corrections, a separate source-submission workflow is more appropriate than trying to smuggle a URL into a customer review. Different forms can serve different purposes while keeping the public discussion clear and manageable." ], [ "Use reviews to ask better questions", "A pattern of comments about missing documentation may suggest a useful enquiry to a supplier. A detailed account of responsive support may indicate what another researcher can request. Reviews can therefore help identify practical questions even when they cannot establish product quality directly. The key is to follow the observation with verification rather than treating the observation as the final answer.\n\nFor example, if several reviewers mention a report library, inspect the library and evaluate the documents yourself. If a comment describes a disputed batch result, look for an authenticated source before repeating the allegation. If a reviewer reports a health effect, consult the relevant clinical evidence rather than using the star score as a treatment guide. Reviews become most useful when they point toward better questions and sources. They become misleading when they are used to bypass the work needed to assess those questions properly." ], [ "Keep opinions and evidence visible together", "A strong supplier page can display both documentary findings and community experiences without merging them. The editorial section can explain identity, purity, quantity, laboratory verification and missing panels. The community section can describe communication, service and individual opinions. Clear labels let readers understand the contribution and limits of each.\n\nThat structure also makes updates easier. A new laboratory report can change the documentary assessment under published rules. A new customer comment can add another experience without silently changing the chemical-evidence score. Corrections can be tied to a specific statement rather than a vague overall impression. The result is a more useful public resource: people can speak about what happened to them, suppliers can respond with evidence through an appropriate process, and readers can distinguish a personal account from a tested sample or a controlled clinical finding." ] ], "sources": [ [ "Bremelanotide RECONNECT trials, an example of structured patient-reported outcomes", "https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/" ], [ "Google guidance on helpful, reliable content", "https://developers.google.com/search/docs/fundamentals/creating-helpful-content" ], [ "Cloudflare explanation of server-side CAPTCHA validation principles", "https://developers.cloudflare.com/turnstile/get-started/server-side-validation/" ] ], "checked": "2026-09-10", "wordCount": 1574 }, { "slug": "semaglutide-tirzepatide-retatrutide-comparison", "title": "Semaglutide, Tirzepatide and Retatrutide: How to Compare the Evidence", "summary": "Three widely discussed metabolic peptides have different mechanisms, development histories and evidence. A useful comparison goes beyond the largest weight-loss headline.", "category": "Long-form guides", "level": "Evidence literacy · in-depth", "sections": [ [ "Start with the clinical question", "People often ask which peptide is best for weight loss. The question is understandable, but best depends on the outcome and the person. Weight change, glucose regulation, tolerability, other health conditions, treatment burden and access can all affect the decision. A comparison that considers only one trial average cannot settle every individual treatment question.\n\nFirst identify the purpose of the comparison. Are you trying to understand receptor mechanisms, compare published obesity trials or learn whether a product is an approved medicine? Those questions require different information. A mechanism table can explain pharmacology without ranking clinical suitability. A trial table can compare study results while acknowledging differences in participants. A regulatory source can establish an indication without predicting an individual's response. Keeping these tasks separate makes the eventual comparison clearer and prevents a single impressive number from carrying more meaning than it can support." ], [ "Understand the mechanisms without overranking them", "Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts at GIP and GLP-1 receptors. Retatrutide is designed to act at GIP, GLP-1 and glucagon receptors. These distinctions help explain why the compounds are scientifically different, but receptor count is not a clinical league table. More targets do not automatically mean a better benefit–risk balance for every person or outcome.\n\nMechanisms are useful for forming hypotheses about effects. Clinical studies are needed to determine what happens in the intended population. A well-written comparison therefore places mechanism beside evidence rather than using it as a substitute. The same principle applies to descriptions such as next generation. That phrase can refer to a development strategy, but it does not establish approval, long-term safety or superiority. Readers should be able to distinguish a pharmacological design feature from a result measured in a controlled clinical study." ], [ "What the established obesity trials contribute", "STEP 1 studied semaglutide in adults with overweight or obesity without diabetes, with lifestyle intervention in both groups. SURMOUNT-1 studied tirzepatide in a similarly defined broad category but used its own protocol, treatment arms and follow-up. Both provide substantial randomized human evidence of weight reduction in their studied settings. They are not reports about research powders purchased from online suppliers.\n\nThe studies are useful starting points because their methods and outcomes can be inspected. Read the participant criteria, analysis approach, treatment duration and adverse-event information alongside the main result. A summary that copies only the largest reduction loses much of what makes the study informative. It can also conceal whether the result concerns all assigned participants, a particular analysis population or a subgroup. The full context is essential before using the figures to compare treatments or to form expectations about what a different person might experience." ], [ "Why separate trials are not a head-to-head contest", "Two trials can differ in baseline characteristics, background care, follow-up, discontinuation and statistical methods. Those differences can affect the apparent outcomes. Comparing the largest number in one study with the largest number in another is therefore an indirect comparison, not a randomized contest between the two drugs. It may be informative, but its limitations should remain visible.\n\nA direct head-to-head study asks a more focused comparative question under a shared protocol. Even then, the result applies most directly to the studied population and conditions. The lesson is not that comparisons are impossible. It is that the confidence should match the design. If a website ranks treatments using separate trials, it should state that clearly and avoid implying that the ranking was experimentally established. A comparison can be useful without pretending that differences in study design have disappeared." ], [ "Retatrutide's development status matters", "Retatrutide has published phase 2 evidence and later phase 3 development updates. Lilly reported topline results from its TRIUMPH programme during 2026. Those updates matter when describing the current state of research. However, a sponsor announcement, a full peer-reviewed report and a regulatory authorization remain different events. A page should not treat them as interchangeable.\n\nWhen you encounter a retatrutide claim, identify which source supports it and when that source was published. A historical phase 2 paper can still be important even after newer announcements. Newer results should be assessed with the detail available, while remaining clear about whether the complete dataset has been published. The sponsor's current material describes the molecule as investigational. Availability on an unrelated retail website does not establish authorization or equivalence to the clinical-trial product. Development progress is evidence about a programme, not authentication of every item using its name." ], [ "Benefits require an outcome, not a slogan", "Weight reduction can be clinically important, but it is not the only outcome people care about. Daily functioning, symptoms, quality of life and specific disease outcomes may also matter. These should be evaluated using the relevant trials rather than assumed from a change in body weight. A treatment's value may differ depending on which outcome is most important to the eligible patient.\n\nA useful comparison asks what benefit was measured, how large it was and how certain the estimate is. It also asks whether the observation period was long enough for the claimed outcome. A short study cannot establish lifelong durability. A biomarker improvement cannot automatically stand in for every downstream health benefit. The goal is to preserve the clinical meaning of the result. Broad phrases such as metabolic transformation may attract attention, but they are less useful than a clear statement of what changed in whom over what period." ], [ "Tolerability belongs in the main comparison", "Gastrointestinal adverse effects are prominent in the clinical experience with these treatment programmes. A fair comparison should include tolerability and discontinuation alongside efficacy. It should not imply that a medicine with a larger average effect is automatically preferable if a person cannot tolerate it or has a relevant contraindication. Current product information and clinical assessment are essential for approved treatments.\n\nRead how adverse events were collected and reported. Distinguish common symptoms from serious events, and avoid comparing percentages without considering the study design. A small trial may not detect uncommon risks. A selected group of treatment completers may not reflect everyone who started. These details affect real-world expectations. They also explain why a personal treatment decision cannot be reduced to a chart of maximum weight-loss results. Benefits and burdens belong in the same conversation, with the exact medicine and patient context kept visible." ], [ "Patient experiences can add context", "People often describe changes in hunger, eating habits, digestive comfort and day-to-day life. Such experiences can be meaningful and help articulate questions for clinical care. They are not automatically representative of everyone using the medicine. Online groups select their own participants, and people with striking experiences may be more likely to post than people with ordinary or disappointing results.\n\nA useful account distinguishes the product, duration, concurrent changes and reason for continuing or stopping. It should not be treated as a controlled comparison between ingredients. Someone switching medicines may also change lifestyle, support or expectations. That makes the experience valuable as a personal narrative but limited as evidence of comparative efficacy. Structured patient-reported outcomes within trials provide another way to study experience while preserving a comparator. The best guide respects personal accounts without converting them into invented population statistics." ], [ "Ingredient names do not make products equivalent", "A prescription medicine is a defined product with a formulation, manufacturing controls and approved information. A research-labelled vial using the same ingredient name has not thereby become that medicine. The distinction is especially important when a supplier places a clinical-study link beside a product listing. The study supports conclusions about its own intervention, not automatic conclusions about the listed item.\n\nProduct-quality evidence is a separate assessment. A COA may help characterize a sample, but it does not establish clinical interchangeability or replace a licensed supply chain. The FDA's material on unapproved GLP-1 products is a useful source for the concerns in that setting. For readers using our directory, supplier matches mean that a named product was listed in the recorded catalogue. They are not recommendations to obtain research material for personal treatment, and they do not transfer approval from a medicine to a seller's product." ], [ "Build a comparison you can update", "Create a simple record for each compound: mechanism, development or approval context, key study, population, outcome, follow-up and main limitation. Keep the source date visible. Add new evidence by updating the relevant field rather than rewriting the whole story around the latest headline. This helps prevent older claims from persisting after development changes and newer announcements from being overstated before the full evidence is available.\n\nFor an individual treatment discussion, bring the question back to the person's goals and clinical context. Which approved option is relevant? What outcome would count as success? What monitoring and follow-up are planned? What happens if treatment is not tolerated? Those questions are more useful than deciding that one molecule wins because it has more receptor targets or the largest number in an isolated trial. A scientifically strong comparison provides a map of the evidence and its boundaries. It does not promise that the same route is right for everyone." ], [ "Separate access from evidence", "A medicine can have strong evidence while access is constrained by cost, availability or clinical eligibility. An investigational compound can be heavily advertised online without acquiring the same regulatory status. These are separate dimensions of the comparison. Do not infer that easier access means better evidence, or that a higher price proves a better product. A useful guide identifies the actual source of the claim and the authorized product context, then leaves individual access and treatment questions to the appropriate licensed channels. This makes the comparison more informative for readers in different countries, where brand names and approved indications may differ." ] ], "sources": [ [ "STEP 1 semaglutide randomized trial", "https://pubmed.ncbi.nlm.nih.gov/33567185/" ], [ "SURMOUNT-1 tirzepatide randomized trial", "https://pubmed.ncbi.nlm.nih.gov/35658024/" ], [ "Retatrutide phase 2 trial", "https://pubmed.ncbi.nlm.nih.gov/37366315/" ], [ "Lilly current retatrutide development information", "https://www.lilly.com/news/stories/what-to-know-about-retatrutide" ], [ "EMA Wegovy information", "https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy" ], [ "EMA Mounjaro information", "https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro" ], [ "FDA concerns with unapproved GLP-1 products", "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" ] ], "checked": "2026-09-10", "wordCount": 1544 } ], "methodologyVersion": "0.2" }